Compositions and methods for sample analysis

Abstract

Provided herein are systems and methods for analyzing biomolecules (e.g., nucleic acid molecules, proteins). A method of nucleic acid analysis can comprise: (a) providing a sample comprising a cell comprising a target polynucleotide comprising a first exon segment and a second exon segment, wherein the first exon segment and the second exon segment flank opposite ends of a splice junction site of the target polynucleotide. The method can further comprise (b) contacting the cell with: (i) a first probe, wherein the first probe hybridizes to a first target sequence of the first exon segment, and (ii) a second probe, wherein the second probe hybridizes to a second target sequence of the second exon segment. The method can further comprise (c) linking the first probe and the second probe together, thereby generating a probe-linked nucleic acid molecule comprising the first probe and the second probe. The method can further comprise (d) identifying a sequence of the probe-linked nucleic acid molecule or derivative thereof, thereby locating the splice junction site of the target polynucleotide.

Description

Attorney Docket No.43487-1029601 COMPOSITIONS AND METHODS FOR SAMPLE ANALYSIS CROSS REFERENCE

[0001] This application claims benefit of U.S. Provisional Application No. 63 / 627,995, filedFebruary 1, 2024, which is incorporated by reference herein in its entirety for all purposes. SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submittedelectronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on January 29, 2025, is named 43487-1029_601_SL.xml and is 23,446 bytes in size. BACKGROUND

[0003] A sample may be processed for various purposes, such as identification of a type ofmoiety within the sample. The sample may be a biological sample. Biological samples may be processed, such as for detection of a disease (e.g., cancer) or identification of a particular species. There are various approaches for processing samples, such as polymerase chain reaction (PCR) and sequencing.

[0004] Biological samples may be processed within various reaction environments, such aspartitions. Partitions may be wells or droplets. Droplets or wells may be employed to process biological samples in a manner that enables the biological samples to be partitioned and processed separately. For example, such droplets may be fluidically isolated from other droplets, enabling accurate control of respective environments in the droplets.

[0005] Biological samples in partitions may be subjected to various processes, such aschemical processes or physical processes. Samples in partitions may be subjected to heating or cooling, or chemical reactions, such as to yield species that may be qualitatively or quantitatively processed.

[0006] Biological molecules, such as nucleic acids and proteins, within biological samplesmay be probed and / or processed for quantitative or qualitative assessment. SUMMARY

[0007] In one aspect, the present disclosure provides a method of nucleic acid analysis,comprising: (a) providing a sample comprising a cell comprising a target polynucleotide comprising a first exon segment and a second exon segment, wherein the first exon segment and the second exon segment flank opposite ends of a splice junction site of the targetAttorney Docket No.43487-1029601 polynucleotide; (b) contacting the cell with: (i) a first probe, wherein the first probe hybridizes to a first target sequence of the first exon segment, and (ii) a second probe, wherein the second probe hybridizes to a second target sequence of the second exon segment; (c) linking the first probe and the second probe together, thereby generating a probe-linked nucleic acid molecule comprising the first probe and the second probe; and (d) identifying a sequence of the probe- linked nucleic acid molecule or derivative thereof, thereby locating the splice junction site of the target polynucleotide.

[0008] In some embodiments, the method further comprises, prior to or during (b),permeabilizing the cell. In some embodiments, the target polynucleotide is a mature mRNA transcript. In some embodiments, the first target sequence and the second target sequence are directly adjacent on the target polynucleotide. In some embodiments, (c) comprises ligating a first end of the first probe with a second end of the second probe to generate the probe-linked nucleic acid molecule. In some embodiments, the first target sequence and the second target sequence are separated by a gap region of up to 1000 nucleotides on the target polynucleotide. In some embodiments, (c) comprises performing a nucleic acid extension reaction to fill the gap region to generate the probe-linked nucleic acid molecule.

[0009] In some embodiments, in (b), the second probe comprises a barcode sequence. Insome embodiments, the probe-linked nucleic acid molecule generated in (c) comprises the barcode sequence, and (d) further comprises identifying the barcode sequence or reverse complement thereof in the probe-linked nucleic acid molecule or derivative thereof. In some embodiments, the barcode sequence identifies the sample and the method further comprises (e) associating the splice junction site located in (d) with the sample based on the identity of the barcode sequence. In some embodiments, the sample is associated with a disease, and (e) comprises associating the splice junction site with the sample, and thereby, the disease, based on the identity of the barcode sequence. In some embodiments, in (a), the target polynucleotide is a distinct mRNA isoform among a plurality of distinct mRNA isoforms, wherein the splice junction site is associated with the distinct mRNA isoform; in (d), locating the splice junction site thereby identifies the distinct mRNA isoform; and (e) comprises associating the distinct mRNA isoform with the sample, and thereby, the disease, based on the identity of the barcode sequence. In some embodiments, the distinct mRNA isoform encodes a cell surface protein.

[0010] In some embodiments, the method comprises, prior to (d), using the probe-linkednucleic acid molecule and an oligonucleotide comprising an additional barcode sequence to generate a barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, (iii) the barcode sequence or reverse complement thereof, and (iv) the additional barcode sequence orAttorney Docket No.43487-1029601 reverse complement thereof. In some embodiments, generating the barcoded nucleic acid molecule occurs in a partition among a plurality of partitions. In some embodiments, the additional barcode sequence identifies the partition from other partitions of the plurality of partitions. In some embodiments, the partition is a droplet or a well. In some embodiments, generating the barcoded nucleic acid molecule comprises hybridizing a capture sequence in the oligonucleotide to a capture binding sequence in the probe-linked nucleic acid molecule, and extending the oligonucleotide to generate the barcoded nucleic acid molecule. In some embodiments, the oligonucleotide is coupled to a bead.

[0011] In some embodiments, the method further comprises, prior to (d), using the probe-linked nucleic acid molecule and an oligonucleotide comprising a barcode sequence to generate a barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, and (iii) the barcode sequence or reverse complement thereof. In some embodiments, the barcode sequence identifies the cell, and (d) comprises identifying the splice junction site as associated with the cell based on the identity of the barcode sequence. In some embodiments, the oligonucleotides is coupled to a bead.

[0012] In some embodiments, the target polynucleotide comprises a third exon segment anda fourth exon segment, wherein the third exon segment and the fourth exon segment flank opposite ends of an additional splice junction site of the target polynucleotide. In some embodiments, (b) further comprises contacting the cell with: (iii) a third probe, wherein the third probe hybridizes to a third target sequence of the third exon segment, and (iv) a fourth probe, wherein the fourth probe hybridizes to a fourth target sequence of the fourth exon segment. In some embodiments, (c) further comprises linking the third probe and the fourth probe together, thereby generating an additional probe-linked nucleic acid molecule comprising the third probe and the fourth probe. In some embodiments, the first target sequence and the second target sequence are directly adjacent on the target polynucleotide, and wherein the third target sequence and the fourth target sequence are directly adjacent on the first target polynucleotide. In some embodiments, (c) comprises (i) ligating a first end of the first probe and a second end of the second probe together to generate the probe-linked nucleic acid molecule, and (ii) ligating a third end of the third probe and a fourth end of the fourth probe together to generate the additional probe-linked nucleic acid molecule.

[0013] In some embodiments, the first target sequence and the second target sequence areseparated by a gap region of up to 1000 nucleotides on the target polynucleotide, and wherein the third target sequence and the fourth target sequence are directly adjacent on the target polynucleotide. In some embodiments, (c) comprises (i) performing a nucleic acid extensionAttorney Docket No.43487-1029601 reaction to fill the gap region to generate the probe-linked nucleic acid molecule, and (ii) ligating a third end of the third probe and a fourth end of the fourth probe together to generate the additional probe-linked nucleic acid molecule.

[0014] In some embodiments, first target sequence and the second target sequence areseparated by a first gap region of up to 1000 nucleotides on the target polynucleotide, and wherein the third target sequence and the fourth target sequence are separated by a second gap region of up to 1000 nucleotides on the target polynucleotide. In some embodiments, (c) comprises (i) performing a first nucleic acid extension reaction to fill the first gap region to generate the probe-linked nucleic acid molecule, and (ii) performing a second nucleic acid extension reaction to fill the second gap region to yield the additional probe-linked nucleic acid molecule.

[0015] In some embodiments, the method further comprises generating the probe-linkednucleic acid molecule and generating the additional probe-linked nucleic acid molecule simultaneously. In some embodiments, the method further comprises generating the probe-linked nucleic acid molecule and generating the additional probe-linked nucleic acid molecule sequentially.

[0016] In some embodiments, (d) further comprises identifying an additional sequence of theadditional probe-linked nucleic acid molecule or derivative thereof, thereby locating the additional splice junction site of the target polynucleotide. In some embodiments, in (b), the first probe and the third probe each comprises a common barcode sequence. In some embodiments, the probe-linked nucleic acid molecule and the additional probe-linked nucleic acid molecule generated in (c) each comprises the common barcode sequence, and (d) further comprises: (i) identifying the common barcode sequence or reverse complement thereof in the probe-linked nucleic acid molecule or derivative thereof, and (ii) identifying the common barcode sequence or reverse complement thereof in the additional probe-linked nucleic acid molecule or derivative thereof. In some embodiments, the common barcode sequence identifies the sample and wherein the method further comprises (e) associating the splice junction site and the additional splice junction site located in (d) with the sample based on the identity of the common barcode sequence. In some embodiments, the sample is associated with a disease, and (e) comprises associating the splice junction site and the additional splice junction site with the sample, and thereby, the disease, based on the identity of the common barcode sequence. In some embodiments, in (a), the target polynucleotide is a distinct mRNA isoform among a plurality of distinct mRNA isoforms, wherein the splice junction site and the additional splice junction site are collectively associated with the distinct mRNA isoform; in (d), locating the splice junction site and the additional splice junction site thereby identifies the distinct mRNA isoform; and (e)Attorney Docket No.43487-1029601 comprises associating the distinct mRNA isoform with the sample, and thereby, the disease, based on the identity of the common barcode sequence. In some embodiments, the distinct mRNA isoform encodes a cell surface protein.

[0017] In some embodiments, the method of claim further comprises, prior to (d): using theprobe-linked nucleic acid molecule and a first oligonucleotide comprising an additional barcode sequence to generate a first barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, (iii) the common barcode sequence or reverse complement thereof, and (iv) the additional barcode sequence or reverse complement thereof; and using the additional probe- linked nucleic acid molecule and a second oligonucleotide comprising the additional barcode sequence to generate a second barcoded nucleic acid molecule comprising (i) the third target sequence or reverse complement thereof, (ii) the fourth target sequence or reverse complement thereof, (iii) the common barcode sequence or reverse complement thereof, and (iv) the additional barcode sequence or reverse complement thereof.

[0018] In some embodiments, generating the first barcoded nucleic acid molecule andgenerating the second barcoded nucleic acid molecule occur in a partition among a plurality of partitions. In some embodiments, the additional barcode sequence identifies the partition from other partitions of the plurality of partitions. In some embodiments, the partition is a droplet or a well. In some embodiments, generating the first barcoded nucleic acid molecule comprises hybridizing a first capture sequence in the first oligonucleotide to a first capture binding sequence in the probe-linked nucleic acid molecule, and extending the first oligonucleotide to generate the first barcoded nucleic acid molecule; and generating the second barcoded nucleic acid molecule comprises hybridizing a second capture sequence in the second oligonucleotide to a second capture binding sequence in the additional probe-linked nucleic acid molecule, and extending the second oligonucleotide to generate the second barcoded nucleic acid molecule. In some embodiments, the first oligonucleotide is coupled to a first bead and the second oligonucleotide is coupled to a second bead.

[0019] In some embodiments, the method further comprises, prior to (d): (I) using the probe-linked nucleic acid molecule and a first oligonucleotide comprising a barcode sequence to generate a first barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, and (iii) the barcode sequence or reverse complement thereof; and (II) using the additional probe-linked nucleic acid molecule and a second oligonucleotide comprising the additional barcode sequence to generate a second barcoded nucleic acid molecule comprising (i) the third target sequence or reverse complement thereof, (ii) the fourth target sequence or reverse complement thereof, andAttorney Docket No.43487-1029601 (iii) the barcode sequence or reverse complement thereof. In some embodiments, the barcode sequence identifies the cell, and (d) comprises identifying the splice junction site and the additional splice junction site as associated with the cell based on the identity of the barcode sequence. INCORPORATION BY REFERENCE

[0020] All publications, patents, and patent applications mentioned in this specification areherein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The novel features of the invention are set forth with particularity in the appendedclaims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:

[0022] FIG. 1 shows an example of a microfluidic channel structure for partitioningindividual biological particles.

[0023] FIG. 2 shows an example of a microfluidic channel structure for the controlledpartitioning of beads into discrete droplets.

[0024] FIG. 3 illustrates an example of a barcode carrying bead.

[0025] FIG. 4 illustrates another example of a barcode carrying bead.

[0026] FIG. 5 schematically illustrates an example microwell array.

[0027] FIG. 6 schematically illustrates an example workflow for processing nucleic acidmolecules.

[0028] FIG. 7 schematically illustrates another example workflow for processing nucleicacid molecules.

[0029] FIG. 8 schematically illustrates another example workflow for processing nucleicacid molecules.

[0030] FIG. 9 schematically illustrates another example workflow for processing nucleicacid molecules.Attorney Docket No.43487-1029601

[0031] FIG. 10 schematically illustrates an example workflow for analyzing cells, nuclei orcell beads.

[0032] FIG. 11 schematically illustrates example labelling agents with nucleic acidmolecules attached thereto.

[0033] FIG. 12A schematically shows an example of labelling agents. FIG. 12Bschematically shows another example workflow for processing nucleic acid molecules. FIG. 12B shows “AAAAAAAAAAA” (SEQ ID NO: 1) and “TTTTTTTTTTTTT” (SEQ ID NO: 2). FIG.12C schematically shows another example workflow for processing nucleic acid molecules. FIG.12C shows “AAAAAAAAAAA” (SEQ ID NO: 1).

[0034] FIG. 13 schematically shows another example of a barcode-carrying bead.

[0035] FIG. 14 shows a computer system that is programmed or otherwise configured toimplement methods provided herein.

[0036] FIGs. 15A-15C shows an example processed nucleic acid molecule described herein.FIG.15A shows 1506 (SEQ ID NO: 3), 1516 (SEQ ID NO: 4), 1519 (SEQ ID NO: 5), 1520 (SEQ ID NO: 6), 1500 (SEQ ID NO: 7), and 1517 (SEQ ID NO: 8). FIG.15B shows 1520 (SEQ ID NO: 6), 1519 (SEQ ID NO: 9), 1506 (SEQ ID NO: 10), 1516 (SEQ ID NO: 11), 1517 (SEQ ID NO: 12), and 1500 (SEQ ID NO: 13). FIG.15C discloses 1506 (SEQ ID NO: 3), 1520 (SEQ ID NO: 6), 1500 (SEQ ID NO: 7), 1516 (SEQ ID NO: 11), 1517 (SEQ ID NO: 14).

[0037]

[0038] FIG. 16A shows an example workflow for processing multiple analytes in a partition.FIG.16B shows another example workflow for processing multiple analytes in a partition.

[0039] FIG. 17 schematically shows a feature-binding group described herein.

[0040] FIG. 18 shows example data from a workflow described herein.

[0041] FIG. 19 shows additional example data from a workflow described herein.

[0042] FIG. 20 shows additional example data from a workflow described herein.

[0043] FIG. 21A shows example data comparing fixed cells and unfixed cells. FIG. 21Bshows additional example data comparing fixed cells and unfixed cells. FIG.21C shows additional example data comparing fixed cells and unfixed cells.

[0044] FIG. 22 schematically shows an example workflow for assaying two different analytetypes.

[0045] FIG. 23 shows example data of a barcoding approach described herein.

[0046] FIG. 24 shows example data of different analyte types using the barcodingapproaches described herein.

[0047] FIG. 25 schematically shows an example method for processing nucleic acidmolecules.Attorney Docket No.43487-1029601

[0048] FIG. 26 shows another example method for processing nucleic acid molecules.

[0049] FIG. 27 shows an example workflow for generating probe-linked nucleic acidmolecules. FIG.27 shows “AAAAAAAAAA” (SEQ ID NO: 15).

[0050] FIG. 28 shows another example workflow for generating probe-linked nucleic acidmolecules.

[0051] FIG. 29 shows an example workflow for processing cells according to the methodsdescribed herein.

[0052] FIG. 30A shows example protein expression data resulting from barcoding ofmultiple analytes using different sample preparation parameters. FIG.30B shows additional protein expression data resulting from barcoding of multiple analytes using different sample preparation parameters.

[0053] FIG. 31 shows example gene expression data resulting from barcoding of multipleanalytes using different sample preparation parameters.

[0054] FIGs. 32A-32C shows example data of multiple analyte probing for a negativecontrol group. FIG.32A shows example data showing different immune cell clusters. FIG.32B shows example data of gene expression of GZMB gene. FIG.32C shows example data of protein expression resulting from antibody staining.

[0055] FIGs. 33A-33C shows example data of multiple analyte probing for an experimentalgroup. FIG.33A shows example data showing different immune cell clusters. FIG.33B shows example data of gene expression of GZMB gene. FIG.33C shows example data of protein expression resulting from antibody staining.

[0056] FIGs. 34A-34C shows example data of multiple analyte probing for an experimentalgroup. FIG.34A shows example data showing different immune cell clusters. FIG.34B shows example data of gene expression of GZMB gene. FIG.34C shows example data of protein expression resulting from antibody staining.

[0057] FIGs. 35A-35C shows example data of multiple analyte probing for an experimentalgroup. FIG.35A shows example data showing different immune cell clusters. FIG.35B shows example data of gene expression of GZMB gene. FIG.35C shows example data of protein expression resulting from antibody staining.

[0058] FIGs. 36A-36C shows example data of multiple analyte probing for an experimentalgroup. FIG.35A shows example data showing different immune cell clusters. FIG.36B shows example data of gene expression of GZMB gene. FIG.36C shows example data of protein expression resulting from antibody staining.

[0059] FIGs. 37A-37C shows example data of multiple analyte probing for an experimentalgroup. FIG.37A shows example data showing different immune cell clusters. FIG.37B showsAttorney Docket No.43487-1029601 example data of gene expression of GZMB gene. FIG.37C shows example data of protein expression resulting from antibody staining.

[0060] FIG. 38 shows another example workflow for assaying two different analyte types.

[0061] FIGs. 39A-39E are an example of time series data for fixed samples.

[0062] FIG. 40 shows a flowchart of a method for analyzing a nucleic acid molecule of anembedded, fixed tissue, according to some embodiments.

[0063] FIG. 41 shows an example of a nucleic acid profiling workflow, according to someembodiments.

[0064] FIG. 42 shows an example of a nucleic acid profiling workflow, according to someembodiments.

[0065] FIG. 43 show an example of a plurality of probe molecules, according to someembodiments.

[0066] FIGs. 44 - 46 show examples of methods of preparation for fixed samples, accordingto some embodiments.

[0067] FIG. 47 provides a table of the pass percentages and other properties for the variousprocedures of the present example, according to some embodiments.

[0068] FIG. 48, shows examples of various tissues processed by the workflows of FIGs. 44– 46, according to some embodiments.

[0069] FIGs. 49A-49D show example cell type clustering for single cell cancer fixed tissues.

[0070] FIGs. 50A and 50B show example tissue dissociation using pestle dissociation.

[0071] FIG. 51 shows an example gentleMACSTM program for tissue dissociation.

[0072] FIG. 52A shows an example of representative cells after dissociation. FIG. 52Bshows an example of representative cells after post-hybridization wash.

[0073] FIG. 53 shows example cell yield from fixed tissue sections.

[0074] FIG. 54 shows an example of a target polynucleotide profiling workflow combinedwith single-cell analysis.

[0075] FIG. 55 provides an example flowchart for analyzing a target polynucleotide.

[0076] FIG. 56 shows an example workflow for analyzing a target polynucleotide.

[0077] FIG. 57 shows an example workflow for analyzing a target polynucleotide.

[0078] FIGs. 58A-58D show an example workflow for analyzing distinct mRNA isoforms.

[0079] FIGs. 59A-59C show example workflows for analyzing a target polynucleotide.DETAILED DESCRIPTION

[0080] While various embodiments of the invention have been shown and described herein,it will be obvious to those skilled in the art that such embodiments are provided by way ofAttorney Docket No.43487-1029601 example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.

[0081] Where values are described as ranges, it will be understood that such disclosureincludes the disclosure of all possible sub-ranges within such ranges, as well as specific numerical values that fall within such ranges irrespective of whether a specific numerical value or specific sub-range is expressly stated.

[0082] The terms “a,” “an,” and “the,” as used herein, generally refers to singular and pluralreferences unless the context clearly dictates otherwise.

[0083] Whenever the term “at least,” “greater than,” or “greater than or equal to” precedesthe first numerical value in a series of two or more numerical values, the term “at least,” “greater than” or “greater than or equal to” applies to each of the numerical values in that series of numerical values. For example, greater than or equal to 1, 2, or 3 is equivalent to greater than or equal to 1, greater than or equal to 2, or greater than or equal to 3.

[0084] Whenever the term “no more than,” “less than,” or “less than or equal to” precedesthe first numerical value in a series of two or more numerical values, the term “no more than,” “less than,” or “less than or equal to” applies to each of the numerical values in that series of numerical values. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1.

[0085] The terms “about” and “approximately,” as used herein, when preceding a numericalvalue indicates the value plus or minus a range of 10%. For example, about 10 may be reasonably understood to convey 9, 10, or 11, or a range of numerical values spanning from 9 to 11. Whenever “about” or “approximately” precedes the first numerical value in a series of two or more numerical values, the term “about” or “approximately” applies to each of the numerical values in that series of numerical values.

[0086] The term “barcode,” as used herein, generally refers to a label, or identifier, thatconveys or is capable of conveying information about an analyte. A barcode can be part of an analyte. A barcode can be independent of an analyte. A barcode can be a tag attached to an analyte (e.g., nucleic acid molecule) or a combination of the tag in addition to an endogenous characteristic of the analyte (e.g., size of the analyte or end sequence(s)). A barcode may be unique. Barcodes can have a variety of different formats. For example, barcodes can include: polynucleotide barcodes; random nucleic acid and / or amino acid sequences; and synthetic nucleic acid and / or amino acid sequences. A barcode can be attached to an analyte in a reversible or irreversible manner. A barcode can be added to, for example, a fragment of a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sample before, during, and / or afterAttorney Docket No.43487-1029601 sequencing of the sample. Barcodes can allow for identification and / or quantification of individual sequencing-reads.

[0087] The term “real time,” as used herein, can refer to a response time of less than about 1second, a tenth of a second, a hundredth of a second, a millisecond, or less. The response time may be greater than 1 second. In some instances, real time can refer to simultaneous or substantially simultaneous processing, detection or identification.

[0088] The term “subject,” as used herein, generally refers to an animal, such as a mammal(e.g., human, mouse, rat) or avian (e.g., bird), or other organism, such as a plant. For example, the subject can be a vertebrate, such as a mammal, a rodent (e.g., a mouse), a primate, a simian or a human. Animals may include, but are not limited to, farm animals, sport animals, and pets. A subject can be a healthy or asymptomatic individual, an individual that has or is suspected of having a disease (e.g., cancer) or a pre-disposition to the disease, and / or an individual that is in need of therapy or suspected of needing therapy. A subject can be a patient. A subject can be a microorganism or microbe (e.g., bacteria, fungi, archaea, viruses).

[0089] The term “genome,” as used herein, generally refers to genomic information from asubject, which may be, for example, at least a portion or an entirety of a subject’s hereditary information. A genome can be encoded either in DNA or in RNA. A genome can comprise coding regions (e.g., that code for proteins) as well as non-coding regions. A genome can include the sequence of all chromosomes together in an organism. For example, the human genome ordinarily has a total of 46 chromosomes. The sequence of all of these together may constitute a human genome.

[0090] The terms “adaptor(s)”, “adapter(s)” and “tag(s)” may be used synonymously. Anadaptor or tag can be coupled to a polynucleotide sequence to be “tagged” by any approach, including ligation, hybridization, or other approaches.

[0091] The term “sequencing,” as used herein, generally refers to methods and technologiesfor determining the sequence of nucleotide bases in one or more polynucleotides. The polynucleotides can be, for example, nucleic acid molecules such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), including variants or derivatives thereof (e.g., single stranded DNA). Sequencing can be performed by various systems currently available, such as, without limitation, a sequencing system by Illumina®, Pacific Biosciences (PacBio®), Oxford Nanopore®, or Life Technologies (Ion Torrent®). Alternatively or in addition, sequencing may be performed using nucleic acid amplification, polymerase chain reaction (PCR) (e.g., digital PCR, quantitative PCR, or real time PCR), or isothermal amplification. Such systems may provide a plurality of raw genetic data corresponding to the genetic information of a subject (e.g., human), as generated by the systems from a sample provided by the subject. In someAttorney Docket No.43487-1029601 examples, such systems provide sequencing reads (also “reads” herein). A read may include a string of nucleic acid bases corresponding to a sequence of a nucleic acid molecule that has been sequenced. In some situations, systems and methods provided herein may be used with proteomic information.

[0092] The term “bead,” as used herein, generally refers to a particle. The bead may be asolid or semi-solid particle. The bead may be a gel bead. The gel bead may include a polymer matrix (e.g., matrix formed by polymerization or cross-linking). The polymer matrix may include one or more polymers (e.g., polymers having different functional groups or repeat units). Polymers in the polymer matrix may be randomly arranged, such as in random copolymers, and / or have ordered structures, such as in block copolymers. Cross-linking can be via covalent, ionic, or inductive, interactions, or physical entanglement. The bead may be a macromolecule. The bead may be formed of nucleic acid molecules bound together. The bead may be formed via covalent or non-covalent assembly of molecules (e.g., macromolecules), such as monomers or polymers. Such polymers or monomers may be natural or synthetic. Such polymers or monomers may be or include, for example, nucleic acid molecules (e.g., DNA or RNA). The bead may be formed of a polymeric material. The bead may be magnetic or non-magnetic. The bead may be rigid. The bead may be flexible and / or compressible. The bead may be disruptable or dissolvable. The bead may be a solid particle (e.g., a metal-based particle including but not limited to iron oxide, gold or silver) covered with a coating comprising one or more polymers. Such coating may be disruptable or dissolvable.

[0093] As used herein, the term “barcoded nucleic acid molecule” generally refers to anucleic acid molecule that results from, for example, the processing of a nucleic acid barcode molecule with a nucleic acid sequence (e.g., nucleic acid sequence complementary to a nucleic acid primer sequence encompassed by the nucleic acid barcode molecule). The nucleic acid sequence may be a targeted sequence or a non-targeted sequence. For example, in the methods and systems described herein, hybridization and reverse transcription of a nucleic acid molecule (e.g., a messenger RNA (mRNA) molecule) of a cell or nucleus with a nucleic acid barcode molecule (e.g., a nucleic acid barcode molecule containing a barcode sequence and a nucleic acid primer sequence complementary to a nucleic acid sequence of the mRNA molecule) results in a barcoded nucleic acid molecule that has a sequence corresponding to the nucleic acid sequence of the mRNA and the barcode sequence (or a reverse complement thereof). A barcoded nucleic acid molecule may serve as a template, such as a template polynucleotide, that can be further processed (e.g., amplified) and sequenced to obtain the target nucleic acid sequence. For example, in the methods and systems described herein, a barcoded nucleic acid molecule may beAttorney Docket No.43487-1029601 further processed (e.g., amplified) and sequenced to obtain the nucleic acid sequence of the mRNA.

[0094] The term “sample,” as used herein, generally refers to a biological sample of asubject. The biological sample may comprise any number of macromolecules, for example, cellular macromolecules. The sample may be a cell sample. The sample may be a cell line or cell culture sample. The sample can include one or more cells or nuclei. The sample can include one or more microbes. The biological sample may be a nucleic acid sample or protein sample. The biological sample may also be a carbohydrate sample or a lipid sample. The biological sample may be derived from another sample. The sample may be a tissue sample, such as a biopsy, core biopsy, needle aspirate, or fine needle aspirate. The tissue sample may be a fresh tissue sample, a frozen tissue sample (e.g., flash frozen, lyophilized, cryo-sectioned, etc.), or a fixed tissue sample (e.g., a formalin-fixed and paraffin-embedded tissue sample). The sample may be a fluid sample, such as a blood sample, urine sample, or saliva sample. The sample may be a skin sample. The sample may be a cheek swab. The sample may be a plasma or serum sample. The sample may be a cell-free or cell free sample. A cell-free sample may include extracellular polynucleotides. Extracellular polynucleotides may be isolated from a bodily sample that may be selected from the group consisting of blood, plasma, serum, urine, saliva, mucosal excretions, sputum, stool and tears.

[0095] The term “biological particle,” as used herein, generally refers to a discrete biologicalsystem derived from a biological sample. The biological particle may be a macromolecule. The biological particle may be a small molecule. The biological particle may be a virus. The biological particle may be a cell or derivative of a cell. The biological particle may be an organelle. Examples of an organelle from a cell include, without limitation, a nucleus, a ribosome, a Golgi apparatus, an endoplasmic reticulum, a chloroplast, an endocytic vesicle, an exocytic vesicle, a vacuole, and a lysosome. The biological particle may be a rare cell from a population of cells. The biological particle may be any type of cell, including without limitation prokaryotic cells, eukaryotic cells, bacterial, fungal, plant, mammalian, or other animal cell type, mycoplasmas, normal tissue cells, tumor cells, or any other cell type, whether derived from single cell or multicellular organisms. The biological particle may be a constituent of a cell. The biological particle may be or may include DNA, RNA, organelles, proteins, or any combination thereof. The biological particle may be or may include a matrix (e.g., a gel or polymer matrix) comprising a cell or one or more constituents from a cell (e.g., cell bead), such as DNA, RNA, organelles, proteins, or any combination thereof, from the cell. The biological particle may be obtained from a tissue of a subject (e.g., a human, a mouse, a rat, or other mammal). The biological particle may be a hardened cell. Such hardened cell may or may not include a cellAttorney Docket No.43487-1029601 wall or cell membrane. The biological particle may include one or more constituents of a cell, but may not include other constituents of the cell. An example of such constituents is a nucleus or an organelle. A cell may be a live cell. The live cell may be capable of being cultured, for example, being cultured when enclosed in a gel or polymer matrix, or cultured when comprising a gel or polymer matrix.

[0096] The term “macromolecular constituent,” as used herein, generally refers to amacromolecule contained within or from a biological particle. The macromolecular constituent may comprise a nucleic acid. In some cases, the biological particle may be a macromolecule. The macromolecular constituent may comprise DNA. The macromolecular constituent may comprise RNA. The RNA may be coding or non-coding. The RNA may be messenger RNA (mRNA), ribosomal RNA (rRNA) or transfer RNA (tRNA), for example. The RNA may be a transcript. The RNA may be small RNA that are less than 200 nucleic acid bases in length, or large RNA that are greater than 200 nucleic acid bases in length. Small RNAs may include 5.8S ribosomal RNA (rRNA), 5S rRNA, transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNAs), Piwi-interacting RNA (piRNA), tRNA-derived small RNA (tsRNA) and small rDNA-derived RNA (srRNA). The RNA may be double-stranded RNA or single-stranded RNA. The RNA may be circular RNA. The macromolecular constituent may comprise a protein. The macromolecular constituent may comprise a peptide. The macromolecular constituent may comprise a polypeptide.

[0097] The term “molecular tag,” as used herein, generally refers to a molecule capable ofbinding to a macromolecular constituent. The molecular tag may bind to the macromolecular constituent with high affinity. The molecular tag may bind to the macromolecular constituent with high specificity. The molecular tag may comprise a nucleotide sequence. The molecular tag may comprise a nucleic acid sequence. The nucleic acid sequence may be at least a portion or an entirety of the molecular tag. The molecular tag may be a nucleic acid molecule or may be part of a nucleic acid molecule. The molecular tag may be an oligonucleotide or a polypeptide. The molecular tag may comprise a DNA aptamer. The molecular tag may be or comprise a primer. The molecular tag may be, or comprise, a protein. The molecular tag may comprise a polypeptide. The molecular tag may be a barcode.

[0098] The term “partition,” as used herein, generally, refers to a space or volume that maybe suitable to contain one or more species or conduct one or more reactions. A partition may be a physical compartment, such as a droplet or well. The partition may isolate space or volume from another space or volume. The droplet may be a first phase (e.g., aqueous phase) in a second phase (e.g., oil) immiscible with the first phase. The droplet may be a first phase in a second phase that does not phase separate from the first phase, such as, for example, a capsule orAttorney Docket No.43487-1029601 liposome in an aqueous phase. A partition may comprise one or more other (inner) partitions. In some cases, a partition may be a virtual compartment that can be defined and identified by an index (e.g., indexed libraries) across multiple and / or remote physical compartments. For example, a physical compartment may comprise a plurality of virtual compartments.

[0099] The term “solid medium,” as used herein, generally refers to a non-gaseous or non-liquid material. The solid medium may comprise a long chain hydrophobic compound, glycerin, gels, hydrogels, epoxy, resin, or any combination thereof. A long chain hydrophobic compound may include a wax, such as paraffin wax.

[0100] Provided herein are methods for sample processing and / or analysis. A method of thepresent disclosure comprise barcoding one or more types of biomolecules (e.g., a nucleic acid molecule, a protein, a lipid, a carbohydrate, or a combination thereof). The biomolecule may be, for instance, a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule) or a protein. Such a method may involve attaching one or more probes (e.g., nucleic acid probes) to the biomolecules and subsequently attaching a nucleic acid barcode molecule comprising a barcode sequence to the one or more probes. For example, the nucleic acid barcode molecule may attach to an overhanging sequence of a probe or to the end of a probe. Extension from an end of the probe to an end of the nucleic acid barcode molecule may form an extended nucleic acid molecule comprising both a sequence complementary to the barcode sequence and a sequence complementary to a target region of the nucleic acid molecule. The extended nucleic acid molecule may then be denatured from the nucleic acid barcode molecule and the nucleic acid molecule may be duplicated. One or more processes of the method may be carried out within a partition such as a droplet or well.

[0101] The present disclosure also provides a method of processing a sample (e.g., a cellsample or a tissue sample) that provides a barcoded nucleic acid molecule having linked probe molecules attached thereto. The method may comprise providing a sample comprising a nucleic acid molecule (e.g., an RNA molecule) having a first and second target region; a first probe having a (i) first probe sequence that is complementary to the first target region and (ii) an additional probe sequence; and a second probe having a second probe sequence that is complementary to the second target region. In some instances, the first target region and the second target region are adjacent. The first and second probe sequences may also comprise first and second reactive moieties, respectively. Upon hybridization of the first probe sequence of the first probe to the first target region of the nucleic acid molecule, and hybridization of the second probe sequence of the second probe to the second target region of the nucleic acid molecule, the reactive moieties may be adjacent to one another. Subsequent reaction between the adjacent reactive moieties under sufficient conditions may link the first and second probes to yield aAttorney Docket No.43487-1029601 probe-linked nucleic acid molecule. The probe-linked nucleic acid molecule may also be referred to as a probe-ligated nucleic acid molecule. In other instances, the first target region and the second target region are not adjacent, and a nucleic acid reaction (e.g., a nucleic acid extension reaction, a gap-filling reaction) may be performed to yield a probe-linked nucleic acid molecule.

[0102] The probe-linked nucleic acid molecule may be barcoded with a barcode sequence ofa nucleic acid barcode molecule to provide a barcoded probe-linked nucleic acid molecule. Barcoding may be achieved by hybridizing a binding sequence of the nucleic acid barcode molecule to the additional probe sequence of the first probe of the probe-linked nucleic acid molecule. The barcoded probe linked-nucleic acid molecule may be subjected to amplification reactions to yield an amplified product comprising the first and second target regions and the barcode sequence or sequences complementary to these sequences. Accordingly, the method may provide amplified products without the use of reverse transcription. One or more processes may be performed within a partition such as a droplet or well.

[0103] The present disclosure also provides a method of generating barcoded, probe-linkednucleic acid molecules. The method may comprise providing a sample comprising a nucleic acid molecule (e.g., an RNA molecule) having a first target region and a second target region; a first probe having a first probe sequence that is complementary to the first target region and optionally an additional probe sequence; and a second probe having a second probe sequence that is complementary to the second target region. The additional probe sequence of the first probe may comprise a probe capture sequence. Alternatively or in addition to, the second probe may comprise a probe capture sequence. The first probe sequence of the first probe may hybridize to the first target region of the nucleic acid molecule, generating a probe-associated nucleic acid molecule, and a nucleic acid reaction (e.g., a nucleic acid extension reaction using a polymerase or reverse transcriptase) may be performed to generate an extended nucleic acid molecule comprising a sequence complementary to the second target region. Prior to, during, or subsequent to the nucleic acid extension reaction, the second probe may hybridize to the nucleic acid molecule (or extended nucleic acid molecule, or complement thereof), and optionally, a nucleic acid extension reaction may be performed. The extended nucleic acid molecule may be barcoded, such as by (a) hybridization of a barcode binding sequence of the nucleic acid barcode molecule to the first probe (e.g., the additional probe sequence of the first probe) or the second probe (e.g., a probe capture sequence of the second probe), or (b) via a probe binding molecule (also referred to herein as a “splint molecule” or “splint oligonucleotide”), in which the probe binding molecule comprises (i) a probe binding sequence complementary to the additional probe sequence of the first probe (which may comprise the probe capture sequence) and / or a captureAttorney Docket No.43487-1029601 sequence of the second probe and a (ii) barcode binding sequence complementary to a sequence (e.g., a common sequence) of the barcode molecule. In some instances, the barcoding may be performed prior to hybridization of the second probe to the second target region. In such cases, the barcoded nucleic acid molecule may be subjected to conditions sufficient for hybridization of the second probe sequence of the second probe to the second target region of the nucleic acid molecule (or barcoded nucleic acid molecule). A nucleic acid reaction (e.g., nucleic acid extension) may be performed, thereby generating a barcoded, probe-linked nucleic acid molecule.

[0104] Another aspect of the present disclosure provides a method of barcoding multipleanalytes, such as the probe-linked nucleic acid molecules described herein, as well as other types of biomolecules (e.g., proteins). The method may comprise providing (i) a sample comprising a nucleic acid molecule (e.g., an RNA molecule) having first and second target regions and (ii) a feature-binding moiety comprising a reporter oligonucleotide comprising a capture sequence; (iii) a first probe having a first probe sequence that is complementary to the first target region and an additional probe sequence; (iv) a second probe having a second probe sequence that is complementary to the second target region; and (v) a third probe having a third probe sequence that is complementary to a sequence of the reporter oligonucleotide. The first probe and the second probe may be subjected to conditions sufficient to hybridize to the first target region and the second target region, respectively, and to generate a probe-linked nucleic acid molecule. The third probe sequence of the third probe may be subjected to conditions sufficient to hybridize to the capture sequence of the reporter oligonucleotide, generating a probe-binding moiety complex. The probe-linked nucleic acid molecule and the probe-binding moiety complex may be subjected to conditions sufficient for barcoding, thereby generating a barcoded probe-linked nucleic acid molecule and a barcoded probe-binding moiety complex. The barcoded probe- linked molecule may be subjected to amplification reactions to yield an amplified product comprising the first and second target regions and the barcode sequence or sequences complementary to these sequences. The barcoded probe-binding moiety complex may similarly be subjected to amplification reactions to yield an amplified product comprising the fourth probe sequence and the barcode sequence. One or more processes may be performed within a cell bead and / or a partition, such as a droplet or well. Beneficially, the methods described herein may be useful in indexing cells, nuclei, or cell beads to partitions; such indexing may be useful in partitions occupied by more than one cell and identifying the cell, nucleus, cell bead or partition from which an analyte was derived.Attorney Docket No.43487-1029601 Fixed Samples

[0105] A sample may be a fixed sample. For example, a sample may comprise a plurality offixed samples, such as a plurality of fixed cells or fixed nuclei. Alternatively or in addition, a sample may comprise a fixed tissue. Fixation of cell or cellular constituent, or a tissue comprising a plurality of cells or nuclei, may comprise application of a chemical species or chemical stimulus. The term “fixed” as used herein with regard to biological samples generally refers to the state of being preserved from decay and / or degradation. “Fixation” generally refers to a process that results in a fixed sample, and in some instances can include contacting the biomolecules within a biological sample with a fixative (or fixation reagent) for some amount of time, whereby the fixative results in covalent bonding interactions such as crosslinks between biomolecules in the sample. A “fixed biological sample” may generally refer to a biological sample that has been contacted with a fixation reagent or fixative. For example, a formaldehyde- fixed biological sample has been contacted with the fixation reagent formaldehyde. “Fixed cells”, “fixed nuclei” or “fixed tissues” refer to cells / nuclei or tissues that have been in contact with a fixative under conditions sufficient to allow or result in the formation of intra- and inter- molecular covalent crosslinks between biomolecules in the biological sample. Generally, contact of biological sample (e.g., a cell or nucleus) with a fixation reagent (e.g., paraformaldehyde or PFA) results in the formation of intra- and inter-molecular covalent crosslinks between biomolecules in the biological sample. In some cases, the fixation reagent, formaldehyde, may result in covalent aminal crosslinks within RNA, DNA, and / or protein molecules. For example, the widely used fixative reagent, paraformaldehyde or PFA, fixes tissue samples by catalyzing crosslink formation between basic amino acids in proteins, such as lysine and glutamine. Both intra-molecular and inter-molecular crosslinks can form in the protein. These crosslinks can preserve protein secondary structure and also eliminate enzymatic activity in the preserved tissue sample. Examples of fixation reagents include but are not limited to aldehyde fixatives (e.g., formaldehyde, also commonly referred to as “paraformaldehyde,” “PFA,” and “formalin”; glutaraldehyde; etc.), imidoesters, NHS (N-Hydroxysuccinimide) esters, and the like.

[0106] In some embodiments, the fixative or fixation reagent useful for fixing samples isformaldehyde. The term “formaldehyde” when used in the context of a fixative may also refer to “paraformaldehyde” (or “PFA”) and “formalin”, both of which are terms with specific meanings related to the formaldehyde composition (e.g., formalin is a mixture of formaldehyde and methanol). Thus, a formaldehyde-fixed biological sample may also be referred to as formalin- fixed or PFA-fixed. Protocols and methods for the use of formaldehyde as a fixation reagent to prepare fixed biological samples are well known in the art and can be used in the methods and compositions of the present disclosure. For example, suitable ranges of formaldehydeAttorney Docket No.43487-1029601 concentrations for use in preparing a fixed biological sample is 0.1 to 10%, 1-8%, 1-4%, 1-2%, 3-5%, or 3.5-4.5%. In some embodiments of the present disclosure the biological sample is fixed using a final concentration of 1% formaldehyde, 4% formaldehyde, or 10% formaldehyde. The formaldehyde can be diluted from a more concentrated stock solution – e.g., a 35%, 25%, 15%, 10%, 5% PFA stock solution.

[0107] Other examples of fixatives include, for example, organic solvents such as alcohols(e.g., methanol or ethanol), ketones (e.g., acetone), and aldehydes (e.g., paraformaldehyde, formaldehyde (e.g., formalin), or glutaraldehyde). As described herein, cross-linking agents may also be used for fixation including, without limitation, disuccinimidyl suberate (DSS), dimethylsuberimidate (DMS), formalin, and dimethyladipimidate (DMA), dithio-bis(- succinimidyl propionate) (DSP), disuccinimidyl tartrate (DST), and ethylene glycol bis(succinimidyl succinate) (EGS). In some cases, a cross-linking agent may be a cleavable cross-linking agent (e.g., thermally cleavable, photocleavable, etc.).

[0108] In some cases, more than one fixation reagent can be used in combination whenpreparing a fixed biological sample. For example, a first fixation agent, such as an organic solvent, may be used in combination with a second fixation agent, such as a cross-linking agent. The organic solvent may be an alcohol (e.g., ethanol or methanol), ketone (e.g., acetone), or aldehyde (e.g., paraformaldehyde, formaldehyde, or glutaraldehyde). The cross-linking agent may be selected from the group consisting of disuccinimidyl suberate (DSS), dimethylsuberimidate (DMS), formalin, and dimethyladipimidate (DMA), dithio-bis(- succinimidyl propionate) (DSP), disuccinimidyl tartrate (DST), and ethylene glycol bis(succinimidyl succinate) (EGS). In some cases, a first fixation agent may be provided to or brought into contact with the cell or nucleus to bring about a change in a first characteristic or set of characteristics of the cell / nucleus, and a fixation agent may be provided to or brought into contact with the cell or nucleus to bring about a change in a second characteristic or set of characteristics of the cell or nucleus. For example, a first fixation agent may be provided to or brought into contact with a cell or nucleus to bring about a change in a dimension of the cell (e.g., a reduction in cross-sectional diameter, see, e.g., U.S. Pat. Pub. No.2020 / 0033237, which is incorporated herein by reference in its entirety), and a second fixation agent may be provided to or brought into contact with a cell or nucleus to bring about a change in a second characteristic or set of characteristics of the cell (e.g., forming crosslinks within and / or surrounding the cell or nucleus). The first and second fixation agents may be provided to or brought into contact with the cell or nucleus at the same or different times. Other suitable fixing agents include those disclosed in, e.g., International PCT App. No. PCT / US2020 / 066705, which is incorporated herein by reference in its entirety.Attorney Docket No.43487-1029601

[0109] In an example, a first fixation agent that is an organic solvent may be provided to acell to change a first characteristic (e.g., cell size) and a second fixation agent that is a cross- linking agent may be provided to a cell to change a second characteristic (e.g., cell fluidity or rigidity). The first fixation agent may be provided to the cell before the second fixation agent.

[0110] In another embodiment, biomolecules (e.g., biological samples such as tissuespecimens) are contacted with a fixation reagent containing both formaldehyde and glutaraldehyde, and thus the contacted biomolecules can include fixation crosslinks resulting both from formaldehyde induced fixation and glutaraldehyde induced fixation. A suitable concentration of glutaraldehyde can be used for use as a fixation reagent can be 0.1 to 1%. Fixation and wash reagents may also include commercially available products, e.g., BioLegend® Fixation Buffer (420801) and Permeabilization Wash Buffer (421002).

[0111] Changes to a characteristic or a set of characteristics of a cell or cellular constituents(e.g., incurred upon interaction with one or more fixation agents) may be at least partially reversible (e.g., via rehydration or de-crosslinking). Alternatively, changes to a characteristic or set of characteristics of a cell or cellular constituents (e.g., incurred upon interaction with one or more fixation agents) may be substantially irreversible.

[0112] A sample (e.g., a cell sample) may be subjected to a fixation process at any usefulpoint in time. For example, cells, nuclei and / or cellular / nuclear constituents of a sample may be subjected to a fixation process involving one or more fixation agents (e.g., as described herein) prior to commencement of any subsequent processing, such as for storage. Cells, nuclei and / or cellular / nuclear constituents, such as cells, nuclei and / or cellular / nuclear constituents of a tissue sample, subjected to a fixation process prior to storage, may be stored in an aqueous solution, optionally in combination with one or more preserving agents configured to preserve morphology, size, or other features of the cells and / or cellular components. Fixed cells, nuclei and / or cellular / nuclear constituents may be stored below room temperature, such as in a freezer. Alternatively, cells, nuclei and / or cellular / nuclear constituents of a sample may be subjected to a fixation process involving one or more fixation agents subsequent to one or more other processes, such as filtration, centrifugation, agitation, selective precipitation, purification, permeabilization, isolation, heating, etc. For example, cells, nuclei, and / or cellular / nuclear constituents of a given type from a sample may be subjected to a fixation process following a separation and / or enrichment procedure (e.g., as described herein). In an example, a sample comprising a plurality of cells including a plurality of cells of a given type may be subjected to a positive separation process to provide a sample enriched in the plurality of cells of the given type. The enriched sample may then be subjected to a fixation process involving one or more fixation agents (e.g., as described herein) to provide an enriched sample comprising a plurality ofAttorney Docket No.43487-1029601 fixed cells. A fixation process may be performed in a bulk solution. In some cases, fixed samples (e.g., fixed cells, fixed nuclei, and / or cellular / nuclear constituents) may be partitioned amongst a plurality of partitions (e.g., droplets or wells) and subjected to processing as described elsewhere herein. In some cases, fixed samples may undergo additional processing, such as partial or complete reversal of a fixation process by, for example, rehydration or de-crosslinking, prior to partitioning and any subsequent processing. In some cases, fixed samples may undergo partial or complete reversal of a fixation process within a plurality of partitions (e.g., prior to or concurrent with additional processing described elsewhere herein).

[0113] In some cases, a tissue specimen comprising a plurality of cells, nuclei and / orcellular / nuclear constituents may be processed to provide formalin-fixed paraffin-embedded (FFPE) tissue. A tissue specimen may be contacted (e.g., saturated) with formalin and then embedded in a solid medium. In an example, the solid medium may be paraffin wax. FFPE processing may facilitate preservation of a tissue sample (e.g., prior to subsequent processing and analysis). A tissue sample, including an FFPE tissue sample, may additionally or alternatively be subjected to storage in a low-temperature freezer. Cells, nuclei and / or cellular / nuclear constituents may be dissociated from a tissue sample (e.g., FFPE tissue sample) prior to undergoing subsequent processing. In some cases, individual cells, nuclei and / or cellular / nuclear constituents of a tissue sample such as an FFPE tissue sample may be optically detected, labeled, or otherwise processed prior to any such dissociation. Such detection, labeling, or other processing may be performed according to a 2- or 3-dimensional array and optionally according to a pre-determined pattern. In some cases, a tissue specimen may be embedded in other materials such as, for example, optimal cutting temperature (OCT) compound, crosslinking-based supports (e.g., polymers), or the like.

[0114] The tissue specimen may have been fixed at least about 1 day (d), 2 d, 3 d, 4 d, 5 d, 6d, 1 week (wk), 2 wk, 3 wk, 1 month (m), 2 m, 3 m, 4 m, 5 m, 6 m, 7 m, 8 m, 9 m, 10 m, 11 m, 1 year (y), 2 y, 3 y, 4 y, 5 y, 6 y, 7 y, 8 y, 9 y, 10 y, 15 y, 20 y, 25 y, 30 y, 35 y, 40 y, 45 y, 50 y, or longer before use in the methods and systems described elsewhere herein.

[0115] In some cases, preparation of a fixed sample may comprise securing and sectioning atleast a portion of a fixed sample (e.g., via microtomy, ultramicrotomy, etc.). The fixed sample may be sectioned into one or more (e.g., a plurality) of scrolls. The fixed tissue (e.g., a scroll) may be at least about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more micrometers in thickness. The sectioning and / or securing may be performed at ambient temperature. The sectioning and / or securing may be performed at temperatures above or below ambient temperature. The fixed tissue (e.g., a scroll) may have a mass of at least about 100 micrograms (µg), 150 µg, 200 µg 250 µg, 300 µg, 350 µg, 400 µg, 450 µg, 500 µg, 550 µg, 600 µg, 650 µg,Attorney Docket No.43487-1029601 700 µg, 750 µg, 800 µg, 850 µg, 900 µg, 950 µg, 1 milligram (mg), 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1 gram (g), 1.25 g, 1.5 g, 1.75 g, 2 g, 2.25 g, 2.5 g, 2.75 g, 3 g, 3.25 g, 3.5 g, 3.75 g, 4 g, 4.25 g, 4.5 g, 4.75 g, 5 g, 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 40 g, 45 g, 50 g, or more. The fixed tissue (e.g., a scroll) may have a mass of at most about 50 g, 45 g, 40 g, 35 g, 30 g, 25 g, 20 g, 15 g, 10 g, 5 g, 4.75 g, 4.5 g, 4.25 g, 4 g, 3.75 g, 3.5 g, 3.25 g, 3 g, 2.75 g, 2.5 g, 2.25 g, 2 g, 1.75 g, 1.5 g, 1.25 g, 1 g, 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg, 100 mg, 95 mg, 90 mg, 85 mg, 80 mg, 75 mg, 70 mg, 65 mg, 60 mg, 55 mg, 50 mg, 45 mg, 40 mg, 35 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg, 9 mg, 8 mg, 7 mg, 6 mg, 5 mg, 4 mg, 3 mg, 2 mg, 1 mg, 950 µg, 900 µg, 850 µg, 800 µg, 750 µg, 700 µg, 650 µg, 600 µg, 550 µg, 500 µg, 450 µg, 400 µg, 350 µg, 300 µg, 250 µg, 200 µg, 150 µg, 100 µg, or less. The fixed tissue (e.g., a scroll) may have a mass in a range as defined by any two of the preceding values. For example, a fixed tissue or a scroll can have a mass from about 100 micrograms to about 5 grams.

[0116] In some cases, the scroll can be mechanically and / or enzymatically dissociated. Themechanical dissociation may comprise sonication (e.g., sonication at below ambient temperatures). The sonication may comprise a sonication at a power of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 65, 80, 85, 90, 95, or 100 percent power. The sonication may comprise sonication at a power of at most about 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, or less percent power. The sonication may be for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 30, 45, 60, or more minutes. The sonication may be for at most about 60, 45, 30, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or fewer minutes. The mechanical dissociation may comprise use of a shake plate. For example, the sample can be placed in a sample tube, and the sample tube can be shaken on a shake plate. The mechanical dissociation may comprise stirring the sample.

[0117] In some optional cases, the fixed sample may be processed to remove one or morefixatives and / or supports (e.g., solid medium). For example, the fixed sample can be deparaffinized. In some cases, the fixed sample may not be processed to remove the one or more fixatives and / or supports (e.g., solid medium). For example, a fixed sample can be used as sectioned (e.g., a scroll). Examples of processes include use of one or more non-polar solvents (e.g., linear alkanes, cyclic alkanes, benzene, xylenes, neo-clear, orange oil, other substituted or non-substituted alkanes, or the like, or any combination thereof). In an example, the non-polar solvent is xylene. The removal of the one or more fixatives and / or supports (e.g., solid medium)Attorney Docket No.43487-1029601 may be repeated (e.g., for more complete removal of the one or more fixatives and / or supports). In some optional cases, the sample may be rehydrated (e.g., via water addition, ethanol rehydration, gaseous rehydration, or the like, or any combination thereof). For example, ethanolic solutions of water with increasing water concentration can be used to rehydrate the sample. In some cases, the sample can be analyzed without rehydration. The sample may be washed using a polar (e.g., aqueous) solution to remove additional impurities. For example, an aqueous solution of phosphate buffered saline can be used to remove impurities from a sample.

[0118] One or more dissociation solutions comprising, for example, liberase with lowthermolysis (TL), liberase with medium thermolysis (TM), liberase with high thermolysis (TH), collagenases, or the like, or any combination thereof may be added to process a sample. The dissociation sample may be added at ambient (e.g., room) temperature. The dissociation solution be heated prior to the addition. The dissociation solution may be cooled prior to the addition. The dissociation sample may be at a temperature of at least about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34, 36, 37, 38, 39, 40, or more degrees Celsius when added. The dissociation solution may be at a temperature of at most about 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, or fewer degrees Celsius when added. The dissociation solution may be added at a temperature in a range as defined by any two of the proceeding values. The sample may be titrated at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or more times to form a cellular suspension. In some cases, impurities (e.g., paraffin) can be removed by allowing the suspension to rest, and the impurities can precipitate from the solution, and the purified solution can be removed and further processed.

[0119] A liberase can comprise one or more enzymes configured to degrade at least a portionof a biological molecule. For example, the liberase can comprise one or more collagenases. The collagenases can comprise one or more isoforms of collagenase, collagenase I, collagenase II, or the like, or any combination thereof. The collagenase isoforms may be present in ratios between the various isoforms of at least about 1:20, 1:19, 1:18, 1:17, 1:16, 1:15, 1:14, 1:13, 1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, or more. In some cases, a composition comprising the one or more enzymes can comprise a dispase. The dispase may be a protease (e.g., a neutral protease, etc.). The dispase may be a non-clostridial dispase. A composition comprising the one or more enzymes may comprise thermolysin. The thermolysin can be a protease (e.g., a neutral protease, etc.). The thermolysin can be a non-clostridial thermolysin. A composition comprising the one or more enzymes may comprise a plurality of additional components as described elsewhere herein (e.g., a dispase, a thermolysin, etc.).Attorney Docket No.43487-1029601

[0120] The sample may be filtered one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more)times. The filtration may comprise use of one or more different sizes (e.g., pore sizes) of filter. The filter may comprise a pore size of at most about 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, 1, or less micrometers. For example, a first filtration with a 70 micrometer pore size filter can be performed. In this example, a second filtration with a 30 micrometer filtration can be performed, which can reduce debris (e.g., undissolved paraffin or other support) without reducing cellular recovery from the sample. The filtrate and the cellular suspension may be combined and subsequently centrifuged. The centrifugation may occur at a value of at least about 100, 200, 300, 400, 500, 600, 700, 850, 900, 950, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 3,000, or more reciprocal centrifugal force (rcf). The centrifugation may occur at a value of at most about 3,000, 2,500, 2,400, 2,300, 2,200, 2,100, 2,000, 1,900, 1,800, 1,700, 1,600, 1,500, 1,400, 1,300, 1,200, 1,100, 1,000, 950, 900, 850, 800, 700, 600 ,500, 400, 300, 200, 100, or fewer rcf. The centrifugation may be performed at a value within a range as defined by any two of the proceeding values. For example, the centrifugation may be performed at a value of about 850 to about 2,000 rcf.

[0121] In some cases, the solution can be removed from the centrifuged pellet (e.g., withoutdisturbing the pellet). In some cases, the pellet can be resuspended into solution. For example, the pellet can be resuspended into a buffer solution.

[0122] The resuspended solution can then be analyzed (e.g., to determine cellularconcentration). Examples of cellular concentration determination systems include, but are not limited to the Countess II FL Automated Cell Counter, Cellaca MX High-Throughput Automated Cell Counter, or the like using a fluorescent dye (e.g., ethidium homodimer-1, etc.) or AO / PI staining solution, or the like. The resuspended solution may then be used as a sample for the methods and systems described elsewhere herein (e.g., RNA profiling, etc.).

[0123] In some cases, use of a fixed sample (e.g., an FFPE sample) with the methods andsystems described elsewhere herein may provide different information as compared to use of a fresh sample. For example, the fixation process may capture ephemeral states of the cells of the sample and / or ephemeral types of cells in the sample that may not be captured in fresh samples. In this way, cellular processes can be investigated in different ways by use of fixed samples. In some cases, use of the methods and systems described elsewhere herein on fixed samples may provide unexpected improvements to the analysis of the fixed samples, such as improved sensitivity versus other analysis methods as well as the aforementioned analysis of different ephemeral states / types within the sample. In some cases, the use of fixed samples may permit time series analysis of samples (e.g., samples can be fixed at different times and later analyzed).Attorney Docket No.43487-1029601 Such a time series analysis may provide information related to the evolution of states and / or cell types within the samples. Methods of Nucleic Acid Analysis

[0124] In an aspect, the present disclosure provides a method for barcoding nucleic acidmolecules. The method may generally comprise contacting a nucleic acid molecule with a pair of probes and a barcode molecule to generate a barcoded molecule (e.g., a barcoded probe-linked molecule). The nucleic acid molecule may comprise a sequence corresponding to a target sequence or a template sequence. One or more nucleic acid reactions (e.g., a ligation, a nucleic acid extension reaction, amplification, etc.) may be performed to generate the barcoded molecule. In some aspects, the method comprises: contacting a nucleic acid molecule with a first probe to generate a probe-associated nucleic acid molecule, wherein the nucleic acid molecule comprises a first target region and a second target region, wherein the first probe comprises a first probe sequence complementary to the first target region; performing a nucleic acid reaction (e.g., a nucleic acid extension reaction, e.g., by using a polymerase or reverse transcriptase, etc.) to generate an extended probe molecule comprising a sequence complementary to the second target region; providing (i) a second probe comprising a second probe sequence corresponding to or complementary to the second target region and (ii) a nucleic acid barcode molecule; and subjecting the extended probe molecule or derivative thereof to conditions sufficient to generate a barcoded molecule. The first target region and the second target region may be disposed adjacent to one another or may be separate from one another (e.g., disposed on opposite ends of a gap region). In some instances, barcoding may be facilitated by providing a probe binding molecule (also referred to herein as a “splint molecule” or in some instances, a “splint oligonucleotide”). For example, the first probe and / or the second probe may comprise a probe capture sequence, and the probe-binding molecule may comprise a probe-binding sequence complementary to the probe capture sequence. In addition to or alternatively, the nucleic acid barcode molecule may comprise a barcode sequence and a barcode capture sequence, and the probe-binding molecule may comprise a barcode binding sequence complementary to the barcode capture sequence. In some instances, the probe-binding molecule may be pre-annealed to the nucleic acid barcode molecule. Barcoding may comprise hybridization of the probe binding molecule to the probe capture sequence (or complement thereof) of the first probe and / or second probe and to the barcode capture sequence of the nucleic acid barcode molecule. Accordingly, the barcoded molecule may comprise a sequence corresponding to the first target region, a sequence corresponding to the second target region, a sequence corresponding to theAttorney Docket No.43487-1029601 probe capture sequence, and a sequence corresponding to the barcode sequence. One or more operations may be performed within a partition (e.g., droplet or well).

[0125] The methods described herein may facilitate gene expression profiling with single-cell, single-nucleus or single-cell bead resolution using, for example, nucleic acid extension reactions, probe hybridization, chemical or enzymatic ligation, barcoding, amplification, and sequencing. The methods described herein may allow for gene expression analysis while avoiding the use of specialized imaging equipment and, in certain instances, reverse transcription, which may be highly error prone and inefficient. In some instances, the methods may be used to analyze a pre-determined panel of target genes in a population of single cells, nuclei, or cell beads in a sensitive and accurate manner. The methods described herein may also be useful in detecting or characterizing genetic variants, for example, in instances where the sequence of a region disposed between the target regions (e.g., a gap region) is not known. In some cases, the methods described herein may be useful in analyzing a single nucleotide polymorphism (SNP), an alternative-spliced junction, an insertion, a mutation, a deletion, a gene rearrangement (e.g., V(D)J rearrangements), a transposon, or other genetic element or variants. In some cases, the nucleic acid molecule analyzed by the methods described herein may comprise a fusion gene (e.g., a hybrid gene generated via translocation, interstitial deletion, or chromosomal inversion). In some cases, the methods described herein may be useful in analyzing genomic, transcriptomic, exomic and / or proteomic elements in cells, nuclei, cell beads, tissue samples, spatial arrays of cells, nuclei or tissues, etc.

[0126] The nucleic acid molecule analyzed by the methods described herein may be a single-stranded or a double-stranded nucleic acid molecule. A double-stranded nucleic acid molecule may be completely or partially denatured to provide access to a target region (e.g., a target sequence) of a strand of the nucleic acid molecule. Denaturation may be achieved by, for example, adjusting the temperature or pH of a solution comprising the nucleic acid molecule; using a chemical agent such as formamide, guanidine, sodium salicylate, dimethyl sulfoxide, propylene glycol, urea, or an alkaline agent (e.g., NaOH); or using mechanical agitation (e.g., centrifuging or vortexing a solution including the nucleic acid molecule).

[0127] The nucleic acid molecule may be a target nucleic acid molecule. The target nucleicacid molecule may be an RNA molecule. The RNA molecule may be, for example, a transfer RNA (tRNA) molecule, ribosomal RNA (rRNA) molecule, mitochondrial RNA (mtRNA) molecule, messenger RNA (mRNA) molecule, non-coding RNA molecule, synthetic RNA molecule, or another type of RNA molecule. For example, the RNA molecule may be an mRNA molecule. In some cases, the nucleic acid molecule may be a viral or pathogenic RNA. In some cases, the nucleic acid molecule may be a synthetic nucleic acid molecule previously introducedAttorney Docket No.43487-1029601 into or onto a cell. For example, the nucleic acid molecule may comprise a plurality of barcode sequences, and two or more barcode sequences may be target regions of the nucleic acid molecule. In some instances, the nucleic acid molecule is a guide RNA (gRNA), which may be exogenously introduced in a cell or cell bead. In some instances, the nucleic acid molecule is an RNA molecule derived from an exogenously introduced nucleic acid molecule, e.g., an RNA derived from a plasmid, an integrated DNA sequence (e.g. using viral transduction in a cell), a gRNA from a CRISPR genetic element, etc.

[0128] The nucleic acid molecule (e.g., RNA molecule) may comprise one or more featuresselected from the group consisting of a 5’ cap structure, an untranslated region (UTR), a 5’ triphosphate moiety, a 5’ hydroxyl moiety, a Kozak sequence, a Shine-Dalgarno sequence, a coding sequence, a codon, an intron, an exon, an open reading frame, a regulatory sequence, an enhancer sequence, a silencer sequence, a promoter sequence, and a poly(A) sequence (e.g., a poly(A) tail). For example, the nucleic acid molecule may comprise one or more features selected from the group consisting of a 5’ cap structure, an untranslated region (UTR), a Kozak sequence, a Shine-Dalgarno sequence, a coding sequence, and a poly(A) sequence (e.g., a poly(A) tail).

[0129] Features of the nucleic acid molecule may have any useful characteristics. A 5’ capstructure may comprise one or more nucleoside moieties joined by a linker such as a triphosphate (ppp) linker. A 5’ cap structure may comprise naturally occurring nucleoside and / or non- naturally occurring (e.g., modified) nucleosides. For example, a 5’ cap structure may comprise a guanine moiety or a modified (e.g., alkylated, reduced, or oxidized) guanine moiety such as a 7- methylguanylate (m7G) cap. Examples of 5’ cap structures include, but are not limited to, m7GpppG, m7Gpppm7G, m7GpppA, m7GpppC, GpppG, m2,7GpppG, m2,2,7GpppG, and anti- reverse cap analogs such as m7,2’OmeGpppG, m7,2’dGpppG, m7,3’OmeGpppG, and m7,3’dGpppG. An untranslated region (UTR) may be a 5’ UTR or a 3’ UTR. A UTR may include any number of nucleotides. For example, a UTR may comprise at least 3, 5, 7, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more nucleotides. In some cases, a UTR may comprise fewer than 20 nucleotides. In other cases, a UTR may comprise at least 100 nucleotides, such as more than 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides. Similarly, a coding sequence may include any number of nucleotides, such as at least 3, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more nucleotides. A UTR, coding sequence, or other sequence of a nucleic acid molecule may have any nucleotide or base content or arrangement. For example, a sequence of a nucleic acid molecule may comprise any number or concentration of guanine, cytosine, uracil, and adenine bases. A nucleic acid molecule may also include non-naturally occurring (e.g., modified) nucleosides. AAttorney Docket No.43487-1029601 modified nucleoside may comprise one or more modifications (e.g., alkylations, hydroxylation, oxidation, or other modification) in its nucleobase and / or sugar moieties.

[0130] The nucleic acid molecule may comprise one or more target regions. In some cases, atarget region may correspond to a gene or a portion thereof. Each region may have the same or different sequences. For example, the nucleic acid molecule may comprise two target regions having the same sequence located at different positions along a strand of the nucleic acid molecule. Alternatively, the nucleic acid molecule may comprise two or more target regions having different sequences. Different target regions may be interrogated by different probes. Target regions may be located adjacent to one another or may be spatially separated along a strand of the nucleic acid molecule. The target regions may be located on the same strand or different strands. As used herein with regard to two entities, “adjacent,” may mean that the entities directly next to one other (e.g., contiguous) or in proximity to one another. For example, a first target region may be directly next to a second target region (e.g., having no other entity disposed between the first and second target regions) or in proximity to a second target region (e.g., having an intervening sequence or molecule between the first and second target regions). In some cases, a double-stranded nucleic acid molecule may comprise a target region in each strand that may be the same or different. For a nucleic acid molecule comprising multiple target regions, the methods described herein may be performed for one or more target regions at a time. For example, a single target region of the multiple target regions may be analyzed (e.g., as described herein) or two or more target regions may be analyzed at the same time. Analyzing two or more target regions may involve providing two or more probes, where a first probe has a sequence that is complementary to the first target region, a second probe has a sequence that is complementary to the second target region, etc.

[0131] Each probe (e.g., the first probe and the second probe) may further comprise one ormore additional sequences (e.g., additional probe sequences, unique molecular identifiers (UMIs), a barcode sequence, a primer sequence, a capture sequence, or other functional sequence). For example, in some instances, the first probe and / or the second probe may comprise the same or different barcode sequences. In some examples, the first probe and the second probe may be configured to hybridize to one or more nucleic acid barcode molecules. For example, the first probe and / or the second probe may comprise a probe capture sequence, which may be configured to hybridize to a nucleic acid barcode molecule or to a probe binding molecule (e.g., a splint oligonucleotide) that is configured to hybridize to a nucleic acid barcode molecule (e.g., via a barcode binding sequence that is complementary to a capture sequence of the nucleic acid barcode molecule). The probe capture sequence may be any useful length; for example, the probe capture sequence may be about 1, about 2, about 3, about 4, about 5, about 6, about 7,Attorney Docket No.43487-1029601 about 8, about 9, about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100 or more nucleotides in length. The probe capture sequence may be at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100 or more nucleotides in length. The probe capture sequence may be at most 100, at most 90, at most 80, at most 70, at most 60, at most 50, at most 40, at most 30, at most 20, at most 10, at most 9, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2, or at most 1 nucleotide in length. A range of lengths of the probe capture sequence, such as from about 8 to about 50 nucleotides in length, etc. In some instances, the probe capture sequence length may be varied based on any useful application and properties, e.g., melting temperature, annealing temperature, annealing strength (e.g., GC content), hybridization stringency, etc.

[0132] Similarly, the probe binding molecule and nucleic acid barcode molecule may furthercomprise one or more additional sequences (e.g., unique molecular identifiers (UMIs), a barcode sequence, a primer sequence, a capture sequence, or other functional sequence). For example, in some instances, the probe binding molecule or barcode molecule may comprise a functional sequence, a primer sequence (e.g., sequencing primer sequence or partial sequencing primer sequence), a UMI, etc. The probe binding molecule and the nucleic acid barcode molecule may be any useful length; for example, either or both may be about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100 or more nucleotides in length. The probe binding molecule or the barcode molecule may be at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100 or more nucleotides in length. The probe capture binding molecule or the barcode molecule may be at most 100, at most 90, at most 80, at most 70, at most 60, at most 50, at most 40, at most 30, at most 20, at most 10, at most 9, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2, or at most 1 nucleotide in length. A range of lengths of the probe binding molecule or barcode molecule may be used, such as from about 16 to about 100 nucleotides in length, etc. In some instances, the probe binding molecule or barcode molecule length may be varied based on any useful application and properties, e.g., melting temperature, annealing temperature, etc. In some instances, the first target region and the second target region of the nucleic acid molecule are not adjacent. For instance, the first target region and the second target region may be separated by one or more gap regions disposed between the first target region and the second target region. The gap region may comprise, for example, at least one nucleotide base, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at leastAttorney Docket No.43487-1029601 about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, or more bases. The gap region may comprise at most about 1000, at most about 500, at most about 400, at most about 300, at most about 200, at most about 100, at most about 90, at most about 80, at most about 70, at most about 60, at most about 50, at most about 40, at most about 30, at most about 20, at most about 10, or at most about 5 bases. The gap region may comprise a range of number of bases, such as between about 1 and 30 bases.

[0133] A target region of the nucleic acid molecule may have one or more usefulcharacteristics. For example, a target region may have any useful length, base content, sequence, melting point, or other characteristic. A target region may comprise, for example, at least 10 bases, such as at least about 20, 25, 30, 35, 40, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, or more bases. A target region may have any useful base content and any useful sequence and combination of bases. For example, a target region may comprise one or more adenine, thymine, uracil, cytosine, and / or guanine bases (e.g., natural or canonical bases). A target region may also comprise one or more derivatives or modified versions of a natural or canonical base, such as an oxidized, alkylated (e.g., methylated), hydroxylated, or otherwise modified base. Similarly, a target region may comprise ribose or deoxyribose moieties and phosphate moieties or derivatives or modified versions thereof.

[0134] A target region of the nucleic acid molecule may comprise one or more sequences orfeatures, or portions thereof, of the nucleic acid molecule. For example, a target region may comprise all or a portion of a UTR (e.g., a 3’ UTR or a 5’ UTR), a Kozak sequence, a Shine- Dalgarno sequence, a coding sequence, a polyA sequence, a cap structure, an intron, an exon, or any other sequence or feature of the nucleic acid molecule.

[0135] The nucleic acid molecule (e.g., RNA molecule, such as an mRNA molecule) of asample may be included within a cell, nucleus or cell bead. For example, the sample may comprise a cell or nucleus comprising the nucleic acid molecule. The cell, nucleus, or cell bead may comprise additional nucleic acid molecules that may be the same as or different from the nucleic acid molecule of interest. In some cases, the sample may comprise a plurality of cells, and each cell may contain one or more nucleic acid molecules. The cell may be, for example, a human cell, an animal cell, or a plant cell. In some cases, the cell may be derived from a tissue or fluid, as described herein. The cell may be a prokaryotic cell or a eukaryotic cell. The cell may be a lymphocyte such as a B cell or T cell. The cell may be comprised within a bead, such as those disclosed in U.S. Pat. No.10,428,326, which is incorporated by reference herein in itsAttorney Docket No.43487-1029601 entirety. In some instances, the cell is comprised within a tissue sample and may be fixed to a substrate. For example, the cell may be a cell of a formalin-fixed, paraffin-embedded (FFPE) sample, as described above. In such instances, the method may comprise additional operations for preparing the cell or nucleic acid molecule comprised therein, e.g., deparaffinization, staining (e.g., using immunological agents) or destaining, decrosslinking, washing, enzymatic treatment, etc. Additional examples of treating FFPE samples prior to and following hybridization of probes are included in PCT / US2020 / 066720, which is included by reference herein in its entirety.

[0136] Access to a nucleic acid molecule included in a cell, nucleus or cell bead may beprovided by lysing or permeabilizing the cell or nucleus. Lysing the cell, nucleus or cell bead may release the nucleic acid molecule contained therein from the cell, nucleus or cell bead. A cell or nucleus may be lysed using a lysis agent such as a bioactive agent. A bioactive agent useful for lysing a cell or nucleus may be, for example, an enzyme (e.g., as described herein). An enzyme used to lyse a cell or nucleus may or may not be capable of carrying out additional functions such as degrading, extending, reverse transcribing, or otherwise altering a nucleic acid molecule. Alternatively, an ionic or non-ionic surfactant such as TritonX-100, Tween 20, sarcosyl, or sodium dodecyl sulfate may be used to lyse a cell or nucleus. Cell / nucleus lysis may also be achieved using a cellular disruption method such as an electroporation or a thermal, acoustic, or mechanical disruption method. Alternatively, a cell or nucleus may be permeabilized to provide access to a nucleic acid molecule included therein. Permeabilization may involve partially or completely dissolving or disrupting a cell / nuclear membrane or a portion thereof. Permeabilization may be achieved by, for example, contacting a cell membrane with an organic solvent (e.g., methanol) or a detergent such as Triton X-100 or NP-40. The cell, nucleus or cell bead may be fixed, as described elsewhere herein.

[0137] In some cases, the cell may be lysed within the cell bead, and a subset of theintracellular contents may associate with the bead. In some cases, the cell bead may comprise thioacrydite-modified nucleic acid molecules that can hybridize with nucleic acids from the cell. For example, a poly-T nucleic acid sequence may be thioacrydite-modified and bound to the cell bead matrix. Upon cell or nucleus lysis, the cellular nucleic acids (e.g., mRNA) may hybridize with the poly-T sequence. The retained intracellular / intranuclear contents may be released, for example, by addition of a reducing agent, e.g., DTT, TCEP, etc. The release may occur at any convenient step, such as before or after partitioning.

[0138] The nucleic acid molecule or probe-associated nucleic acid molecule may besubjected to conditions sufficient to generate a probe-linked molecule. For instance, the first target region may be adjacent to the second target region, and the first probe and the secondAttorney Docket No.43487-1029601 probe may hybridize to the first target region and the second target region, respectively. The first probe may comprise a first reactive moiety, and the second probe may comprise a second reactive moiety. In some instances, the first reactive moiety of the first probe is adjacent to the second reactive moiety of the second probe. The reactive moieties may then be subjected to conditions sufficient to cause them to react to yield a probe-linked nucleic acid molecule comprising the first probe linked to the second probe. For example, the reactive moieties may be joined together via click chemistry or enzymatic ligation, such as those disclosed in in U.S. Pat. Pub. No.2020 / 0239874, International Pub. No. WO 2019 / 165318, and International Pat. Pub. No. WO2021 / 237087, each of which is incorporated by reference herein in its entirety. In some examples, the first probe or the second probe may comprise an adenylated oligonucleotide or moiety (e.g., an adenylated phosphate group), which may be useful in reducing non-specific ligation reactions. In some instances, the linking of the probes (e.g., via ligation) may be performed in substantially ATP-free conditions, optionally using an enzyme (e.g., ligase) that does not require ATP (e.g., truncated T4 RNA ligase) or that is pre-activated (e.g., a preactivated T4 DNA ligase). Additional examples of such ligation schemes can be found in PCT / US2020 / 066720 and International Pat. App. No. PCT / US2021 / 33649, filed May 21, 2021, which is incorporated by reference herein in its entirety.

[0139] In some instances, the first target region of the nucleic acid molecule (e.g., RNAmolecule) may not be adjacent to the second target region. In such cases, the nucleic acid molecule may be subjected to conditions sufficient for hybridization of the first probe sequence of the first probe to the first target region to generate a probe-associated nucleic acid molecule. The probe-associated nucleic acid molecule may be subjected to a nucleic acid reaction (e.g., a nucleic acid extension reaction, reverse transcription, etc.) to generate an extended probe molecule comprising a sequence complementary to the second target region. A second probe comprising a second probe sequence may hybridize to the extended probe molecule (or complement thereof) and subjected to conditions sufficient (e.g., nucleic acid extension, amplification, hybridization of additional probe molecules, ligation, etc.) to generate a probe- linked molecule comprising a sequence corresponding to the first target region and a sequence corresponding to the second target region. Alternatively or in addition to, the first probe and the second probe may be provided simultaneously, and following hybridization of the first probe sequence and the second probe sequence to the first target region and the second target region, respectively, to generate a dual-probe-associated nucleic acid molecule, the gap (e.g., the region disposed between the first target region and the second region) may be filled (e.g., via a nucleic acid extension or gap-fill reaction and / or hybridization of additional probe molecules that hybridize to at least a portion of the gap region). In some instances, one or both probes mayAttorney Docket No.43487-1029601 comprise an overhang or flap sequence (e.g., at a 5’ end) that is recognizable or cleavable by an enzyme (e.g., an endonuclease such as FEN1 endonuclease). For example, the second probe may comprise a 5’ flap sequence that is cleaved by FEN1 endonuclease if at least a specific portion of the second probe hybridizes to the nucleic acid molecule (e.g., target molecule). Subsequent to hybridization of the second probe to the second target sequence of the nucleic acid molecule, an endonuclease (e.g., FEN1) may be used to cleave the flap sequence and leave a ligatable end (e.g., a phosphorylated end) of the second probe. In instances in which the first target region is not adjacent to the second target region, the gap region may be filled, followed by cleavage of the flap sequence. In some instances, the first probe or the second probe and the gap-filled region may be ligated, e.g., chemically or enzymatically. Additional examples of systems and methods for generating probe-linked nucleic acid molecules and gap-filling reactions can be found, for example in U.S. Pat. Pub. No.2020 / 0239874, International Pub. No. WO 2019 / 165318, and International Pat. Pub. No. WO2021 / 237087, each of which is incorporated by reference herein in its entirety.

[0140] The probe-linked nucleic acid molecule may be barcoded to provide a barcodedprobe-linked nucleic acid molecule, or barcoding may occur prior to generation of the probe- linked nucleic acid molecule. Barcoding may be performed using a variety of techniques. For example, the first probe or the second probe may comprise a probe capture sequence. The nucleic acid barcode molecule may comprise a barcode capture sequence capable of hybridizing to the probe capture sequence. Alternatively, barcoding may be mediated by a probe binding molecule (e.g., a splint oligonucleotide) comprising (i) a probe binding sequence, which may be complementary to the probe capture sequence of the first probe or the second probe, and (ii) a barcode binding sequence, which may be complementary to the barcode capture sequence of the nucleic acid barcode molecule. In some instances, the barcoding may be followed by ligation, e.g., chemically or enzyme-mediated, to covalently link the nucleic acid barcode molecule to the probe (or to the probe binding sequence, and the probe binding sequence may be ligated to the probe). Examples of chemical ligation of nucleic acid molecules may include “click chemistry” approaches, e.g., reaction of azide and alkyne moieties, as described in U.S. Pat. Pub. No. 2020 / 0239874, which is incorporated by reference herein in its entirety.

[0141] By way of example, the first probe may comprise a first probe sequence and a probecapture sequence, and the first probe may be subjected to conditions sufficient to hybridize the first probe sequence to the first target region, thereby generating a probe-associated nucleic acid molecule. In some instances, the probe-associated nucleic acid molecule may be subjected to washing or other conditions to remove unannealed probes from a mixture. The probe-associated nucleic acid molecule may be extended from an end of the first probe towards an end of theAttorney Docket No.43487-1029601 nucleic acid molecule to which it is hybridized (towards the end which is proximal to the second target region) to provide an extended nucleic acid molecule. The extended nucleic acid barcode molecule may comprise the first probe sequence and a complement to the second target region. In some instances, the extended nucleic acid molecule may be barcoded, e.g., by hybridizing the barcode capture sequence of the nucleic acid barcode molecule to the probe capture sequence, or by hybridizing (i) a probe-binding molecule comprising a probe binding sequence and a barcode binding sequence to the probe capture sequence and (ii) the barcode capture sequence of the nucleic acid barcode molecule to the barcode binding sequence of the probe binding molecule. In some instances, the probe-binding molecule may be provided pre-annealed to the nucleic acid barcode molecule. Subsequently, a second probe comprising a second probe sequence may be provided. The barcoded, extended nucleic acid molecule may be subjected to conditions sufficient to hybridize the second probe sequence to the second target region or complement thereof. A nucleic acid extension reaction may be performed, thereby generating a barcoded molecule (e.g., barcoded probe-linked molecule) comprising a sequence corresponding to the first target region, a sequence corresponding to the second target region, a sequence corresponding to the probe capture sequence, and a sequence corresponding to the barcode sequence.

[0142] FIG. 7 schematically shows a method for generating a barcoded nucleic acidmolecule, as described herein. A nucleic acid molecule (e.g., RNA molecule) 700 comprising a first target region 702 and a second target region 704 may be provided. The nucleic acid molecule 700 may be contacted with a first probe 706 comprising a first probe sequence 708 and, optionally, a functional sequence 710, thereby generating a probe-associated nucleic acid molecule. The first probe sequence 708 may be complementary to the first target region 702. The functional sequence 710 may comprise, for instance, a probe capture sequence used for downstream barcoding, or it may comprise a different functional sequence, such as a primer sequence, a partial primer sequence, a barcode sequence, a sequencing primer sequence, etc.

[0143] In operation 701, the probe-associated nucleic acid molecule may be subjected toconditions sufficient to extend the first probe 706, thereby generating an extended probe molecule 712 comprising a sequence complementary to the second target region 704. In some instances, the extended probe molecule 712 may be released from the nucleic acid molecule 700, e.g., via denaturing and / or degrading the nucleic acid molecule 700 (e.g., using an RNAse, increased temperature or heat cycling, pH, etc.). In operation 703, a nucleic acid barcode molecule may be provided. In some instances, the nucleic acid barcode molecule may be partially double-stranded and may comprise a first strand 720 comprising a barcode sequence, and a second strand 722 comprising a sequence 724 at least partially complementary to theAttorney Docket No.43487-1029601 barcode sequence and a probe binding sequence 726, which may be at least partially complementary to the functional sequence (e.g., probe capture sequence) 710 of the first probe 706. In some instances, the nucleic acid barcode molecule is single-stranded and comprises only first strand 720 comprising the barcode sequence and a barcode capture sequence. A probe binding molecule (e.g., a splint oligonucleotide) 722 may be provided, comprising barcode- binding sequence 724, which is at least partially complementary to the barcode capture sequence, and the probe binding sequence 726. In some instances, the probe binding molecule and the nucleic acid barcode molecule may be provided as a pre-annealed complex. The nucleic acid barcode molecule (or the pre-annealed complex) may be coupled to a bead, such as a gel bead, as described herein, and may comprise additional functional sequences, including, but not limited to, a unique molecular identifier (UMI), a capture sequence, a primer sequence (e.g., a R1 / R2 sequence).

[0144] In operation 705, the extended probe molecule may be barcoded by hybridizing theprobe binding sequence 726 to the functional sequence (e.g., probe capture sequence 710). In some instances, the nucleic acid barcode molecule may be covalently linked to the extended probe molecule (e.g., via the probe capture sequence), e.g., enzymatically (e.g., using a ligase) or chemically (e.g., using click chemistry). In operation 707, a second probe molecule 716 may be provided. In some instances, operation 707 may also include a denaturation of the double- stranded molecule. The second probe molecule 716 may comprise a second probe sequence 714 corresponding to the second target region 704 and optionally a functional sequence 718, which may comprise a probe capture sequence, a barcode sequence, a primer sequence, a sequencing primer sequence, etc. In operation 709, a nucleic acid extension reaction may be performed, e.g., using a polymerase, to extend the second probe 716 along the extended probe molecule, thereby generating a barcoded molecule comprising a sequence corresponding to the first target region 702, the second target region 704, a sequence corresponding to the probe capture sequence 710, and a sequence corresponding to the barcode sequence 720.

[0145] In another example, the first probe and the second probe may be linked (e.g., bychemical ligation or enzymatic extension and / or ligation) prior to barcoding. In such an example, the first probe may be hybridized to the nucleic acid molecule (e.g., via hybridization of the first probe sequence to the first target region) to generate a probe-associated nucleic acid molecule. The probe-associated nucleic acid molecule may be extended from an end of the first probe to an end of the nucleic acid molecule to which it is hybridized, to provide an extended nucleic acid molecule. The extended molecule may be subjected to conditions sufficient to hybridize the second probe to the second target region or complement thereof (e.g., via hybridization of the second probe sequence to the second target region or complement thereof). An additional nucleicAttorney Docket No.43487-1029601 acid extension reaction may be performed, to generate an extended, and the resultant extension product may be barcoded, generating a barcoded molecule. The barcoded molecule may comprise a sequence corresponding to the first target region, a sequence corresponding to the second target region, a sequence corresponding to the probe capture sequence, and a sequence corresponding to the barcode sequence. In some instances, the nucleic acid barcode molecule (or the probe binding molecule) may be chemically linked to the first probe or the second probe, such as by ligation or click chemistry. For example, the nucleic acid barcode molecule may comprise a first reactive moiety, and the first or the second probe may comprise a second reactive moiety; the first reactive moiety may be configured to react with the second reactive moiety to generate a covalent linkage. Barcoded nucleic acid molecules or derivatives thereof may then be optionally further processed and analyzed by any suitable technique, including nucleic acid sequencing (e.g., Illumina sequencing).

[0146] FIG. 8 schematically shows another method for generating a barcoded nucleic acidmolecule, as described herein. A nucleic acid molecule (e.g., RNA molecule) 800 comprising a first target region 802 and a second target region 804 may be provided. The nucleic acid molecule 800 may be contacted with a first probe 806 comprising a first probe sequence 808 and, optionally, a functional sequence 810, thereby generating a probe-associated nucleic acid molecule. The first probe sequence 808 may be complementary to the first target region 802. The functional sequence 810 may comprise, for instance, a probe capture sequence used for downstream barcoding, or it may comprise a different functional sequence, such as a primer sequence, a partial primer sequence, a barcode sequence, a sequencing primer sequence, etc.

[0147] In operation 801, the probe-associated nucleic acid molecule may be subjected toconditions sufficient to extend the first probe 806, thereby generating an extended probe molecule 812 comprising a sequence complementary to the second target region 804. In some instances, the extended probe molecule 812 may be released from the nucleic acid molecule 800, e.g., via denaturing and / or degrading the nucleic acid molecule 800 (e.g., using an RNAse, increased temperature or heat cycling, pH, etc.). In operation 803, a nucleic acid barcode molecule and a second probe 816 may be provided. The second probe 816 may comprise a second probe sequence 814 corresponding to the second target region 804 and optionally a functional sequence 818, which may comprise a probe capture sequence. In some instances, the nucleic acid barcode molecule may be partially double-stranded and may comprise a first strand 820 comprising a barcode sequence, and a second strand 822 comprising a sequence 824 complementary to the barcode sequence and a probe binding sequence 826, which may be complementary to the functional sequence (e.g., probe capture sequence) 818 of the second probe 816. In some instances, the nucleic acid barcode molecule is single-stranded andAttorney Docket No.43487-1029601 comprises only first strand 820 comprising the barcode sequence and a barcode capture sequence. A probe binding molecule (e.g., a splint oligonucleotide) 822 may be provided, comprising barcode-binding sequence 824 that is complementary to the barcode capture sequence, and the probe binding sequence 826. In some instances, the probe binding molecule and the nucleic acid barcode molecule may be provided as a pre-annealed complex. The nucleic acid barcode molecule (or the pre-annealed complex) may be coupled to a bead, such as a gel bead, as described herein, and may comprise additional functional sequences, including, but not limited to, a unique molecular identifier (UMI), a capture sequence, a primer sequence (e.g., a R1 / R2 sequence). In operation 803, the second probe 816 may hybridize to the extended probe molecule 812 (e.g., via hybridization of the second probe sequence 814 to the second target region 804 or complement thereof), and the nucleic acid barcode molecule may be attached or coupled to the second probe 816, e.g., via hybridization of the probe binding sequence 826 to the probe capture sequence 818. In some instances, the nucleic acid barcode molecule or the probe binding molecule may be ligated to the second probe 816, e.g., using a ligase or via chemical linkage, such as click chemistry.

[0148] In operation 805, a nucleic acid extension reaction may be performed, e.g., using apolymerase (e.g., DNA polymerase, Hot Start polymerase, etc.), to extend the nucleic acid barcode molecule and the second probe 816 along the extended probe molecule, thereby generating a barcoded molecule comprising a sequence corresponding to the first target region 802, the second target region 804, a sequence corresponding to the probe capture sequence 818, and a sequence corresponding to the barcode sequence 820. Barcoded nucleic acid molecules or derivatives thereof may then be optionally further processed and analyzed by any suitable technique, including nucleic acid sequencing (e.g., Illumina sequencing).

[0149] FIG. 9 schematically shows another method for generating a barcoded nucleic acidmolecule, similar to that shown in FIG.8. A nucleic acid molecule (e.g., RNA molecule) 900 comprising a first target region 902 and a second target region 904 may be provided. The nucleic acid molecule 900 may be contacted with a first probe 906 comprising a first probe sequence 908 and, optionally, a functional sequence 910, thereby generating a probe-associated nucleic acid molecule. The first probe sequence 908 may be complementary to the first target region 902. The functional sequence 910 may comprise, for instance, a probe capture sequence, or it may comprise a different functional sequence, such as a primer sequence, a partial primer sequence, a barcode sequence, a sequencing primer sequence, etc.

[0150] In operation 901, the probe-associated nucleic acid molecule may be subjected toconditions sufficient to extend the first probe 906, thereby generating an extended probe molecule 912 comprising a sequence complementary to the second target region 906. In someAttorney Docket No.43487-1029601 instances, the extended probe molecule 912 may be released from the nucleic acid molecule 900, e.g., via denaturing and / or degrading the nucleic acid molecule 900 (e.g., using an RNAse, increased temperature or heat cycling, pH, etc.). In operation 903, a second probe 916 may be provided. The second probe 916 may comprise a second probe sequence 914 corresponding to the second target region 904 and optionally a functional sequence 918, which may comprise a probe capture sequence. In operation 905, a nucleic acid extension reaction may be performed, e.g., using a polymerase, to extend the nucleic acid barcode molecule and the second probe 916 along the extended probe molecule, thereby generating a probe-linked molecule comprising a sequence corresponding to the first target region 902 and the second target region 904.

[0151] In operation 905, a nucleic acid barcode molecule may also be provided with thesecond probe. In some instances, the nucleic acid barcode molecule may be partially double- stranded and may comprise a first strand 920 comprising a barcode sequence, and a second strand 922 comprising a sequence 924 complementary to the barcode sequence and a probe binding sequence 926, which may be complementary to the functional sequence (e.g., probe capture sequence) 918 of the second probe 916. In some instances, the nucleic acid barcode molecule is single-stranded and comprises only first strand 920 comprising the barcode sequence and a barcode capture sequence. A probe binding molecule (e.g., a splint oligonucleotide) 922 may be provided, comprising barcode-binding sequence 924 that is complementary to the barcode capture sequence, and the probe binding sequence 926. In some instances, the probe binding molecule and the nucleic acid barcode molecule may be provided as a pre-annealed complex. The nucleic acid barcode molecule (or the pre-annealed complex) may be coupled to a bead, such as a gel bead, as described herein, and may comprise additional functional sequences, including, but not limited to, a unique molecular identifier (UMI), a capture sequence, a primer sequence (e.g., a R1 / R2 sequence). In operation 907, the nucleic acid barcode molecule may be attached or coupled to the second probe 916, e.g., via hybridization of the probe binding sequence 926 to the probe capture sequence 918. The resultant barcoded product may comprise a sequence corresponding to the first target region 902, the second target region 904, a sequence corresponding to the probe capture sequence 918, and a sequence corresponding to the barcode sequence 920. In some instances, the nucleic acid barcode molecule may be covalently linked to the extended probe molecule (e.g., via the probe capture sequence 918), e.g., enzymatically (e.g., using a ligase) or chemically (e.g., using click chemistry). Barcoded nucleic acid molecules or derivatives thereof may then be optionally further processed and analyzed by any suitable technique, including nucleic acid sequencing (e.g., Illumina sequencing).

[0152] In additional examples, the methods of the present disclosure may comprisegenerating probe-associated nucleic acid molecules, and barcoding the probe-associated nucleicAttorney Docket No.43487-1029601 acid molecules, optionally with a linking operation (e.g., prior to or subsequent to barcoding of the probe-associated nucleic acid molecules). For example, a nucleic acid molecule (e.g., RNA molecule) comprising a first target region and a second target region may be provided. The nucleic acid molecule may be contacted with (i) a first probe comprising a first probe sequence complementary to the first target region and (ii) a second probe comprising a second probe sequence complementary to the second target region, thereby generating a probe-associated nucleic acid molecule. In some instances, the probe-associated nucleic acid molecule may be subjected to conditions sufficient to link the first probe to the second probe (e.g., enzymatically, such as with a polymerase, reverse transcriptase, and / or ligase, or chemically), thereby generating a probe-linked nucleic acid molecule. The probe-associated nucleic acid molecule or the probe-linked molecule may subsequently be barcoded (e.g., in a partition) to generate a barcoded nucleic acid molecule.

[0153] For example, FIG. 25 schematically shows an example method for generating aprobe-linked nucleic acid molecule, which may subsequently be barcoded, e.g., in a partition, to generate a barcoded nucleic acid molecule. A nucleic acid molecule (e.g., RNA molecule) 2500 comprising a first target region 2502 and a second target region 2504 may be provided. In some instances, the first target region is adjacent to the second target region. The nucleic acid molecule 2500 may be contacted, in operation 2501, with a first probe 2506 comprising a first probe sequence 2508 complementary to the first target region 2502 and a second probe 2516 comprising a second probe sequence 2514 complementary to the second target region 2504, thereby generating a probe-associated nucleic acid molecule. The first probe 2506 and / or the second probe 2516 may comprise a functional sequence, e.g., a probe capture sequence, a primer sequence, a partial primer sequence, a barcode sequence, a sequencing primer sequence, etc.

[0154] In some instances, one of the probes (e.g., the second probe 2516) comprises a flap oroverhang sequence 2530, which may be recognized by an endonuclease (e.g., FEN1) upon annealing of the second probe sequence 2514 to the second target region 2504. For example, the second probe 2516 may comprise a 5’ flap sequence 2530, and subsequent to annealing of the first probe 2506 and the second probe 2516 to the nucleic acid molecule 2500, the flap sequence may be adjacent to an end of the first probe (e.g., a 3’ end) as well as an end of the second probe (e.g., a 5’ end). In operation 2503, an endonuclease, e.g., FEN1 may be used to remove the flapsequence 2530 ļeaving a ligatable end (e.g., 5’phosphorylated end) of the second probe 2516. Inoperation 2507, a ligation reaction may be performed (e.g., using a ligase) to link the first probe to the second probe, thereby generating a probe-linked nucleic acid molecule. The probe-linked nucleic acid molecule may subsequently be barcoded, e.g., in partitions, as is describedAttorney Docket No.43487-1029601 elsewhere herein. In some instances, the probe-associated nucleic acid molecules may be barcoded and linked (e.g., in partitions).

[0155] FIG. 26 shows another example workflow, similar to that shown in FIG. 25, inwhich the target regions of the nucleic acid molecule are not adjacent. Such a workflow may comprise an additional gap-fill reaction to generate the probe-associated molecule. In one such example, the first target region 2602 of nucleic acid molecule 2600 may not be adjacent to the second target region 2604. For example, the a gap region may be disposed between the first target region and the second target region. In operation 2601, the first probe 2606 may anneal to the first target region 2602 and the second probe 2616 may anneal to the second target region 2604. In operation 2603, an extension reaction (e.g., using a polymerase, reverse transcriptase, etc.) may be performed to fill in the gap region between the first probe 2606 and the second probe 2616, yielding a gap-filled nucleic acid molecule. In some instances, the second probe2616 comprises a flap sequence 2630. In such instances, in operation 2605, an endonuclease,e.g., FEN1 may be used to remove the flap sequence 2630 ̧leaving a ligatable end (e.g.,5’phosphorylated end) of the second probe 2616. In operation 2607, a ligation reaction may be performed (e.g., using a ligase) to link the first probe to the second probe, thereby generating a probe-linked nucleic acid molecule. The probe-linked nucleic acid molecule, or alternatively, the un-linked molecule, may be barcoded, e.g., in a partition.

[0156] FIG. 27 shows an additional scheme of generating a probe-linked nucleic acidmolecule by performing a gap-filling reaction using a third probe. In FIG.27 Panel A, a first probe 2706 and a second probe 2716 anneal (e.g., via a first probe sequence and a second probe sequence, respectively) to a first target region 2702 and a second target region 2704 of nucleic acid molecule 2700 to generate a probe-associated nucleic acid molecule. A gap sequence may be disposed between the first target region 2702 and the second target region 2704. Third probe molecules 2770 may be provided (illustrated as two different probe molecules, which may be used for SNP detection), which may anneal to the gap sequence (FIG.27 Panel B). In FIG.27 Panel C, the first probe, the third probe, and the second probe may be ligated (e.g., using a ligase) to generate a probe-linked nucleic acid molecule. The probe-linked nucleic acid molecule, or alternatively, the probe-associated nucleic acid molecule, may be barcoded, e.g., in a partition.

[0157] FIG. 28 shows an example of a ligation scheme used to generate probe-linked nucleicacid molecules. In such an example, the probe molecules may hybridize to the nucleic acid molecule. The first probe may be ligated to the second probe, optionally with a gap-fill operation, as described above, using an enzyme. In some instances, the enzyme may be a pre-Attorney Docket No.43487-1029601 activated enzyme, e.g., a preactivated T4 DNA ligase, and the ligation may occur under ATP- reduced or ATP-removed conditions, e.g. using Apyrase.

[0158] Additional examples of methods and systems for generating probe-associated nucleicacid molecules, and barcoding the probe-associated nucleic acid molecules, can be found in, for example U.S. Pat. Pub. No.2020 / 0239874, International Pub. No. WO 2019 / 165318, International App. No. PCT / US2020 / 066720, and International Pat. App. No. PCT / US2021 / 33649, filed May 21, 2021, each of which is incorporated by reference herein in its entirety.

[0159] It will be appreciated that, e.g., referring to FIGs. 7-9 and FIGs. 25-28, the nucleicacid barcode molecule may be attached (e.g., via hybridization) to either the first probe and / or the second probe (e.g., via a probe capture sequence comprised in the first probe or the second probe). Similarly, the first probe and the second probe may comprise any useful functional sequences, such as primer sequences, barcode sequences, unique molecular identifier (UMI) sequences, flow cell attachment sequences, primer-binding sequences, capture sequences, etc. The first probe may hybridize to the left-hand side (e.g., a 3’ end) of a nucleic acid molecule (e.g., 700, 800, or 900) or to the right-hand side (e.g., a 5’ end). Similarly, the second probe may hybridize to the left-hand side or to the right-hand side of the nucleic acid molecule.

[0160] As described herein, one or more extension reactions may be performed on the probe-hybridized nucleic acid molecules. For example, the probe may be extended from an end of the probe to an end of the nucleic acid barcode molecule, or a second probe may be extended from an end of the second probe to an end of the first probe of a probe-associated nucleic acid molecule. Extension may comprise the use of an enzyme (e.g., a polymerase, reverse transcriptase) to add one or more nucleotides to the end of the probe. Extension may provide an extended nucleic acid molecule comprising sequences complementary to the target region of the nucleic acid molecule of interest, the barcode sequence, and optionally, one or more additional sequences of the nucleic acid barcode molecule such as one or more binding sequences. In some instances, appropriate conditions and or chemical agents (e.g., as described herein) may be applied to denature the extended nucleic acid molecule from the nucleic acid barcode molecule and the target nucleic acid molecule. In some cases, one or more processes may involve the use of thermosensitive agents. For example, in some cases, probes may be annealed or hybridized under one set of temperature conditions, and extension may occur under a different set of temperature conditions. In some cases, a Warm or Hot Start polymerase may be used. In some cases, hybridization of the nucleic acid barcode molecule to one or more of the probes (e.g., directly hybridizing or via a probe binding molecule such as a splint oligonucleotide) may precede hybridization of the probe to the target region of the nucleic acid molecule. FollowingAttorney Docket No.43487-1029601 barcoding, the barcoded nucleic acid molecule may be duplicated or amplified by, for example, one or more amplification reactions. The amplification reactions may comprise polymerase chain reactions (PCR) and may involve the use of one or more primers or polymerases. The extension, denaturation, and / or amplification processes may take place within a partition, or in bulk. In some cases, the extended nucleic acid molecule or derivatives thereof (e.g., the barcoded molecule) may be duplicated or amplified within a partition to provide an amplified product. The barcoded product, or a complement thereof (e.g., an amplified product), may be detected via sequencing (e.g., as described herein).

[0161] The nucleic acid molecule or a derivative thereof (e.g., a probe-linked nucleic acidmolecule, a nucleic acid molecule having one or more probes hybridized thereto, a barcoded probe-linked nucleic acid molecule, or an extended nucleic acid molecule or complement thereof) or a cell or cell bead comprising the nucleic acid molecule or a derivative thereof may be provided within a partition such as a well or droplet, e.g., as described herein. One or more reagents may be co-partitioned with a nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof. For example, a nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof may be co-partitioned with one or more reagents selected from the group consisting of lysis agents or buffers, permeabilizing agents, enzymes (e.g., enzymes capable of digesting one or more RNA molecules, extending one or more nucleic acid molecules, reverse transcribing an RNA molecule, permeabilizing or lysing a cell, or carrying out other actions), fluorophores, oligonucleotides, primers, probes, barcodes, nucleic acid barcode molecules (e.g., nucleic acid barcode molecules comprising one or more barcode sequences), buffers, deoxynucleotide triphosphates, detergents, reducing agents, chelating agents, oxidizing agents, nanoparticles, beads, and antibodies. In some cases, a nucleic acid molecule or a derivative thereof, or a cell comprising the nucleic acid molecule or a derivative thereof (e.g., a cell bead), may be co- partitioned with one or more reagents selected from the group consisting of temperature- sensitive enzymes, pH-sensitive enzymes, light-sensitive enzymes, reverse transcriptases, proteases, ligase, polymerases, restriction enzymes, nucleases, protease inhibitors, exonucleases, and nuclease inhibitors. For example, a nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof may be co-partitioned with a polymerase and nucleotide molecules. Partitioning a nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof and one or more reagents may comprise flowing a first phase comprising an aqueous fluid, the cell, and the one or more reagents and a second phase comprising a fluid that is immiscible with the aqueous fluid toward a junction. Upon interaction of the first and second phases, a discrete droplet of the firstAttorney Docket No.43487-1029601 phase comprising the nucleic acid molecule or a derivative thereof or a cell comprising the nucleic acid molecule or a derivative thereof (e.g., a cell bead) and the one or more reagents may be formed. In some cases, the partition may comprise a single cell. The cell may be lysed or permeabilized within the partition (e.g., droplet) to provide access to the nucleic acid molecule of the cell.

[0162] One or more processes may be carried out within a partition (e.g., droplet, well, etc.).For instance, the nucleic acid molecule, or a cell or cell bead comprising the nucleic acid molecule, may be co-partitioned with one or more reagents (e.g., as described herein) at any useful stage of the method. For example, the probe-associated nucleic acid molecule (e.g., the nucleic acid molecule with the first probe hybridized thereto) may be generated in bulk (e.g., in a population of cells, which may be alive or fixed and / or permeabilized, in a tissue sample, etc.) and subjected to conditions sufficient for generating for generating an extended probe molecule. The extended probe molecule may be subsequently partitioned in a partition among a plurality of partitions. The partition may comprise the second probe and a nucleic acid barcode molecule and optionally, a probe binding molecule. As described herein, the second probe may hybridize (e.g., via the second probe sequence) to the second target region or complement thereof of the probe- associated molecule. The partition may comprise additional reagents for performing a nucleic acid reaction (e.g., digestion, ligation, extension, amplification). For instance, the probe- associated nucleic acid molecule may comprise or be hybridized to the nucleic acid molecule, and the partition may comprise a degrading enzyme (e.g., RNAse), which may be useful in digesting or removing the template strand (e.g., the nucleic acid molecule, such as an RNA molecule) from the extended probe molecule. The partition may comprise a polymerase, which may be used to extend the second probe hybridized to the extended probe molecule. In some instances, the partition comprises a linking enzyme (e.g., ligase), which may be used to ligate the nucleic acid barcode molecule to the first probe or the second probe (e.g., via a probe capture sequence). The ligase may in some instances be used to ligate the probe binding molecule to the probe capture sequence of the first probe or the second probe. In some instances, the probe binding molecule, the probe capture sequence, and / or the barcode capture sequence comprises one or more reactive moieties, which may be used to chemically or enzymatically link the nucleic acid barcode molecule to the probe capture sequence, or complement thereof. The resultant barcoded product may comprise a sequence corresponding to the first target region, a sequence corresponding to the second target region, a sequence corresponding to the probe capture sequence, and a sequence corresponding to the barcode sequence.

[0163] For example, referring again to FIG. 7, operation 701 may be performed in bulk (e.g.,outside a partition), while operations 703, 705 may be performed in a partition. Operations 707Attorney Docket No.43487-1029601 and 709 may be performed in bulk or within the partition. Similarly, referring to FIG.8, operation 801 may be performed in bulk, while operation 803 may be performed in a partition. Operation 805 may be performed in bulk or in a partition. Referring to FIG.9, operation 901 may be performed in bulk, while operations 903, 905, and 907 may be performed in a partition. It will be appreciated that any of the operations may be performed in bulk or in partitions at any convenient step and that the order of the operations may be changed for a suitable or useful purpose.

[0164] Similarly, the nucleic acid molecule or the cell or cell bead comprising the nucleicacid molecule, or derivatives thereof (e.g., the probe-associated molecule, the extended molecule, the barcoded molecule, etc.) may be released from a partition at any useful stage of the method. For example, the extended probe molecule may be hybridized to the second probe and released from the partition subsequent to hybridization of the barcode capture sequence of the nucleic acid barcode molecule to the first probe, the second probe, or the probe binding molecule. Alternatively, the extended probe molecule may be released from the partition subsequent to (i) hybridization of the second probe and nucleic acid barcode molecule and (ii) extension of the second probe to generate the barcoded molecule comprising a sequence corresponding to the first target region, a sequence corresponding to the second target region, a sequence corresponding to the probe capture sequence, and a sequence corresponding to the barcode sequence. Duplication and / or amplification of the extended nucleic acid molecule may be carried out within the partition or in bulk, e.g., within a solution. In some cases, the solution may comprise additional extended nucleic acid molecules generated through the same process carried out in different partitions. Each extended nucleic acid molecule may comprise a different barcode sequence, and the barcode sequence may be useful in identifying the partition or cell from whence the extended nucleic acid molecules originated. In such cases, the solution may comprise a pooled mixture comprising the contents of two or more partitions (e.g., droplets).

[0165] Additional processes or operations may be performed within a partition, including,but not limited to: lysis, permeabilization, denaturation, hybridization, extension, duplication, and amplification of one or more components of a sample. In some cases, multiple processes are carried out within a partition.

[0166] Hybridization of the probe sequences to the target regions of the nucleic acidmolecule may be performed within or outside of a partition. In some cases, hybridization may be preceded by denaturation of a double-stranded nucleic acid molecule to provide a single- stranded nucleic acid molecule or by lysis or permeabilization of a cell. In some cases, the hybridization may occur in a cell bead comprising a cell. The sequence of the probe that is complementary to the target region may be situated at an end of the probe. Alternatively, thisAttorney Docket No.43487-1029601 sequence may be disposed between other sequences such that when the probe sequence is hybridized to the target region, additional probe sequences extend beyond the hybridized sequence in one or more directions. The probe sequence that hybridizes to the target region of the nucleic acid molecule may be of the same or different length as the target region. For example, the probe sequence may be shorter than the target region and may only hybridize to a portion of the target region. Alternatively, the probe sequence may be longer than the target region and may hybridize to the entirety of the target region and extend beyond the target region in one or more directions. In addition to a probe sequence complementary to a target region of the nucleic acid molecule, the probe may comprise one or more additional probe sequences. For example, the probe may comprise the probe sequence complementary to the target region and a second probe sequence. The second probe sequence may have any useful length and other characteristics.

[0167] The probe (e.g., the first probe or the second probe) may comprise one or moreadditional sequences or moieties, such as one or more barcode sequences or unique molecule identifier (UMI) sequences, adapter sequences, functional sequences (e.g., primer sequences, sequencing primer sequences, etc.). In some cases, one or more probe sequences of the probe may comprise a detectable moiety such as a fluorophore or a fluorescent moiety. In some instances, the first probe or the second probe may comprise a reactive moiety, as described elsewhere herein. For example, the first probe or the second probe may comprise an azide moiety, an alkyne moiety, a phosphorothioate moiety, an iodide moiety, an amine moiety, a phosphate moiety, or a combination thereof. The first probe may comprise a first reactive moiety and the second probe may comprise a second reactive moiety, and reaction of the first reactive moiety and the second reactive moiety may be sufficient to yield a probe-linked molecule comprising the first probe linked to the second probe. In some instances, the first reactive moiety and the second reactive moiety is linked via ligation. Accordingly, the first probe or the second probe may comprise one or more moieties or modified nucleotides to facilitate ligation, e.g., one or more ribonucleotides or dideoxynucleotides (ddNTPs), which may be ligated to a phosphorylated end of the second probe using a ligase (e.g., T4 DNA ligase, SplintR ligase). In some instances, the probe (e.g., the first probe or the second probe) may comprise an overhang or flap sequence which is recognizable or cleavable by an endonuclease (e.g., FEN1 endonuclease). Other suitable enzymes, e.g., ligases, may be used, for example, the enzymes and ligases disclosed in U.S. Provisional App. No.63 / 171,031, filed April 5, 2021, which is incorporated herein by reference in its entirety.

[0168] As described herein, a probe sequence of the probe may be capable of hybridizingwith a sequence of a nucleic acid barcode molecule or a probe binding molecule (e.g., splintAttorney Docket No.43487-1029601 oligonucleotide). A nucleic acid barcode molecule may comprise a first binding sequence (e.g., a barcode capture sequence) that is complementary to a probe sequence of the probe (e.g., a probe capture sequence). The nucleic acid barcode molecule may comprise one or more additional functional sequences , e.g., primer sequences, primer annealing sequences, and immobilization sequences. The binding sequences may have any useful length and other characteristics. In some cases, the binding sequence (e.g., barcode capture sequence) that is complementary to a probe sequence of the probe may be the same length as the probe sequence. Alternatively, the binding sequence may be a different length of the probe sequence. For example, the binding sequence may be shorter than the probe sequence and may only hybridize to a portion of the probe sequence. Alternatively, the binding sequence may be longer than the probe sequence and may hybridize to the entirety of the probe sequence and extend beyond the probe sequence in one or more directions. Similarly, in instances when a probe-binding molecule is used, the binding sequence (e.g., barcode capture sequence) of the nucleic acid barcode molecule may be the same length as the barcode binding sequence of the probe-binding molecule, or the binding sequence may be longer or shorter than the barcode binding sequence.

[0169] One or more processes described herein may be performed in a cell, nucleus or cellbead. For example, in some embodiments, a plurality of cells, nuclei or cell beads may comprise a plurality of nucleic acid molecules. The cells, nuclei or cell beads may be alive or fixed and / or permeabilized. In some instances, the first probes may be provided to the cells, nuclei or cell beads, such as in a bulk solution. Optionally, the cells, nuclei or cell beads may be washed to remove unbound first probes, and the nucleic acid extension reaction, as described herein, may be performed. Subsequently, the cells, nuclei or cell beads comprising the plurality of nucleic acid molecules (or the extended, probe nucleic acid molecules) may be partitioned into a plurality of separate partitions, where at least a subset of the plurality of separate partitions comprises a single cell, single nucleus, or single cell bead. Access to a target nucleic acid molecule contained within a cell, nucleus or cell bead in a partition may be provided by lysing or permeabilizing the nucleus or cell (e.g., as described herein), which may be performed prior to or during partitioning. Alternatively, access to a target nucleic acid molecule contained within a cell, nucleus, or cell bead may be performed in a bulk solution using the methods described herein. Barcoding of the target nucleic acid may be performed within a cell, within a cell bead, or within a partition comprising the cell or cell bead. In an example, the target nucleic acid molecule may be barcoded in a partition and outside the cell, cell nucleus, or cell bead. Additional probe hybridization (e.g., providing of the second probe) and / or barcoding may be performed within the separate partitions. Barcoding, as described herein, may comprise using a nucleic acid barcode molecule to attach or hybridize to the target nucleic acid molecule orAttorney Docket No.43487-1029601 derivative thereof (e.g., the extended probe molecule, or complement thereof). Nucleic acid barcode molecules provided within each partition of the plurality of separate partitions may be provided attached to beads. In some instances, as described elsewhere herein, the nucleic acid barcode molecule may be releasably attached to a bead (e.g., via a labile bond). Each partition (or a subset of partitions) of the plurality of separate partitions may comprise a bead comprising a plurality of nucleic acid barcode molecules attached thereto (e.g., as described herein). The plurality of nucleic acid barcode molecules attached to each bead may comprise a unique barcode sequence, such that each partition of the plurality of separate partitions comprises a different barcode sequence. Upon release of components from the plurality of different partitions of the plurality of separate partitions (e.g., following barcoding), the barcoded molecules arising from a single cell, single nucleus, or single cell bead may have a same barcode sequence (e.g., a common barcode sequence), such that each barcoded nucleic acid molecule can be traced to a given partition and / or, in some instances, a given cell, nucleus or cell bead.

[0170] The methods described herein may comprise additional barcoding operations, whichmay be useful, for example, in indexing nucleic acid molecules to a cell, nucleus, cell bead, a sample, a partition, or a plurality of partitions. Such indexing may be useful in situations when a single partition is occupied by multiple cells, nuclei, or cell beads. In some instances, it may be beneficial to overload partitions such that a partition comprises more than a single cell, single nucleus, or single cell bead; for example, it may be useful in certain situations to overload partitions, e.g., to overcome Poisson loading statistics in partitions and / or to prevent reagent waste (e.g., from unoccupied partitions). Accordingly, such indexing may be useful in attributing cells, nuclei or nucleic acid molecules in multiply-occupied partitions to the originating cell, nucleus, cell bead, partition, sample, etc.

[0171] In an example, a barcoded molecule, such as the barcoded molecules generated usingthe methods described herein (e.g., in FIGs.7-9, FIGs.25-28, as well as barcoded, probe-linked nucleic acid molecules described in U.S. Pat. Pub. No.2020 / 0239874 and International Pub. No. WO 2019 / 165318, each of which is incorporated by reference herein) may be provided. The barcoded molecule may comprise, as described herein, a sequence corresponding to the first target region, a sequence corresponding to the second target region, a sequence corresponding to the probe capture sequence (which may be disposed on the first probe or the second probe), and a sequence corresponding to the barcode sequence of the nucleic acid barcode molecule. Such a barcode sequence may be specific to the partition and may differ from other barcode sequences of other partitions and thus may be used to identify a partition from which a nucleic acid molecule (or derivative thereof) originated. In some instances, some of the partitions may comprise a single cell, single nucleus, or single cell bead and thus the nucleic acid barcodeAttorney Docket No.43487-1029601 molecule or barcode sequence may be used to identify a cell, nucleus, or cell bead from which a nucleic acid molecule (or derivative thereof) originated.

[0172] In some instances, the barcoded molecule may be subjected to an additionalbarcoding operation, e.g., in partitions or in bulk. For example, the barcoded molecule may be re-partitioned in a partition among a plurality of partitions comprising a plurality of additional nucleic acid barcode molecules. The plurality of additional nucleic acid barcode molecules may comprise additional barcode sequences that differ across the partitions. The barcoded molecules may be subjected to conditions sufficient to barcode the barcoded molecules to generate a combinatorially barcoded molecule comprising two barcode sequences. As each barcode sequence pertains to a unique partition, the combination of barcodes may be useful in generating a greater diversity of barcoded molecules, as well as for identifying the originating partitions of the combinatorially barcoded molecule.

[0173] In some cases, combinatorial assembly of barcode segments may be performed using,e.g., a split-pool approach. For example, in some embodiments, the probe-linked nucleic acidmolecules may be combinatorially barcoded using a split pool approach. In one such example, aplurality of permeabilized cells (or permeabilized nuclei or cell beads) comprising, e.g., probe- linked nucleic acid molecule, which may optionally be barcoded (e.g., the product following operation 709 of FIG.7, 805 of FIG.8, or 905 or 907 of FIG.9) may be partitioned into a plurality of partitions (e.g., a plurality of wells), wherein each partition of the plurality of partitions comprises a different (e.g., unique) barcode sequence segment. Alternatively, the plurality of permeabilized cells (or permeabilized nuclei or cell beads) may be partitioned, and then the different barcode sequence segments delivered to the respective partitions containing the cells, nuclei, and / or cell beads. After addition of the barcode sequence segment, cells (or nuclei or cell beads) can be collected from the plurality of partitions, pooled, and partitioned into an additional plurality of partitions (e.g., a plurality of wells) wherein each partition of the additional plurality of partitions comprises a different (e.g., unique) second barcode sequence segment. Repeating this split-pool process allows the generation of barcodes or barcoded molecules comprising any suitable amount of barcode sequence segments. Combinatorial barcoding as described herein may comprise at least 1, 2, 3, 4, 5, 6, 7, 8 or more operations (e.g., split-pool cycles). Combinatorial barcoding comprising multiple operations may be useful, for example, in generation of greater barcode diversity and to synthesize a unique barcode sequence on nucleic acid molecules derived from each single cell, nucleus, or cell bead of a plurality of cells, nuclei, cell beads. For example, combinatorial barcoding comprising three operations, each comprising attachment of a unique nucleic acid sequence in each of 96 partitions, will yield up to 884,736 unique barcode combinations. Generally, where there are M partitions, and NAttorney Docket No.43487-1029601 number of split-pool iterations are performed, up to MNunique barcode combinations may be generated. Cells or nuclei or cell beads may be partitioned such that at least one cell (or nuclei or cell bead) is present in each partition of a plurality of partitions. Cells, nuclei, or cell beads may be partitioned such that at least 1; 2; 3; 4; 5; 10; 20; 50; 100; 500; 1,000; 5,000; 10,000; 100,000; 1,000,000; or more cells, nuclei, or cell beads are present in a single partition. Cells, nuclei, or cell beads may be partitioned such that at most 1,000,000; 100,000; 10,000; 5,000; 1,000; 500; 100; 50; 20; 10; 5; 4; 3; 2; or 1 cell (or nucleus or cell bead) is present in a single partition. Cells, nuclei, and / or cell beads may be partitioned in a random configuration.

[0174] In some instances, the additional barcoding operations may be performed prior tosome of the operations described herein. For example, it may be beneficial to combinatorially barcode the first probe in a bulk solution, e.g., prior to or following generation of the extended probe molecule or probe-linked molecule. In such cases, the nucleic acid molecule may be contacted, e.g., in bulk, with a first probe to generate a probe-associated molecule. The probe- associated molecule may optionally be extended, e.g., using the methods described herein, to generate an extended probe molecule. The probe-associated molecule or the extended probe molecule may then be subjected to combinatorial barcoding, e.g., in partitions, as described above, to generate a combinatorially barcoded molecule. The combinatorially barcoded molecule may then be partitioned with a second probe and a nucleic acid barcode molecule, which, as described herein, may attach to either the first probe (or combinatorially barcoded probe), the second probe, or both probes. As each partition of the combinatorial barcoding process comprises a different barcode sequence segment, a plurality of the combinatorially barcoded molecules may be traced back to the individual partitions from which they originated. Moreover, the combinatorial barcoding may be useful in generating greater probe diversity.

[0175] Beneficially, the combinatorial barcoding of the first probe may be particularly usefulwhen combined with the second probe and nucleic acid barcode molecule, which may comprise a barcode sequence that is specific to the partition. For example, the presence of the probe- specific barcode(s) and the partition-specific barcode sequence may allow for indexing of individual cells (or nuclei or cell beads) within a partition. For instance, partitions comprising cell / nucleus / cell bead multiplets (e.g., cell doublets, triplets, etc.) can be computationally deconvolved into single cells / nuclei / cell beads. Thus, in some instances, cells, nuclei, or cell beads may be “overloaded” into partitions using conditions such that a higher probability of cell / nucleus / cell bead multiplets (2,3,4,5+ cells, nuclei, or cell beads per partition) are formed, wherein target libraries of these cell multiplets may be computationally deconvolved into single cells, nuclei, or cell beads.Attorney Docket No.43487-1029601

[0176] FIG. 10 schematically shows an example workflow of barcoding nucleic acidmolecules in partitions comprising cell / nucleus / cell bead multiplets. In operation 1010, one or more populations of cells / nuclei / cell beads (or nucleic acid molecules contained therein) may be subjected to barcoding, as described herein (e.g., using processes shown and described in FIGs. 7-9 and FIGs.15-16). For example, a first population of cells (or nuclei or cell beads) 1002 (comprising a first plurality of nucleic acid molecules) may be subjected to barcoding in a first subset of a first plurality of partitions, generating a first plurality of barcoded nucleic acid molecules comprising a first barcode sequence. A second population of cells (or nuclei or cell beads) 1004 may be barcoded in a second subset of the first plurality of partitions, generating a second plurality of barcoded nucleic acid molecules comprising a second barcode sequence. The first barcode sequence may be different than the second barcode sequence. In operation 1020, the first population of cells (or nuclei or cell beads) 1002 may be pooled together with the second population of cells (or nuclei or cell beads) 1004 to generate a mixture of cells. In operation 1030, the mixture of cells (or nuclei or cell beads) may be partitioned into a second plurality of partitions. In some instances, the mixture of cells / nuclei / cell beads may be partitioned into the second plurality of partitions such that some partitions of the second plurality of partitions comprises more than one cell (e.g., a cell multiplet partition). For example, a partition 1035 of the second plurality of partitions may comprise a cell, nucleus, or cell bead (“Cell A”) from the first population of cells 1002 and a cell, nucleus, or cell bead (“Cell B”) from the second population of cells 1004. The partition 1035 may comprise an additional barcode sequence, which may be unique to the partition. The cells / nuclei / cell beads in each partition may be subjected to an additional barcoding operation to append the additional barcode sequence on the barcoded nucleic acid molecules. In operation 1040, the barcoded nucleic acid molecules may be deconvolved, using the different barcode sequences (e.g., the first barcode sequence, the second barcode sequence, and the additional barcode sequences), to identify the originating cell / nucleus / cell bead. For instance, a barcoded nucleic acid molecule comprising the additional barcode sequence from partition 1035 and the first barcode sequence from the first population of cells (or nuclei or cell beads) 1002 may be used to identify that barcoded nucleic acid molecule as originating from Cell A. Similarly, a barcoded nucleic acid molecule comprising the additional barcode sequence from partition 1035 and the second barcode sequence from the second populations of cells (or nuclei or cell beads) 1004 may be used to identify that barcoded nucleic acid molecule as originating from Cell B.

[0177] Following partition-based barcoding, the contents of the partitions may be pooled andthe barcoded molecules (e.g., barcoded probe-linked nucleic acid molecules) may be duplicatedor amplified by, for example, one or more amplification reactions, which may in some instancesAttorney Docket No.43487-1029601 be isothermal. The amplification reactions may comprise polymerase chain reactions (PCR) and may involve the use of one or more primers or polymerases. The one or more primers may comprise one or more functional sequences (e.g., a primer sequence / primer binding sequence, a sequencing primer sequence (e.g., R1 or R2), a partial sequencing primer sequence (e.g., partial R1 or partial R2), a sequence configured to attach to the flow cell of a sequencer (e.g., P5 or P7, or partial sequences thereof), etc.) and may facilitate addition of said one or more functional sequences to the extended nucleic acid molecule. The barcoded molecules, or derivatives thereof, may be detected via nucleic acid sequencing (e.g., as described herein).

[0178] In some aspects, provided herein are systems useful for barcoding nucleic acidmolecules. The systems may comprise any of the components described herein, e.g., a plurality of partitions (e.g., droplets, wells), which may be provided in any useful format, e.g., a microfluidic device, a multi-well array or plate, etc. The systems may include nucleic acid barcode molecules, optionally coupled to supports (e.g., particles, beads, gel beads, etc.). In some instances, the systems may comprise any of the probes described herein, such as a first probe or plurality of first probes, a second probe or plurality of second probes, and any useful reaction components (e.g., for performing a nucleic acid reaction, e.g., extension, ligation, amplification, etc.). Such useful reaction components can include, in non-limiting examples, enzymes (e.g., ligases, polymerases, reverse transcriptases, restriction enzymes, etc.), nucleotides bases, etc.

[0179] Also provided herein are compositions useful for systems and methods for barcodingnucleic acid molecules. A composition may comprise any of the probes described herein. For example, a composition may comprise a plurality of first probes, a plurality of second probes, and / or a plurality of first probes and a plurality of second probes. A probe or a set of probes may be designed to target a specific sequence or a set of specific sequences. Such probes may be designed to have the same or different sequences within different partitions. For example, a first composition may comprise a first probe and a second probe designed to target two regions of a first gene, and a second composition may comprise a first probe and a second probe designed to target two regions of a second gene, which second gene is different than the first gene. A composition may comprise nucleic acid barcode molecules, and / or probe binding molecules, which may optionally be provided coupled to a support (e.g., particle, bead). A composition may be a part of or comprise a reaction mixture, which can include reaction components or reagents, e.g., enzymes, nucleotide bases, catalysts, buffers etc.Attorney Docket No.43487-1029601 Multiplexed analysis of nucleic acids and proteins

[0180] In another aspect, the present disclosure provides methods for performingmultiplexed assays. Such a multiplexed assay may comprise assaying or analyzing one or more biomolecules (e.g., nucleic acid molecules, proteins, lipids, carbohydrates, etc.). A method may comprise using one or more probes and a nucleic acid barcode molecule to barcode a nucleic acid molecule of a cell / nucleus / cell bead, thereby generating a first barcoded nucleic acid molecule; attaching or coupling a feature-binding group to a feature of the cell / nucleus / cell bead, wherein the feature-binding group comprises a reporter oligonucleotide comprising a reporter sequence that identifies the feature-binding group; using an additional nucleic acid barcode molecule, and optionally, an additional probe, to barcode the reporter sequence to generate a second barcoded nucleic acid molecule; and optionally barcoding the first barcoded nucleic acid molecule and the second barcoded nucleic acid molecule to generate a third barcoded nucleic acid molecule and a fourth barcoded nucleic acid molecule. One or more operations may be performed within a partition (e.g., droplet or well).

[0181] The methods described herein may facilitate profiling of one or more biomoleculeswith single-cell / single nucleus / single cell bead resolution, using, for example, probe hybridization, feature binding groups (e.g., antibodies, antibody fragments, epitope-binding groups, etc.), barcoding, amplification, and sequencing. The methods may be useful in providing genomic, transcriptomic, proteomic, exomic, or other “-omic” information from a single cell / nucleus / cell bead. As described herein, the methods may be used to analyze a pre- determined panel of target genes and a pre-determined panel of target features (e.g., proteins, peptides, or other biomolecules) in a sensitive and accurate manner. Alternatively or in addition to, the methods may be used to analyze whole genomic, whole transcriptomic, whole exomic, etc. characteristics of a cell.

[0182] In some aspects, the methods comprise contacting a cell / nucleus / cell bead with a firstprobe, a second probe, and a third probe under conditions sufficient to generate a first probe- associated molecule and a second probe-associated molecule. The cell / nucleus / cell bead may comprise (i) a nucleic acid molecule (e.g., a target nucleic acid molecule such as RNA or DNA) comprising a first target region and a second target region and (ii) a feature (e.g., protein, peptide, or other biomolecule) coupled to a feature-binding group. The feature binding group may comprise or be coupled to (i) a reporter oligonucleotide comprising a reporter sequence, which may be associated with the feature or may be used to identify the feature, and (ii) a feature probe-binding sequence. The first probe may comprise a first probe sequence complementary to the first target region of the nucleic acid molecule and, optionally, an additional probe sequence,Attorney Docket No.43487-1029601 such as a probe capture sequence or other functional sequence. The second probe may comprise a second probe sequence complementary to the second target region and, optionally, a probe capture sequence or functional sequence. The third probe may comprise (i) a third probe sequence complementary to the feature probe-binding sequence and (ii) a probe capture sequence or functional sequence, which may be the same sequence as the probe capture sequence of the first probe and / or second probe.

[0183] In some instances, the first probe-associated molecule may comprise the nucleic acidmolecule, the first probe, the second probe, or combinations or complements thereof. The second probe-associated molecule may comprise the reporter oligonucleotide (which comprises the reporter sequence) and the third probe, or complements thereof.

[0184] In some aspects, the method comprises providing the first probe-associated moleculeand the second probe-associated molecule, and barcoding the first probe-associated molecule and the second probe-associated molecules. Such barcoding operations may occur in a first set of partitions (e.g., droplets or wells). Such an example method may comprise contacting the first probe-associated molecule and the second-probe-associated molecule with probe binding molecules (e.g., a splint oligonucleotide) and barcode molecules (e.g., nucleic acid barcode molecules) under conditions sufficient to generate a first barcoded nucleic acid molecule and a second barcoded nucleic acid molecule. The barcode molecules may comprise (i) a barcode capture sequence, e.g., a common sequence that is common to a plurality of barcode molecules and (ii) a first barcode sequence. In instances where partitions are used, the first barcode sequence may be unique to a first partition of a first set of partitions, and the barcode molecules within the first partition may share the same first barcode sequence. The probe-binding molecule may comprise (i) a probe-binding sequence complementary to the probe capture sequence (of the first probe, the second probe, and / or the third probe) and (ii) a barcode binding sequence complementary to the barcode capture sequence (e.g., common sequence) of the plurality of barcode molecules. As such, barcoding of the first probe-associated molecule and the second probe-associated molecule may comprise hybridization of the probe binding molecule to (i) the probe capture sequence (or complement thereof) of the first probe, the second probe, and / or the third probe, and (ii) the barcode capture sequence (or common sequence) of the nucleic acid barcode molecule. In some examples, the first barcoded nucleic acid molecule comprises a sequence corresponding to the first probe sequence, a sequence corresponding to the second probe sequence, and a sequence corresponding to the first barcode sequence. Similarly, the second barcoded nucleic acid molecule may comprise a sequence corresponding to the reporter sequence, a sequence corresponding to the third probe sequence, and a sequence corresponding to the first barcode sequence.Attorney Docket No.43487-1029601

[0185] The method may further comprise providing a second set of partitions, and in asecond partition of the second set of partitions, (i) contacting the first barcoded nucleic acid molecule, or derivative thereof (e.g., complements, amplicons, extension products thereof), to a first capture molecule of a plurality of capture molecules under conditions sufficient to generate a third barcoded nucleic acid molecule, and (ii) contacting the second barcoded nucleic acid molecule, or derivative thereof, to a second capture molecule of the plurality of capture molecules under conditions sufficient to generate a fourth barcoded nucleic acid molecule. The plurality of capture molecules may each comprise a second barcode sequence, which may be the same or different than the first barcode sequence from the first set of partitions. The second barcode sequence may be unique to the partition (e.g., differ across partitions). The third barcoded nucleic acid molecule and the fourth barcoded molecule may each comprise a sequence corresponding to the first barcode sequence and a sequence corresponding to the second barcode sequence. For example, the third barcoded nucleic acid molecule may comprise a sequence corresponding to the first target region, a sequence corresponding to the second target region, a sequence corresponding to a probe capture sequence, the first barcode sequence and the second barcode sequence. The fourth barcoded nucleic acid molecule may comprise a sequence corresponding to the reporter sequence, a sequence corresponding to the feature probe binding sequence, a sequence corresponding to the third probe, the first barcode sequence and the second barcode sequence.

[0186] The feature binding group may comprise a labelling agent, as described elsewhereherein. Accordingly, the feature binding group may comprise, in some examples, an antibody or antibody fragment, an epitope binding moiety, a protein, a peptide, a lipophilic moiety (such as cholesterol), a cell surface receptor binding molecule, a receptor ligand, a small molecule, a bi- specific antibody, a bi-specific T-cell engager, a T-cell receptor engager, a B-cell receptor engager, a pro-body, an aptamer, a monobody, an affimer, a darpin, and a protein scaffold, or any combination thereof.

[0187] The probe capture sequence of the first probe (or the second probe) may be commonto a plurality of first probes (or second probes), a plurality of partitions, and / or a plurality of cells / nuclei / cell beads. For instance, the first set of partitions may comprise one or more additional partitions that comprise additional probe-associated nucleic acid molecules. The additional probe-associated nucleic acid molecules may comprise identical sequences (e.g., first probe sequence, second probe sequence) to the probe-associated nucleic acid molecule of the first partition, or the additional probe-associated nucleic acid molecules of the additional partitions may comprise different sequences (e.g., different probe sequences) than the probe- associated nucleic acid molecule of the first partition. In some instances, each of the one or moreAttorney Docket No.43487-1029601 additional probe-associated nucleic acid molecules comprises a probe capture sequence, which may be identical or different across the first set of partitions.

[0188] The probe-associated molecules may be a probe-linked molecule. For example, theprobe-associated molecules may be the probe-associated molecules or barcoded molecules described herein (e.g., in FIGS.7-9), or a probe-linked molecule, such as those described in U.S. Pat. Pub. No.2020 / 0239874 and International Pub. No. WO 2019 / 165318, each of which is incorporated by reference herein in its entirety. In some examples, two sets of probe-associated molecules may be generated, in which: (i) a first probe-associated molecule comprises the nucleic acid molecule, with the first probe and the second probe hybridized thereto (e.g., via hybridization of the first probe sequence to the first target region and the second probe sequence to the second target region) and (ii) a second probe-associated molecule comprises the reporter oligonucleotide (which comprises the reporter sequence), with the third probe hybridized thereto.

[0189] The first probe, the second probe, and / or the third probe may comprise a probecapture sequence. The probe capture sequence on the first probe may be the same or different than the probe capture sequence of the second probe or the third probe. Similarly, the probe capture sequence of the second probe may be the same or different than the probe capture sequence of the third probe. Accordingly, the barcoding operations described herein may occur on the first probe, the second probe, the third probe, or any combination thereof. For example, for a probe-associated molecule comprising a nucleic acid molecule and the first probe (“probe 1”) and second probe (“probe 2”) hybridized thereto, a first barcode molecule comprising the first barcode sequence (“BC1”) may hybridize (e.g., directly or via a probe-binding molecule) to the first probe to generate a first barcoded nucleic acid molecule, and subsequently, a capture molecule comprising a second barcode sequence (“BC2”) may be annealed to a region of the first barcode molecule, thereby generating a molecule comprising a sequence, or complementary sequences, of BC2-BC1-probe 1-probe 2. Alternatively or in addition to, the first barcode molecule comprising the first barcode sequence (“BC1”) may hybridize (e.g., directly or via a probe-binding molecule) to the second probe to generate a first barcoded nucleic acid molecule, and subsequently, a capture molecule comprising the second barcode sequence (“BC2”) may be annealed to a region of the first barcode molecule, thereby generating a molecule comprising a sequence of probe 1-probe 2-BC1-BC2. Alternatively or in addition to, the barcode molecules and the capture molecules may be annealed to different probes. For example, the first barcode molecule comprising the first barcode sequence (“BC1”) may hybridize (e.g., directly or via a probe-binding molecule) to the first probe to generate a first barcoded nucleic acid molecule, and subsequently, a capture molecule comprising the second barcode sequence (“BC2”) may be annealed to the second probe, thereby generating a molecule comprising a sequence of BC1-Attorney Docket No.43487-1029601 probe 1-probe 2-BC2. Alternatively or in addition to, the first barcode molecule comprising the first barcode sequence (“BC1”) may hybridize (e.g., directly or via a probe-binding molecule) to the second probe to generate a first barcoded nucleic acid molecule, and subsequently, a capture molecule comprising the second barcode sequence (“BC2”) may be annealed to the first probe, thereby generating a molecule comprising a sequence of BC2-probe 1-probe 2-BC1. It will be appreciated that while several examples of barcoding schemes are described herein, additional combinations and positioning of barcode sequences are possible; for example, combinatorial barcoding may be used to generate greater barcode diversity, as described herein, and such barcoding may occur on any of the probe molecules (or already barcoded molecules).

[0190] In some instances, the barcode molecules may comprise a capture-binding sequencecomplementary to a capture sequence of the plurality of capture molecules. For example, the first probe may comprise a probe capture sequence which may hybridize to a probe binding molecule, which may mediate hybridization of the barcode molecule (e.g., via hybridization of the barcode binding sequence of the probe binding molecule to the barcode capture sequence (e.g., common sequence) of the barcode molecule). The barcode molecule may additionally comprise the capture-binding sequence, which may allow for hybridization of the capture sequence of the capture molecules to the barcode molecule.

[0191] FIGs. 15A-15C schematically illustrate an example barcoded nucleic acid moleculeas described herein. Referring to FIG.15A, a nucleic acid molecule (e.g., RNA molecule) 1500 comprising a first target region 1502 and a second target region 1504 may be provided. The nucleic acid molecule 1500 may be contacted with a first probe 1506 comprising a first probe sequence 1508 and, optionally, a first probe capture sequence 1510. The first probe sequence 1508 may be complementary to the first target region 1502. The first probe capture sequence 1510 may additionally, in some instances, comprise a functional sequence, such as a primer sequence, a partial primer sequence, a barcode sequence, a sequencing primer sequence, etc. The nucleic acid molecule 1500 may also be contacted with a second probe 1516 comprising a second probe sequence 1514 and, optionally, a second probe capture sequence 1518. The second probe sequence 1514 may be complementary to the second target region 1504. The second probe capture sequence 1518 may additionally comprise a functional sequence. Hybridization of the first probe 1506 and the second probe 1516 to the nucleic acid molecule 1500 may generate a probe-associated molecule.

[0192] As described herein, the probe-associated molecule may be subjected to one or morebarcoding operations. Such a barcoding operation may occur in one or more partitions (e.g., a first set of partitions) and may include hybridizing a probe binding molecule 1517 and a barcode molecule 1519 comprising a barcode capture sequence (e.g., a common sequence), to the probe-Attorney Docket No.43487-1029601 associated molecule. In some instances, the probe binding molecule 1517 and the barcode molecule 1519 may be provided as a pre-annealed complex, or they may be provided as separate molecules. The barcode capture sequence (e.g., common sequence) may be a sequence that is common to the plurality of barcode molecules in the first set of partitions, or the common sequence may be unique to the barcode molecules in only a single first partition (e.g., the common sequence differs across partitions of the first set of partitions). The probe binding molecule 1517 may comprise a probe binding sequence complementary to the probe capture sequence 1518 of the second probe 1516, as well as a barcode binding sequence complementary to a sequence of the barcode molecule 1519. The probe-associated molecule may be subjected to conditions sufficient to generate a first barcoded nucleic acid molecule, which can include annealing of the probe-binding molecule 1517 to (i) the probe capture sequence 1518 and (ii) the barcode capture sequence (e.g., common sequence) of the barcode molecule 1519. The barcoding process may comprise additional operations, such as ligation, which may be performed chemically or enzymatically, as described elsewhere herein.

[0193] The first barcoded nucleic acid molecule or derivatives thereof (e.g., a complement,an amplicon, an extension product, a combinatorially barcoded nucleic acid molecule, as described elsewhere herein), may be subjected to a second barcoding operation. Such a second barcoding operation may occur in a second set of partitions. For example, the first barcoded nucleic acid molecule may be removed from the first set of partitions, pooled (e.g., with other barcoded nucleic acid molecules from other first partitions of the first set of partitions), and partitioned in a second partition of a second set of partitions. The second partition may comprise a capture molecule 1520. The capture molecule 1520 may comprise a second barcode sequence and a sequence complementary to the probe capture sequence 1510 of the first probe 1506. The second barcode sequence may be a sequence that is common to the plurality of capture molecules in the second set of partitions, or the barcode sequence may be unique to the capture molecules in only the second partition (e.g., differ across partitions). The capture molecule 1520 may hybridize to the probe capture sequence 1510 to generate an additional barcoded molecule (also referred to herein as a “third barcoded nucleic acid molecule”). The additional barcoded molecule may comprise a sequence corresponding to the first barcode sequence (of the barcode molecule 1519), and a sequence corresponding to the second barcode sequence (of the capture molecule 1520).

[0194] FIG. 15B schematically illustrates another example barcoded molecule in which thecapture molecule 1520 is hybridized to the barcode molecule 1519. Similar to Panel A, in Panel B, the nucleic acid molecule (e.g., RNA molecule) 1500 comprising a first target region 1502 and a second target region 1504 may be provided. The nucleic acid molecule 1500 may beAttorney Docket No.43487-1029601 contacted with a first probe 1506 comprising a first probe sequence 1508 and a probe capture sequence 1510. The first probe sequence 1508 may be complementary to the first target region 1502. The probe capture sequence 1510 may additionally comprise a functional sequence, such as a primer sequence, a partial primer sequence, a barcode sequence, a sequencing primer sequence, etc. The nucleic acid molecule 1500 may also be contacted with a second probe 1516 comprising a second probe sequence 1514 and, optionally, an additional sequence 1518. The second probe sequence 1514 may be complementary to the second target region 1504. The additional sequence 1518 may comprise, for instance, a probe capture sequence, or a functional sequence (e.g., primer, primer binding site, sequencing primer sequence, etc.). Hybridization of the first probe 1506 and the second probe 1516 to the nucleic acid molecule 1500 may generate a probe-associated molecule.

[0195] The probe-associated molecule may be contacted with one or more barcodemolecules. Such barcoding operations, as described herein, may occur in a plurality of partitions (e.g., a first partition of a first set of partitions and / or a second partition of a second set of partitions). The probe-associated molecule may be contacted with a probe binding molecule 1517 and a barcode molecule 1519, which may comprise a first barcode capture sequence (e.g., a common sequence) and a second barcode capture sequence 1521 (also referred to herein as “capture binding sequence”). In some instances, the probe binding molecule 1517 and the barcode molecule 1519 may be provided as a pre-annealed complex or as separate molecules. The first barcode capture sequence (e.g., common sequence) may be a sequence that is common to the plurality of barcode molecules in the first set of partitions, or the common sequence may be unique to the barcode molecules in only the first partition (e.g., differ across partitions). The probe binding molecule 1517 may comprise a probe binding sequence complementary to the probe capture sequence 1510 as well as a barcode binding sequence complementary to the first barcode capture sequence (e.g., common sequence) of the barcode molecule 1519. The probe- associated molecule may be subjected to conditions sufficient to generate a first barcoded nucleic acid molecule, which can include annealing of the probe-binding molecule 1517 to (i) the probe capture sequence 1510 and (ii) the first barcode capture sequence (e.g., common sequence) of the barcode molecule 1519. The barcoding process may comprise additional operations, such as ligation, which may be performed chemically or enzymatically, as described elsewhere herein.

[0196] The first barcoded nucleic acid molecule or derivatives thereof, may be subjected to asecond barcoding operation. Such a second barcoding operation may occur in a second set of partitions. For example, the first barcoded nucleic acid molecule may be removed from the first partition and partitioned in a second partition of a second set of partitions (e.g., droplets). The second partition may comprise a capture molecule 1520. The capture molecule 1520 mayAttorney Docket No.43487-1029601 comprise a second barcode sequence and a sequence complementary to the second barcode capture sequence 1521 of the barcode molecule 1519. The second barcode sequence may be a sequence that is common to the plurality of capture molecules in the second set of partitions, or the barcode sequence may be unique to the capture molecules in only the second partition (e.g., differ across partitions). The capture molecule may hybridize to the second barcode capture sequence 1521 to generate an additional barcoded molecule (also referred to herein as a “third barcoded nucleic acid molecule”). The additional barcoded molecule may comprise a sequence corresponding to the first barcode sequence (of the barcode molecule 1519), and a sequence corresponding to the second barcode sequence (of the capture molecule 1520).

[0197] FIG. 15C illustrates another example barcoded nucleic acid molecule. A nucleic acidmolecule (e.g., RNA molecule) 1500 comprising a first target region 1502 and a second target region 1504 may be provided. The nucleic acid molecule 1500 may be contacted with a first probe 1506 comprising a first probe sequence 1508 and, optionally, a first probe capture sequence 1510. The first probe sequence 1508 may be complementary to the first target region 1502. The first probe or first probe capture sequence 1510 may additionally, in some instances, comprise a functional sequence, such as a primer sequence, a partial primer sequence, a barcode sequence, a sequencing primer sequence, etc. The nucleic acid molecule 1500 may also be contacted with a second probe 1516 comprising a second probe sequence 1514 and, optionally, a second probe capture sequence 1518. The second probe sequence 1514 may be complementary to the second target region 1504. The second probe capture sequence 1518 may additionally comprise a functional sequence. Hybridization of the first probe 1506 and the second probe 1516 to the nucleic acid molecule 1500 may generate a probe-associated molecule or complex.

[0198] As described herein, the probe-associated molecule may be subjected to one or morebarcoding operations. Such a barcoding operation may occur in one or more partitions (e.g., a first set of partitions) and may include hybridizing a probe binding molecule 1517 and a barcode molecule 1519 comprising a barcode capture sequence (e.g., a common sequence), to the probe- associated molecule or complex. In some instances, the probe binding molecule 1517 and the barcode molecule 1519 are provided as a pre-annealed complex (e.g., a partially double-stranded molecule comprising the probe binding molecule 1517 and the barcode molecule 1519), or they may be provided as separate molecules, which may separately anneal to the probe-associated molecule or complex (e.g., the probe binding molecule 1517 may hybridize to the probe- associated molecule or complex, e.g., via the second probe capture sequence 1518, and the barcode molecule 1519 may hybridize to the probe binding molecule 1517). The barcode capture sequence (e.g., common sequence) may be a sequence that is common to the plurality of barcode molecules in the first set of partitions, or the common sequence may be unique to the barcodeAttorney Docket No.43487-1029601 molecules in only a single first partition (e.g., the common sequence differs across partitions of the first set of partitions). The probe binding molecule 1517 may comprise a probe binding sequence complementary to the probe capture sequence 1518 of the second probe 1516, as well as a barcode binding sequence complementary to a sequence of the barcode molecule 1519. In some instances, the probe binding molecule 1517 and / or the barcode molecule 1519 comprise an additional sequence, e.g., an adapter sequence, a primer sequence (e.g., sequencing primer sequence or partial sequencing primer sequence), a UMI, a sample index sequence, etc. In some instances, the probe binding molecule 1517 comprises the entire sequence of the barcode molecule 1519, such that no overhang remains. In some instances, the probe binding molecule 1517 and barcode molecule 1519 comprise a sample index sequence, which may be useful in identifying the partition, cell, nucleus, or cell bead from which the target nucleic acid molecule 1500 originates. The probe-associated molecule may be subjected to conditions sufficient to generate a first barcoded nucleic acid molecule, which can include annealing of the probe- binding molecule 1517 to (i) the probe capture sequence 1518 and (ii) the barcode capture sequence (e.g., common sequence) of the barcode molecule 1519. The barcoding process may comprise additional operations, such as ligation (e.g., ligation of the barcode molecule 1519 to the probe capture sequence 1518), which may be performed chemically or enzymatically, as described elsewhere herein.

[0199] The first barcoded nucleic acid molecule or derivatives thereof (e.g., a complement,an amplicon, an extension product, a combinatorially barcoded nucleic acid molecule, as described elsewhere herein), may be subjected to a second barcoding operation. Such a second barcoding operation may occur in a second set of partitions. For example, the first barcoded nucleic acid molecule may be removed from the first set of partitions, pooled (e.g., with other barcoded nucleic acid molecules from other first partitions of the first set of partitions), and partitioned in a second partition of a second set of partitions. The second partition may comprise a capture molecule 1520. The capture molecule 1520 may comprise a second barcode sequence and a sequence complementary to the probe capture sequence 1510 of the first probe 1506 (and / or the second probe 1516). The second barcode sequence may be a sequence that is common to the plurality of capture molecules in the second set of partitions, or the barcode sequence may be unique to the capture molecules in only the second partition (e.g., differ across partitions). The capture molecule 1520 may hybridize to the probe capture sequence 1510 to generate an additional barcoded molecule (also referred to herein as a “third barcoded nucleic acid molecule”). The additional barcoded molecule may comprise a sequence corresponding to the first barcode sequence (of the barcode molecule 1519), and a sequence corresponding to the second barcode sequence (of the capture molecule 1520).Attorney Docket No.43487-1029601

[0200] In addition to barcoding of nucleic acid molecules, the present disclosure provides formethods of multiplexed analysis, e.g., processing of additional biomolecule types, such as proteins and peptides. The method may comprise providing a feature-binding group (e.g., antibody, protein, binding moiety, etc.), which may couple to or bind to a feature (e.g., protein, peptide) of a cell, nucleus or cell bead. Such a method may comprise providing a cell, nucleus or cell bead having a feature of interest (e.g., protein) and contacting the cell, nucleus or cell bead with the feature-binding group. The feature-binding group may couple to the feature of interest. The feature-binding group may comprise a reporter oligonucleotide comprising a reporter sequence coupled thereto, which may be specific for a particular feature and thus be used to identify the feature. For example, the feature-binding group may be an antibody and the reporter oligonucleotide may comprise a reporter sequence that identifies the antigen or binding moiety (e.g., epitope, epitope fragment) to which the antibody couples or binds. Alternatively or in addition to, the feature binding group may comprise a feature probe binding sequence, which may be used for downstream probe-binding and / or barcoding. Following the contacting of the cell (nucleus or cell bead) with the feature binding group, the cell / nucleus / cell bead may comprise the feature coupled to the feature binding group.

[0201] In some instances, the methods described herein may additionally comprise:providing a cell, nucleus or cell bead comprising (i) the nucleic acid molecule comprising the first target region and the second target region and (ii) the feature coupled to the feature binding group and contacting the cell, nucleus or cell bead with a plurality of probes. The cell / nucleus / cell bead may be contacted (e.g., in a first partition) with a first probe, a second probe, and a third probe. As described herein, the first probe and the second probe may associate with the first target region and the second target region of the nucleic acid molecule, thereby generating a first probe-associated molecule. Similarly, the third probe may associate with (e.g., via hybridization) with the feature binding group, thereby generating a second probe-associated molecule. In some instances, the third probe may comprise a third probe sequence that is complementary to the feature probe binding sequence, and in some instances, the third probe may additionally comprise a probe capture sequence. The first probe and / or the second comprise may also comprise a probe capture sequence, which may be the same or different than the probe capture sequence of the third probe.

[0202] In the first set of partitions, the first probe-associated molecule (e.g., the nucleic acidmolecule with the first probe and the second probe associated therewith) and the second-probe- associated molecule (e.g., the feature binding group with the third probe associated therewith) may be barcoded. Such a barcoding operation may comprise, for example, providing barcode molecules comprising a first barcode sequence and a barcode-capture sequence such as aAttorney Docket No.43487-1029601 common sequence, which may hybridize directly with the first probe-associated molecule and the second probe-associated molecule, e.g., via the probe capture sequences. Alternatively or in addition to, the barcode molecules may be provided with probe-binding molecules which comprise (i) a probe binding sequence complementary to the probe capture sequence of the first probe, the second probe, and / or the third probe and (ii) a barcode binding sequence, which may be complementary to the common sequence of the barcode molecules. In some instances, the probe binding molecules and the barcode molecules may be provided as a pre-annealed complex. Barcoding of the first probe-associated molecule and the second probe-associated molecule may include hybridization of the barcode molecules (e.g., the barcode capture sequence such as a common sequence) to a portion (e.g., the probe capture sequence) of the first probe-associated molecule and the second probe-associated molecule, or the barcoding may include hybridization of the barcode molecules to the probe binding molecule and hybridization of the probe binding molecule to the first probe-associated molecule or the second probe-associated molecule. Additional operations such as ligation (e.g., enzymatic or chemical ligation) may be performed to generate the first barcoded molecule and the second barcoded molecule.

[0203] The first barcoded molecule and the second barcoded molecule may be subjected toadditional barcoding operations, e.g., in a second set of partitions. Such additional barcoding operations may include: contacting the first barcoded nucleic acid molecule or derivative thereof to a first capture molecule of a plurality of capture molecules to generate a third barcoded nucleic acid molecule and contacting the second barcoded nucleic acid molecule or derivative thereof to a second capture molecule of the plurality of capture molecules to generate a fourth barcoded nucleic acid molecule. The capture molecules within a partition may each comprise a second barcode sequence, which may be unique to the partition (e.g., differ across partitions). Accordingly, both the third barcoded nucleic acid molecule and the fourth barcoded nucleic acid molecule may comprise a first barcode sequence (or complement thereof) and a second barcode sequence (or complement thereof).

[0204] FIG. 16A schematically illustrates an example workflow for barcoding multipleanalytes of a cell, nucleus or cell bead. The cell, nucleus or cell bead 1600 may comprise a nucleic acid molecule (e.g., RNA molecule or other target nucleic acid molecule) 1601 comprising a first target region 1602 and a second target region 1604. The cell, nucleus or cell bead may additionally comprise a feature (e.g., a protein, such as a cell surface receptor (or nuclear membrane protein) or an intracellular / intranuclear protein) 1650. In some instances, the cell, nucleus or cell bead 1600 may be processed, e.g., fixed, permeabilized, treated with a treatment, etc. In some instances, such processing may include providing one or more feature binding groups (e.g., antibodies, antibody fragments, etc.) 1652, which may couple to the featureAttorney Docket No.43487-1029601 1650. The feature binding group 1652 may comprise or be coupled to a reporter oligonucleotide 1657, which may comprise a reporter sequence 1654. The reporter sequence 1654 may be indicative of the feature binding group 1652 or feature 1650. For instance, the reporter sequence 1654 may be pre-indexed or assigned to a particular antibody or other feature binding group, such that presence of the reporter sequence 1654 indicates presence of the particular feature 1650 in a sample. The feature binding group 1652 or the reporter oligonucleotide 1657 may also comprise or be coupled to feature probe binding sequence 1656. In some instances, the cell, nucleus or cell bead 1600 may be contacted with the feature binding group 1652 and fixed, e.g., either in addition to or alternatively to a fixation and permeabilization operation before the contacting.

[0205] In some cases, the analysis of both intracellular and / or intranuclear proteins andmembrane proteins of a cell (or nucleus) can be performed. In one embodiment, a permeabilized (and optionally fixed) cell (or nucleus) may be contacted with (i) one or more feature binding groups (or labeling agents) that are configured to couple to intracellular proteins (or intranuclear proteins) and / or (ii) one or more feature binding groups (or labeling agents) that are configured to couple to cell membrane proteins (or nuclear membrane proteins). As further described herein, permeabilization may involve partially or completely dissolving or disrupting a cell membrane (or nuclear membrane) or a portion thereof. Permeabilization may be achieved by, for example, contacting a cell membrane (or a nuclear membrane) with an organic solvent (e.g., methanol) or a detergent such as Triton X-100 or NP-40. The cell, nucleus, or cell bead may be fixed, as described elsewhere herein.

[0206] Referring again to FIG. 16A, a second feature binding group (or labeling agent)similar to 1652 (not shown) can be used to couple to an intracellular feature, such as an intracellular protein, and comprise or be coupled to a second reporter oligonucleotide, which may comprise a second reporter sequence. The second reporter sequence may be indicative ofthe second feature binding group or the intracellular feature. For instance, the second reportersequence may be pre-indexed or assigned to a particular antibody or other feature binding group, such that presence of the second reporter sequence indicates presence of the particular intracellular feature in a sample. The second feature binding group or the second reporter oligonucleotide may also comprise or be coupled to a second feature probe binding sequence, similar to that of 1656.

[0207] The cell, nucleus or cell bead 1600 may be contacted with a first probe 1606, asecond probe 1616, and a third probe 1658, under conditions sufficient to generate a first probe- associated molecule (or probe-associated complex) 1630 and a second probe-associated molecule (or probe-associated complex) 1665. The first probe-associated molecule 1630 may beAttorney Docket No.43487-1029601 or comprise a probe-linked molecule, as described elsewhere herein. For example, the first probe-associated molecule 1630 (or probe-linked molecule) may be any of the probe-associated molecules or probe-linked molecules described herein (e.g., generated from an extended probe, a barcoded extended probe, etc.). The first probe 1606 may comprise a first probe sequence 1608 and, optionally, a probe capture sequence 1610. The first probe sequence 1608 may be complementary to the first target region 1602. The second probe 1616 may comprise a second probe sequence 1615 and, optionally, a probe capture sequence 1618. The second probe sequence 1615 may be complementary to the second target region 1604. The third probe 1658 may comprise a third probe sequence 1660 and a probe capture sequence 1662. The third probe sequence 1660 may be complementary to the feature probe binding sequence 1656. In some instances, the probe capture sequence 1662 is the same probe capture sequence as the probe capture sequences 1610, 1618 of the first probe and / or the second probe, respectively.

[0208] In one embodiment, the cell, cell bead or nucleus 1600 may be further contacted withadditional probes under conditions to generate additional probe-associated molecules or probe-associated complexes. The additional probe-associated molecule(s) may be or comprise a probe-linked molecule, as described elsewhere herein. For example, the additional probe-associatedmolecule(s) or probe-linked molecule(s) may be any of the probe-associated molecules or probe-linked molecules described herein (e.g., generated from an extended probe, a barcoded extended probe, etc.). In one embodiment, the cell (or cell bead or nucleus) 1600 may be further contacted with a fourth probe (not shown) similar to 1658 which comprises (i) a fourth probe sequence similar to 1660 and (ii) a fourth probe capture sequence similar to 1662. The fourth probe sequence may be complementary to the second feature probe binding sequence, as further described herein. In some instances, the fourth probe capture sequence is the same probe capture sequence as the probe capture sequences 1610, 1618 of the first probe and / or the second probe, respectively.

[0209] In one embodiment, the cell, nucleus or cell bead 1600 may be partitioned into a firstpartition of a first set of partitions prior to any processing operations described above including, without limitation, fixing, permeabilizing, contacting with probes, and generating probe- associated or probe-linked molecules. In another embodiment, the cell, nucleus or cell bead 1600 may be fixed and optionally permeabilized prior to partitioning in the first partition and then subsequently processed in the first partition, e.g., contacting with probes and generating molecules.

[0210] In operation 1670, the cell, nucleus or cell bead 1600 comprising the first probe-associated molecule 1630 and the second probe-associated molecule 1665 may be partitioned into a first partition of a first set of partitions or further processed in the first partition. In anotherAttorney Docket No.43487-1029601 embodiment, the cell, cell bead or nucleus 1600 may further comprise additional probe- associated molecules or complexes. For instance, referring to FIG.16A, 1600 may comprise a third probe-associated complex (not shown) that is similar to 1665 but comprises (i) a fourth probe comprising a fourth probe sequence complementary to the second feature probe binding sequence and (ii) a reporter oligonucleotide (similar to 1657) as further described herein. The reporter oligonucleotide may be provided as part of or coupled to the second feature binding group, e.g., a feature binding group configured to couple to an intracellular protein. In some instances, the cell, nucleus or cell bead 1600 may be subjected to processing within the partition, such as lysis, to release the cellular / nuclear components (e.g., the first probe-associated molecule and the second probe-associated molecule) within the partition. Alternatively, the cell, nucleus or cell bead 1600 may remain intact. In one embodiment, the cell bead is processed to release cellular components while keeping the cell bead intact. Within the first partition, a probe binding molecule 1617 and a barcode molecule 1619 may be provided. The first probe- associated molecule 1630 and the second probe-associated molecule 1665 may be contacted with one or more probe binding molecules 1617 and barcode molecules 1619. In some examples, the first partition further comprises one or more additional probe-associated molecules or complexes similar to 1665 (not shown). The additional probe-associated complex may comprise the third probe-associated complex described above, which comprises a fourth probe and a reporter oligonucleotide for a second feature binding group, e.g., a feature binding group configured to couple to an intracellular protein. Additional probe-associated complexes, such as the third probe-associated complex, may be contacted with one or more probe binding molecules 1617 and barcode molecules 1619. In one embodiment, the contacting of a cell, nucleus or cell bead 1600 in the first partition with one or more probe binding molecules may be simultaneously as the contacting with the probes (e.g., 1606, 1616, 1658 and optionally the fourth probe) as described above. The barcode molecules 1619 may comprise a barcode capture sequence or a common sequence common to a plurality of barcode molecules and a first barcode sequence common to the first partition of the first set of partitions. The nucleic acid barcode molecule may, in some instances, be coupled to a bead, such as a gel bead, or other support, as described herein, and can comprise additional functional sequences, including, but not limited to, a unique molecular identifier (UMI), a capture sequence, a primer sequence (e.g., a R1 / R2 sequence), additional barcode sequence segments, etc.. The probe binding molecules 1617 may comprise a probe binding sequence complementary to any or a combination of the probe capture sequences1610, 1618, 1662, a fourth probe capture sequence, and a barcode binding sequencecomplementary to the common sequence of the barcode molecule 1619. In some instances, the probe binding molecules 1617 and the barcode molecules 1619 may be provided as a pre-Attorney Docket No.43487-1029601 annealed complex. The probe binding molecules 1617 and the barcode molecules 1619 may hybridize to the first probe-associated molecule 1630 and the second probe-associated molecule 1665 and / or an additional probe-associated complex, such as the third probe-associated complex (e.g., via hybridization of the probe binding molecules 1617 to the probe capture sequences 1610, 1618, 1662, and the fourth probe capture sequence), thereby generating a first barcoded nucleic acid molecule and a second barcoded nucleic acid molecule, and optionally additional barcoded nucleic acid molecules. Additional processing may occur within the first partition, e.g., ligation of the barcode molecules 1619 to the probes (1606, 1616, 1658 or the fourth probe). In one additional embodiment, the additional barcoded nucleic acid molecule is generating using an additional probe-associated complex, e.g., the third probe-associated complex (not shown), probe binding molecules 1617 and barcode molecules 1619.

[0211] In operation 1680, the contents of each partition or a subset of the first set ofpartitions may be collected from the first set of partitions, e.g., from operation 1670, and re- partitioned into a second set of partitions. The contents of the first set of partitions may comprise the cell, nucleus or cell bead 1600 and / or the processed cellular or nuclear components, e.g., the first barcoded nucleic acid molecule, the second barcoded nucleic acid molecule, and optionally the additional barcoded nucleic acid molecule(s). The contents of the partitions of the first set of partitions may be pooled together and re-distributed to a second set of partitions. Accordingly, a second partition of the second set of partitions may comprise the cell, nucleus or cell bead 1600 and / or the processed cellular / nuclear components. In some instances, the cell, nucleus or cell bead 1600 may be subjected to processing within the second partition, such as lysis, to release the cellular / nuclear components (e.g., the first barcoded nucleic acid molecule, the second barcoded nucleic acid molecule, and optionally the additional barcoded nucleic acid molecule(s)) within the second partition. Alternatively, the cell, nucleus or cell bead 1600 may remain intact. Within the second partition, a plurality of capture molecules 1620 may be provided. In some instances, the plurality of capture molecules 1620 may be coupled to a support (e.g., a particle, bead, gel bead, etc.). In some instances, the plurality of capture molecules 1620 may be releasably coupled to the support and the plurality of capture molecules 1620 may be released in the second partition. The capture molecules 1620 may each comprise a second barcode sequence, which may be the same sequence or a different sequence as the first barcode sequence (of the barcode molecule 1619). The second barcode sequence may be unique to the second partition and differ from the second barcode sequences of other partitions of the second set of partitions. The first barcoded nucleic acid molecule and the second barcoded nucleic acid molecule may each be contacted with a capture molecule 1620. The capture molecules 1620 may comprise a second barcode capture sequence, which may be complementary to a sequence of the barcodeAttorney Docket No.43487-1029601 molecule 1619. Hybridization of the capture molecules 1620 to the first barcoded molecule and the second barcoded nucleic acid molecule may be sufficient to generate a third barcoded nucleic acid molecule and a fourth barcoded nucleic acid molecule. In addition, hybridization of capture molecules 1620 to the additional barcoded nucleic acid molecule(s), e.g., from additional reporter oligonucleotides 1657 on additional feature binding groups 1652, may be sufficient to generate a fifth barcoded nucleic acid molecule. Alternatively, hybridization of the capture molecules 1620 to the first barcoded molecule and the second barcoded nucleic acid molecule may be sufficient to couple the capture molecule (comprising the second barcode sequence) to both the first barcoded molecule and the second barcoded nucleic acid molecule. In addition, hybridization of a capture molecule 1620 to the additional barcoded nucleic acid molecule may be sufficient to couple the capture molecule (comprising the second barcode sequence) to the additional barcoded nucleic acid molecule. Optionally, further processing may be performed, e.g., ligation of the capture molecules 1620 to the first barcoded nucleic acid molecule and the second barcode nucleic acid molecule (and optionally the additional barcoded nucleic acid molecule). Following ligation, the first and second barcoded nucleic acid molecule may comprise the capture molecule 1620. The third barcoded nucleic acid molecule, the fourth barcoded nucleic acid molecule, and the fifth barcoded nucleic acid molecule may each comprise a sequence corresponding to the first barcode sequence and a sequence corresponding to the second barcode sequence. In some instances, an extension reaction is performed (e.g., from the capture molecule 1620 toward the reporter oligonucleotide sequence 1657) to generate the fourth barcoded molecule and / or the fifth barcoded nucleic acid molecule. FIG.16B schematically illustrates another example workflow for barcoding multiple analytes of a cell, nucleus or cell bead. In such an example, the workflow for processing a nucleic acid molecule (e.g., RNA molecule) may be substantially similar to that depicted in FIG.16A, but the workflow for processing a feature (e.g., protein) may differ. For instance, the feature binding group 1652 or the reporter oligonucleotide 1657 may comprise a binding sequence that is capable of hybridizing to a probe binding molecule 1617 and / or barcode molecule 1619.

[0212] As described herein, a permeabilized (and optionally fixed) cell or nucleus may becontacted with one or more feature binding groups 1652, which may (a) comprise the reporter oligonucleotide 1657 and (b) be configured to couple to (i) an intracellular protein (or an intranuclear protein) or (ii) a cell membrane protein (or nuclear membrane protein). In some embodiments, the one or more feature binding groups 1652 includes (i) a first feature binding group that comprises the reporter oligonucleotide 1657 and is configured to couple to an intracellular (or an intranuclear protein) and (ii) a second feature binding group that comprisesAttorney Docket No.43487-1029601 the reporter oligonucleotide 1657 and is configured to couple to a cell membrane protein (or a nuclear membrane protein).

[0213] In operation 1670, the cell, nucleus or cell bead 1600 comprising the first probe-associated molecule 1630 and the one or more feature binding group 1652 may be partitioned into a first partition of a first set of partitions or further processed in the first partition. Within the first partition, a probe binding molecule 1617 and a barcode molecule 1619 may be provided. The feature binding group 1652 (e.g., one or more feature binding groups configured to couple to an intracellular protein or an intranuclear protein) coupled to the reporter oligonucleotide 1657 may be contacted with one or more probe binding molecules 1617 and barcode molecules 1619. A barcode molecule 1619 may comprise a barcode capture sequence or a common sequence common to a plurality of barcode molecules and a first barcode sequence common to the first partition of the first set of partitions. The nucleic acid barcode molecule may, in some instances, be coupled to a bead, such as a gel bead, or other support, as described herein, and can comprise additional functional sequences, including, but not limited to, a unique molecular identifier (UMI), a capture sequence, a primer sequence (e.g., a R1 / R2 sequence), additional barcode sequence segments, etc.. The probe binding molecules 1617 may comprise a probe binding sequence complementary to a sequence of the reporter oligonucleotide 1657. In some instances, the probe binding molecules 1617 and the barcode molecules 1619 may be provided as a pre- annealed complex. The probe binding molecules 1617 and the barcode molecules 1619 may hybridize to the first probe-associated molecule 1630 (as described above) and the reporter oligonucleotide 1657 (e.g., via hybridization of the probe binding molecules 1617 to a sequence of the reporter oligonucleotide 1657), thereby generating a first barcoded nucleic acid molecule and a second barcoded nucleic acid molecule. Additional barcoded nucleic acid molecules may be generated using additional reporter oligonucleotides 1657 from additional feature binding groups 1652 (e.g., configured to couple to cell or nuclear membrane proteins and / or intracellular or intranuclear proteins). Additional processing may occur within the first partition, e.g., ligation of the barcode molecules 1619 to the probes (1606, 1616) or to the reporter oligonucleotide 1657.

[0214] In operation 1680, the contents of each partition or a subset of the first set ofpartitions may be collected from the first set of partitions, e.g., from operation 1670, and re- partitioned into a second set of partitions. The contents of the first set of partitions may comprise the cell, nucleus or cell bead 1600 and / or the processed cellular / nuclear components, e.g., the first barcoded nucleic acid molecule, the second barcoded nucleic acid molecule, and optionally the additional barcoded nucleic acid molecule(s). The contents of the partitions of the first set of partitions may be pooled together and re-distributed to a second set of partitions. Accordingly, aAttorney Docket No.43487-1029601 second partition of the second set of partitions may comprise the cell, nucleus or cell bead 1600 and / or the processed cellular / nuclear components (e.g., barcoded products). In some instances, the cell, nucleus or cell bead 1600 may be subjected to processing within the second partition, such as lysis, to release the cellular / nuclear components (e.g., the first barcoded nucleic acid molecule, the second barcoded nucleic acid molecule, and optionally the additional barcoded nucleic acid molecule(s)) within the second partition. Alternatively, the cell, nucleus or cell bead 1600 may remain intact. Within the second partition, a plurality of capture molecules 1620 may be provided. In some instances, the plurality of capture molecules 1620 may be coupled to a support (e.g., a particle, bead, gel bead, etc.). In some instances, the plurality of capture molecules 1620 may be releasably coupled to the support and the plurality of capture molecules 1620 may be released in the second partition. The capture molecules 1620 may each comprise a second barcode sequence, which may be the same sequence or a different sequence as the first barcode sequence (of the barcode molecule 1619). The second barcode sequence may be unique to the second partition and differ from the second barcode sequences of other partitions of the second set of partitions. The first barcoded nucleic acid molecule and the second barcoded nucleic acid molecule may each be contacted with a capture molecule 1620. The capture molecules 1620 may comprise a second barcode capture sequence, which may be complementary to a sequence of the barcode molecule 1619. Alternatively, the capture molecules 1620 may comprise a sequence complementary to an additional probe-binding molecule (e.g., splint oligonucleotide, not shown), and the probe-binding molecule may comprise a sequence complementary to a sequence of the barcode molecule 1619. Hybridization of the capture molecules 1620 to the first barcoded molecule and the second barcoded nucleic acid molecule (or to the additional probe-binding molecule, which may hybridize to the first barcoded molecule and the second barcoded molecule) may be sufficient to generate a third barcoded nucleic acid molecule and a fourth barcoded nucleic acid molecule. In addition, hybridization of 1620 to the additional barcoded nucleic acid molecule(s), e.g., from additional reporter oligonucleotides 1657 on additional feature binding groups 1652, may be sufficient to generate a fifth barcoded nucleic acid molecule. Alternatively, hybridization of the capture molecules 1620 to the first barcoded molecule and the second barcoded nucleic acid molecule may be sufficient to couple the capture molecule (comprising the second barcode sequence) to both the first barcoded molecule and the second barcoded nucleic acid molecule. In addition, hybridization of 1620 to the additional barcoded nucleic acid molecule may be sufficient to couple the capture molecule (comprising the second barcode sequence) to the additional barcoded nucleic acid molecule e.g., generated from additional reporter oligonucleotides 1657 on additional feature binding groups 1652. Optionally, further processing may be performed, e.g.,Attorney Docket No.43487-1029601 performing an extension reaction, ligation of the capture molecules 1620 to the first barcoded nucleic acid molecule, the second barcode nucleic acid molecule, and optionally the additional barcoded nucleic acid molecule. Following ligation, the first and second barcoded nucleic acid molecule may comprise the capture molecule 1620. The third barcoded nucleic acid molecule, the fourth barcoded nucleic acid molecule, and the fifth barcoded nucleic acid molecule may each comprise a sequence corresponding to the first barcode sequence and a sequence corresponding to the second barcode sequence. In some instances, an extension reaction is performed (e.g., from the capture molecule 1620 toward the reporter oligonucleotide sequence 1657) to generate the fourth barcoded molecule and / or the fifth barcoded nucleic acid molecule.

[0215] In some instances, the reporter oligonucleotide (comprising the reporter sequence) ofthe feature binding group may be contacted with a plurality of probes. For example, it may be beneficial for the feature binding group to be contacted with a pair of probes. In some instances, the reporter oligonucleotide comprises one or more feature probe binding sequences, which may comprise sequences complementary to the pair of probes. For example, referring to FIG.17, a cell, nucleus or cell bead 1700 may comprise a feature (e.g., a protein such as a cell / nuclear membrane protein or an intracellular / intranuclear protein) 1750. A feature binding group 1752 may be coupled to the feature 1750. The feature binding group 1752 may comprise or be coupled to an oligonucleotide comprising a reporter oligonucleotide (comprising a reporter sequence) 1754 and, in some instances, additional functional sequences, such as primer sequences, sequencing primer sequences, UMIs, etc., as described elsewhere herein. The reporter oligonucleotide 1754 may comprise any number of target regions. For example, the reporter oligonucleotide 1754 may comprise two target regions to which a first probe 1757 and a second probe 1758 may hybridize. The two target regions may be adjacent or non-adjacent, and they may be disposed on the same strand of the reporter oligonucleotide 1754. As described herein, the probes may comprise sequences that are complementary to the target regions of the reporter oligonucleotide 1754, and each probe may comprise other useful sequences. For example, a probe (e.g., the first probe 1757 or the second probe 1758) may comprise (i) a probe sequence(e.g., 1760) complementary to a target region of the reporter oligonucleotide 1754, and (ii) aprobe capture sequence 1762, which may be complementary to a sequence of a probe binding molecule 1717 (also referred to as a splint or splint oligonucleotide). The probe binding molecule 1717 may also comprise a sequence complementary to a sequence (e.g., capture sequence) of a barcode molecule 1719. Such barcoding (e.g. hybridization of the probe binding molecule 1717 and barcode molecule 1719 to the probe capture sequence 1762) may occur in bulk or in a partition. In some embodiments, barcoding may be performed without a probe binding molecule.Attorney Docket No.43487-1029601 For example, the barcode molecule 1719 may comprise a sequence complementary to the probe capture sequence 1762 and directly anneal to the probe.

[0216] In some instances, after contacting the feature binding group with the probemolecules 1757 and 1758 (e.g., in bulk or in a partition), the feature binding group 1752 is subjected to conditions sufficient for hybridization of the probe molecules to the reporter oligonucleotide 1754, thereby generating a probe-associated reporter oligonucleotide complex. The coupling of the probes to the reporter oligonucleotide 1754 may occur in bulk or in a partition. In some instances, following coupling or hybridization of the probes to the reporter oligonucleotide 1754, the probes may be linked together (e.g., enzymatically or chemically), thereby generating a probe-linked nucleic acid molecule (or complex). For example, the first probe 1757 may comprise a first reactive moiety and the second probe 1758 may comprise a second reactive moiety. The reactive moieties may be positioned such that, following hybridization of the first probe 1757 and the second probe 1758 to the reporter oligonucleotide 1754, the reactive moieties are adjacent. The reactive moieties may then be subjected to conditions sufficient to cause them to react to yield a probe-linked nucleic acid molecule (or complex) comprising the first probe 1757 linked to the second probe 1758. In some instances, the probes comprise “click chemistry” moieties. Alternatively or in addition to, the first probe may be enzymatically linked (e.g., via ligation) to the second probe. In other instances, a gap region (not shown) may be disposed between the first probe 1757 and the second probe 1758, following hybridization of the probes to the reporter oligonucleotide 1754. In such cases, the first probe 1757 may be linked to the second probe 1758 using a gap-fill approach, such as those described above.

[0217] The probe-linked nucleic acid molecule (or complex) may then be subjected tobarcoding (e.g., contacting with the probe binding molecule 1717 and the barcode molecule 1719), which may occur in a partition. Alternatively, the barcoding may occur prior to the linking of the probes. For example, the reporter oligonucleotide 1754 may be hybridized to the probes, partitioned, barcoded, and then the probes may be linked. Alternatively, the reporter oligonucleotide 1754 may be hybridized to the probes, linked, partitioned, then barcoded. In yet another example, the reporter oligonucleotide 1754 may be hybridized to the probes, partitioned, linked, then barcoded. As will be appreciated, the operations described herein (e.g., hybridization, probe-linking, barcoding) may occur at any useful process, or in any useful order. In some instances, multiple partitioning operations maybe performed, e.g., for combinatorial barcoding.

[0218] The reporter oligonucleotide may comprise the same target sequences (e.g., 702, 704,802, 804, 902, 904, 1502, 1504, 1602, 1604, etc.) as the nucleic acid molecule (e.g., RNAAttorney Docket No.43487-1029601 molecule). For example, referring to FIG.17, the first probe may have a first sequence that is complementary to both the first target sequence of a nucleic acid molecule (e.g., 702, 802, 902, 1502, 1602) and a first sequence of the reporter oligonucleotide 1754, and the second probe may have a second sequence that is complementary to both the second target sequence of a nucleic acid molecule (e.g., 704, 804, 904, 1504, and 1604) and a second sequence of the reporter oligonucleotide 1754. In such instances, the provision of just two probe types (e.g., a first probe and a second probe) to a cell, nucleus or cell bead may be sufficient to generate the first barcoded molecule (e.g., generated from the nucleic acid molecule, e.g., RNA molecule), the second barcoded molecule (e.g., generated from the reporter oligonucleotide of the feature binding group, such as a group configured to couple to a cell / nuclear membrane protein), and additional barcoded molecules (e.g., generated from the reporter oligonucleotide of an additional feature binding group, such as a group configured to couple to an intracellular / intranuclear protein). As described herein, each of the probes (e.g., the first probe and the second probe) may be capable of or configured to hybridize to a barcode molecule (e.g., in the first partition) and / or a capture molecule. As is also described elsewhere herein, each of the probes may be multiplexed or combinatorially barcoded, such that multiplet partitions (e.g., partitions comprising more than one cell, one nucleus or cell bead) may be deconvolved, for example to determine the originating partition or sample of each cell, nucleus or cell bead within a partition (see, e.g., FIG.10). Similarly, the barcoded molecules may be used to determine the origin of different analyte types (e.g., proteins, nucleic acid molecule, etc.); for example, two analyte types may be attributed to the same originating cell, nucleus, cell bead, sample, or partition(s).

[0219] In some instances, the reporter oligonucleotide comprises two or more targetsequences which are different than the target sequences of the nucleic acid molecule (e.g., RNA molecule). Accordingly, four probe types may be provided for performing multiplexed assays; a first probe and a second probe may hybridize to a first target region and a second target region of a nucleic acid molecule, and a third probe and a fourth probe may hybridize to target regions of a reporter oligonucleotide (e.g., a reporter oligonucleotide from a feature binding group, such as a feature binding group configured to couple to a cell / nuclear membrane protein). Additional probe types may be provided, such as a fifth probe and a sixth probe, that hybridize to target regions of an additional reporter oligonucleotide (e.g., a reporter oligonucleotide from a feature binding group, such as a feature binding group configured to couple to an intracellular / intranuclear protein). Each of the probes or a combination of the probes may comprise probe capture sequences, which may be used for subsequent barcoding. For example, each of the probes (e.g., the first probe, the second probe, the third probe, the fourth probe, fifth probe, sixth probe, or a combination thereof) may be capable of or configured to hybridize to aAttorney Docket No.43487-1029601 barcode molecule (e.g., in the first partition) and / or a capture molecule (e.g., in a second partition). As is described elsewhere herein, each of the probes may be multiplexed or combinatorially barcoded, such that multiplet partitions (e.g., partitions comprising more than one cell, nucleus or cell bead) may be deconvolved, for example to determine the originating partition or sample of each cell, nucleus or cell bead within a partition (see, e.g., FIG.10). Similarly the barcoded molecules may be used to determine the origin of different analyte types (e.g., proteins, nucleic acid molecules, etc.); for example, two analyte types may be attributed to the same originating cell, nucleus, cell bead, sample, or partition(s).

[0220] As described elsewhere herein, the nucleic acid molecules (e.g., from a cell, a nucleusor cell bead, or a reporter oligonucleotide) may comprise one or more target regions. The one or more target regions may correspond to a gene or a portion thereof, or another known sequence. The target regions may have the same or different sequences, and may be located within the same strand or on different strands. The target regions may be located adjacent to one another or may be spatially separated along a strand of the nucleic acid molecule. The target regions may be located on the same strand or different strands. Analyzing two or more target regions may involve providing two or more probes, where a first probe has a sequence that is complementary to the first target region, a second probe has a sequence that is complementary to the second target region, etc. As described elsewhere herein, the nucleic acid molecule may be a target nucleic acid molecule and may comprise any number of nucleic acid features or nucleotides.

[0221] As is also described elsewhere herein, any of the probes (e.g., the first probe, thesecond probe, the third probe, etc.), reporter oligonucleotides, or the barcode or capture molecules, may comprise any number of additional adaptor or functional sequences, such as an additional probe sequence, a unique molecule identifier, a barcode sequence, a primer sequence, a capture sequence, a sequencing primer sequence, etc.

[0222] As described herein, one or more operations may be performed within a partition,such as a droplet or well. For instance, the nucleic acid molecule (e.g., RNA molecule) and the feature (e.g., protein), or a cell, nucleus or cell bead comprising the nucleic acid molecule and feature, may be co-partitioned with one or more reagents (e.g., as described herein) at any useful stage of the method. For example, the probe-linked or probe-associated nucleic acid molecule, optionally comprised within or on a cell, nucleus or cell bead, may be generated in a bulk solution or in a partition. Similarly, the cell, nucleus or cell bead may be contacted with a feature binding group in a bulk solution or in a partition. Provision of the probes (e.g., the first probe, the second probe, and the third probe) may occur in the bulk solution or in individual partitions. In the instances where partitions are used, a partition (e.g., a first partition of a first set of partitions) may comprise the first probe, the second probe, the third probe, or a combination thereof.Attorney Docket No.43487-1029601 Different partitions within the first set of partitions may comprise the same or different probes (e.g., for different target sequences or different reporter sequences). Alternatively or in addition to, the probe binding molecules and the nucleic acid barcode molecules may be provided in a partition. For example, the cell, nucleus or cell bead comprising the feature and the nucleic acid molecule may be contacted with the probes in bulk, and partitioned into a first set of partitions. The first set of partitions may comprise the probe binding molecule and the nucleic acid barcode molecules comprising a common sequence. Different partitions among the first set of partitions may comprise barcode molecules with different barcode sequences; for instance, an additional partition of the first set of partitions may comprise numerous barcode molecules that each have a barcode sequence that is unique to the partition (e.g. differs across partitions). The partition may comprise additional reagents for performing a nucleic acid reaction (e.g., digestion, ligation, extension, amplification). For example, the partition may comprise a linking enzyme (e.g., ligase), which may be used to ligate the nucleic acid barcode molecule to the first probe, the second probe, or the third probe (e.g., via the probe capture sequence of each probe). In some instances, the probe binding molecule, the probe capture sequence, and / or the barcode capture sequence (e.g., common sequence) comprises one or more reactive moieties, which may be used to chemically link the nucleic acid barcode molecule to the probe capture sequence. The resultant barcoded products may comprise: a first barcoded product comprising a sequence corresponding to the first target region, a sequence corresponding to the second target region, a sequence corresponding to the probe capture sequence of the first probe or the second probe, and a sequence corresponding to the barcode sequence; and a second barcoded product comprising a sequence corresponding to the reporter sequence, the probe capture sequence of the third probe (which may be the same or different than that of the first probe or second probe), and the barcode sequence.

[0223] As described herein, one or more processes described herein may be performed in acell (e.g., a cell in solution, or a cell comprised within a tissue sample), nucleus or cell bead. For example, a plurality of cells, nuclei or cell beads may comprise a plurality of nucleic acid molecules and features. The cells, nuclei or cell beads may be alive or fixed and / or permeabilized. In some instances, the cells, nuclei or cell beads may be contacted with a feature binding group comprising a reporter sequence. The first probe, the second probe, and the third probe may also be provided to the cells, nuclei or cell beads, in bulk solution or in a partition to generate the first probe-associated molecule and the second probe-associated molecule. Optionally, the cells, nuclei or cell beads may be washed to remove unbound probes. Subsequently, the cells, nuclei or cell beads comprising the probe-associated molecules may be partitioned into a plurality of separate partitions, where at least a subset of the plurality ofAttorney Docket No.43487-1029601 separate partitions comprises a single cell, single nucleus, or single cell bead. Barcoding may be performed within the separate partitions. Barcoding, as described herein, may comprise attaching or hybridizing a nucleic acid barcode molecule to the first probe-associated molecule and the second probe-associated molecule. The nucleic acid barcode molecules provided within each partition of the plurality of separate partitions may be provided attached to beads. In some instances, as described elsewhere herein, the nucleic acid barcode molecule may be releasably attached to a bead (e.g., via a labile bond). Each partition (or a subset of partitions) of the plurality of separate partitions may comprise a bead comprising a plurality of nucleic acid barcode molecules attached thereto (e.g., as described herein). The plurality of nucleic acid barcode molecules attached to each bead may comprise a unique barcode sequence, such that each partition of the plurality of separate partitions comprises a different barcode sequence. Upon release of components from the plurality of different partitions of the plurality of separate partitions (e.g., following barcoding), the barcoded molecules arising from a single cell, single nucleus, or single cell bead may have a same barcode sequence (e.g., a common barcode sequence), such that each barcoded nucleic acid molecule can be traced to a given partition and / or, in some instances, a single cell, a single nucleus, or a single cell bead. The released components may then be partitioned, as described herein, in a second set of partitions comprising capture molecules with a second barcode sequence, such that different partitions of the second set of partitions have a unique second barcode sequence.

[0224] The cells, nuclei, or cell beads described herein may be processed either prior to,during, or following barcoding. For example, the cells, nuclei, or cell beads may be fixed or permeabilized at any useful point in time. In some instances, the cells, nuclei, or cell beads may be fixed and permeabilized prior to or following hybridization of the probes, or prior to or following contact with the feature binding groups. In some instances, the cells, nuclei, or cell beads may be fixed and permeabilized prior to contact with the feature binding groups, and then contacted with the probes. The fixation or permeabilization process may be repeated. For example, a cell, nucleus, or cell bead may be fixed and permeabilized, contacted with the probes and the feature binding groups (either simultaneously or in a step-wise fashion), and then fixed again.

[0225] Following fixation and / or permeabilization, the cells, nuclei, or cell beads may bestored for a duration of time prior to further processing, e.g., contacting the cells, nuclei, or cell beads with the probes and / or feature binding groups. For example, the cells, nuclei, or cell beads may be fixed and / or permeabilized and then contacted with the probes and / or feature binding groups after about 1 minute, 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16Attorney Docket No.43487-1029601 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours or more. The cells, nuclei, or cell beads may be fixed and / or permeabilized and then contacted with the probes and / or feature binding groups after about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days or more. The cells, nuclei, or cell beads may be fixed and / or permeabilized and then contacted with the probes and / or feature binding groups after about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 20 weeks, 30 weeks, 40 weeks, 50 weeks or more. The cells, nuclei, or cell beads may be fixed and / or permeabilized and then contacted with the probes and / or feature binding groups after about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. The cells, nuclei, or cell beads may be fixed and / or permeabilized and then contacted with the probes and / or feature binding groups at any useful time, which may fall within a range of times, e.g., after about 2-5 weeks, after about 3-6 months, after about 1-2 years, etc.

[0226] In some instances, the cells, nuclei, or cell beads may be frozen, e.g., subsequent tofixation and / or permeabilization. Such freezing of the cells, nuclei, or cell beads may be useful in storage of samples for longer durations, e.g., if a sample is to be stored for greater than 1-2 weeks prior to contacting the sample with the probes and / or feature binding groups. For example, the cells, nuclei, or cell beads may be fixed, optionally permeabilized, and then frozen for any useful duration of time, followed by contacting of the cells, nuclei, or cell beads with the probes and / or feature binding groups. Alternatively, the cells, nuclei, or cell beads may be fixed, frozen, and permeabilized, either prior to or following contacting of the cells, nuclei or cell beads with the probes and / or feature binding groups. As will be appreciated, the freezing operation may be performed at any useful or convenient time, e.g., prior to, concurrently with, or following fixation, permeabilization, contacting with probes, contacting with feature binding groups, etc.

[0227] The cells, nuclei, or cell beads may be contacted with the probes and feature bindinggroups at any useful time, in partitions or in bulk. For example, the cells, nuclei, or cell beads may be contacted with the probes prior to, during, or following contact with the feature binding groups. Contact with the probes and / or feature binding groups may occur in bulk or in partitions (e.g., droplets, wells). In some instances, the cells, nuclei, or cell beads may be contacted with the probes and feature binding groups (either simultaneously, or in a step-wise fashion), and then barcoded in partitions. In other instances, the cells, nuclei, or cell beads may be contacted with the probes and feature binding groups in partitions.

[0228] FIG. 29 shows an example workflow of processing cells, according to the methodsdescribed herein. A cell may be fixed and permeabilized, e.g., in 4% formaldehyde and 0.01%Attorney Docket No.43487-1029601 Tween-20 or a commercially available fixation and permeabilization buffer (e.g., commercially available BioLegend® fixation and permeabilization buffer). In one example, the fixed and permeabilized cell may be incubated with a first probe and a second probe to generate a first probe-associated molecule (e.g., a probe-associated RNA molecule). The cell may then be contacted with a feature binding group (e.g., antibody) comprising a reporter oligonucleotide to generate a cell comprising a feature coupled to a feature-binding group. Subsequent barcoding may be performed, e.g., in partitions.

[0229] In some examples, the fixed and permeabilized cell may be incubated with a featurebinding group, optionally fixed again, and then contacted with a first probe and a second probe to generate a probe-associated molecule (e.g., a probe-associated RNA molecule). Alternatively, the fixed and permeabilized cell may be incubated with the first probe and the second probe to generate a probe-associated molecule, and then contacted with the feature binding groups. Subsequent barcoding may be performed, e.g., in partitions.

[0230] In some instances, it may be useful (e.g., as a negative control) to permeabilize thecell prior to contacting the cell with a probe or feature-binding group. Accordingly, a cell may be fixed, contacted with the probe and / or feature binding group, then subsequently permeabilized. It will be appreciated that any order of operations of fixation, permeabilization, probe hybridization, contacting with the feature binding groups, etc., may be performed at any convenient or useful step and in any order, and that any of the processes may be repeated. For example, a cell, nucleus, or cell bead may be contacted with the feature binding groups, fixed and / or permeabilized, contacted with additional feature binding groups, which may be beneficial for assaying extracellular and intracellular peptides, polypeptides, or proteins, and optionally, fixed again. Alternatively, the cell, nucleus, or cell bead may be fixed and / or permeabilized, then contacted with feature binding groups (e.g. for intracellular and / or extracellular analytes) and optionally, fixed again. Prior to or following such processes, the cell, nucleus, or cell bead may be contacted with the sets of probes (e.g., first probe, second probe, and / or third probe). See also, Examples 8 and 9.

[0231] The methods, compositions, kits, and systems of the present disclosure may compriseproviding methods for processing fixed biological particles (e.g., a cell, nucleus, or cell bead). In one embodiment, the method comprises a) fixing and permeabilizing a biological particle or providing a fixed and permeabilized biological particle.

[0232] The method may further comprise b) contacting the fixed and permeabilizedbiological particle with a first reagent configured to couple to an analyte of the biological particle. In one embodiment, the analyte is an intracellular analyte, such as a nucleic acid or a polypeptide, and the biological particle is a cell. In another embodiment, the analyte is anAttorney Docket No.43487-1029601 intranuclear analyte, such as a nucleic acid or a polypeptide, and the biological particle is a nucleus. The first reagent configured to couple to an analyte may be (i) a first reagent configured to couple to a nucleic acid (such as one or more nucleic acid probes as described herein) or (ii) a first reagent configured to couple to a peptide, polypeptide, or protein (such as one or more feature binding groups as described herein). In one other embodiment, b) provides a fixed and permeabilized biological particle, e.g., cell or nucleus, comprising the first reagent coupled to the analyte, e.g., nucleic acid or polypeptide, of the biological particle.

[0233] The method may further comprise c) performing an additional fixation of thebiological particle from b). In one embodiment, c) comprises additional fixation of the biological particle from b), wherein the biological particle from b) comprises the first reagent configured to couple to an analyte of the biological particle. The first reagent may be coupled to the analyte (nucleic acid or polypeptide) of the biological particle (e.g., cell or nucleus). The first reagent may be a reagent configured to couple to a nucleic acid analyte or a reagent configured to couple to a polypeptide. In one embodiment, c) comprises additional fixation of the biological particle, such as a cell, wherein the cell comprises a first reagent coupled to a polypeptide. In another embodiment, the polypeptide is an intracellular polypeptide.

[0234] The method may further comprise d) comprising contacting the biological particle(e.g., cell or nucleus) from c) (which has been initially fixed and permeabilized, contacted with the first reagent or comprises the first reagent, and additionally fixed) with a second reagent configured to couple to an analyte (e.g., a nucleic acid or polypeptide), wherein the second reagent is different from the first reagent and / or the second reagent is configured to couple to an analyte that is different than the analyte that the first reagent is configured to couple to. In one embodiment, the first reagent is configured to couple to a polypeptide (such as one or more feature binding groups as described herein) and the second reagent is configured to couple to a nucleic acid (such as one or more nucleic acid probes as described herein). The biological particle of d) may comprise the first reagent coupled to a polypeptide and the second reagent coupled to a nucleic acid.

[0235] Any number of barcoding operations may be performed for a given nucleic acidmolecule and / or feature binding group, e.g., using a combinatorial barcoding (e.g., split-pool) approaches. As described herein, additional barcoding operations may be useful, for example, in indexing nucleic acid molecules and features (e.g., proteins) to a cell, a nucleus, a cell bead, a sample, a partition, or a plurality of partitions. Such indexing may be useful in situations when a single partition is occupied by multiple cells, nuclei, or cell beads. In some instances, it may be beneficial to overload partitions such that a partition comprises more than one cell, nucleus or cell bead; for example, it may be useful in certain situations to overload partitions, e.g., toAttorney Docket No.43487-1029601 overcome Poisson loading statistics in partitions and / or to prevent reagent waste (e.g., from unoccupied partitions). Accordingly, such indexing may be useful in attributing (i) nucleic acid molecules and (ii) features (e.g., proteins) in multiply-occupied partitions to the originating cell, nucleus, cell bead, partition, sample, etc., as is described elsewhere herein.

[0236] For example, the workflow provided in FIG. 10 may be performed for nucleic acidmolecules and features (e.g., proteins) within a population of cells, nuclei or cell beads. In such an example, prior to operation 1010, a first population of cells, nuclei or cell beads 1002 may be contacted with the first probe, the second probe, and optionally, the third probe (e.g., as shown in FIG.16A and FIG.16B). The first probe and the second probe may hybridize to the nucleic acid molecule, generating a first probe-associated molecule (or complex), and optionally, the third probe may hybridize to a reporter oligonucleotide (comprising a reporter sequence) or feature probe-binding sequence of a feature binding group (e.g., a group configured to couple to a cell / nuclear membrane protein) to generate a second probe-associated molecule (or complex). Additional probe(s) may be provided to hybridize to additional reporter oligonucleotide(s) or feature probe-binding sequence(s) of an additional feature binding group (e.g., a group configured to couple to an intracellular / intranuclear protein) of the first population of cells, nuclei or cell beads to generate additional probe-associated molecule(s). A second population of cells, nuclei or cell beads 1004 may be also be treated in the same way, e.g., with a fourth probe, a fifth probe, and optionally a sixth probe. The fourth probe and the fifth probe may hybridize to the nucleic acid molecule of the second population of cells, nuclei or cell beads to generate a third-probe-associated molecule, and optionally, the sixth probe may hybridize to a reporter oligonucleotide or feature probe-binding sequence of a feature binding group of the second population of cells, nuclei or cell beads to generate a fourth probe-associated molecule. Additional probe(s) may be provided to hybridize to additional reporter oligonucleotide(s) or feature probe-binding sequence(s) of an additional feature binding group (e.g., a group configured to couple to an intracellular / intranuclear protein) of the second population of cells, nuclei or cell beads to generate additional probe-associated molecule(s). The first population of cells 1002 (or nuclei or cell beads) and the second population of cells 1004 (or nuclei or cell beads) may be barcoded with a first barcode sequence, as described herein, such that the first population of cells (or components therein, such as the first probe-associated molecule and the second-probe-associated molecule) 1002 has a different first barcode sequence than the second population of cells (or nuclei or cell beads or components within the cell, nuclei or cell beads, such as the third probe-associated molecule and the fourth probe-associated molecule) 1004. In operation 1020, the first population of cells 1002 (or nuclei or cell beads) may be pooled together with the second population of cells 1004 (or nuclei or cell beads) to generate a mixture of cellsAttorney Docket No.43487-1029601 (or nuclei or cell beads). In operation 1030, the mixture of cells (or nuclei or cell beads) may be partitioned into a second plurality of partitions. In some instances, the mixture of cells (or nuclei or cell beads) may be partitioned into the second plurality of partitions such that some partitions of the second plurality of partitions comprises more than one cell (e.g., a cell, nucleus or cell bead multiplet partition). For example, a partition 1035 of the second plurality of partitions may comprise a cell, nucleus, or cell bead (“Cell A”) from the first population of cells 1002 (or nuclei or cell beads) and a cell, nucleus, or cell bead (“Cell B”) from the second population of cells1004 (or nuclei or cell beads). The partition 1035 may comprise an additional barcode sequence,which may be unique to the partition. The cells (or nuclei or cell beads) in each partition may be subjected to an additional barcoding operation to append the additional barcode sequence on the barcoded nucleic acid molecules. In operation 1040, the barcoded nucleic acid molecules may be deconvolved, using the different barcode sequences (e.g., the first barcode sequence, the second barcode sequence, and the additional barcode sequences), to identify the originating cell, nucleus, or cell bead. For instance, a barcoded nucleic acid molecule comprising the additional barcode sequence from partition 1035 and the first barcode sequence from the first population of cells 1002 may be used to identify that barcoded nucleic acid molecule as originating from Cell A. Similarly, a barcoded nucleic acid molecule comprising the additional barcode sequence from partition 1035 and the second barcode sequence from the second populations of cells 1004 may be used to identify that barcoded nucleic acid molecule from originating from Cell B.

[0237] In some instances, the feature binding group(s) (e.g., a feature binding groupconfigured to couple to an intracellular / intranuclear protein and / or a feature binding group configured to couple to an intracellular / intranuclear protein) may be pre-indexed to a partition. For example, rather than the feature binding group having a feature probe-binding sequence that can be hybridized to a probe (e.g., a third probe) and subsequently barcoded (e.g., as described in FIG.16A-B) with barcode sequences that identify the cell, nucleus, cell bead, or partition, the feature binding group may be provided in the partitions in a pre-indexed manner, e.g., using a barcode sequence unique to the partition. For instance, the feature binding group may be provided at a later operation of the method, subsequent to barcoding of the nucleic acid molecules within the cell. For example, during the second barcoding operating (e.g., operation 1680 of FIG.16A-B), the feature binding group may be provided and contacted with the feature 1650 of the cell, nucleus or cell bead (or released from the cell, nucleus or cell bead in the second partition). The feature binding group may comprise or be hybridized to a barcode sequence that is specific to the second partition and that differs across the second partitions. Accordingly, the barcode sequence can be used to index the feature binding group to the particular partition and back to the originating cell or cell bead, instead of using the first barcodeAttorney Docket No.43487-1029601 sequence and the second barcode sequence from the first partition and second partition, respectively, to identify the partition, cell, nucleus, or cell bead.

[0238] In other examples, the feature binding group(s) may be indexed to a partition byattaching or coupling a partition-specific barcode sequence directly to the feature binding group, thus obviating the usage of a third probe. In such instances, the feature binding group may comprise or be coupled to a reporter oligonucleotide comprising the reporter sequence and an attachment sequence, which may be used to attach a barcode molecule directly to the feature binding group. For example, the feature binding group may comprise a probe capture sequence (e.g., 1662), thereby obviating the need for a third probe comprising the probe capture sequence. The probe capture sequence may subsequently be barcoded, e.g., with the first barcode sequence of the barcode molecule within the first partition and with the second barcode sequence of the capture molecule within the second partition. In some instances, the attachment sequence may be used to hybridize a probe-binding molecule (e.g., splint molecule or splint oligonucleotide), which may be partially complementary to the barcode molecule (as described herein). For example, the attachment sequence of the reporter oligonucleotide may be used to hybridize the probe- binding molecule, which may hybridize (or be pre-annealed) to the barcode molecule, e.g., in a first partition. A second barcode sequence from the capture molecule may be provided in the first partition or in a different (e.g., second) partition, which may anneal to a portion of the first barcode molecule. In some instances, additional operations are performed, e.g., extension, ligation, etc. to generate a barcoded molecule comprising sequences corresponding to the first barcode sequence, the second barcode sequence, and the reporter sequence.

[0239] Following partition-based barcoding, the contents of the partitions may be pooled andthe barcoded molecules may be duplicated or amplified by, for example, one or moreamplification reactions, which may in some instances be isothermal. The amplification reactions may comprise polymerase chain reactions (PCR) and may involve the use of one or more primers or polymerases. The one or more primers may comprise one or more functional sequences (e.g., a primer sequence / primer binding sequence, a sequencing primer sequence (e.g., R1 or R2), a partial sequencing primer sequence (e.g., partial R1 or partial R2), a sequence configured to attach to the flow cell of a sequencer (e.g., P5 or P7, or partial sequences thereof), etc.) and may facilitate addition of said one or more functional sequences to the extended nucleic acid molecule. The barcoded molecules, or derivatives thereof, may be detected via nucleic acid sequencing (e.g., as described herein).

[0240] In some aspects, provided herein are systems useful for barcoding nucleic acidmolecules. The systems may comprise any of the components described herein, e.g., a plurality of partitions (e.g., droplets, wells), which may be provided in any useful format, e.g., aAttorney Docket No.43487-1029601 microfluidic device, a multi-well array or plate, etc. In some instances, the system may comprise a first set of partitions and a second set of partitions. The first set of partitions may be the same or different types of partitions as the second set of partitions. For example, the first set of partitions may comprise microwells and the second set of partitions may comprise droplets. As another example, both the first set of partitions and the second set of partitions may comprise droplets. The systems may include nucleic acid barcode molecules, optionally coupled to supports (e.g., particles, beads, gel beads, etc.). In some instances, the systems may comprise any of the probes described herein, such as a first probe or plurality of first probes, a second probe or plurality of second probes, a third probe or plurality of third probes, and any useful reaction components (e.g., for performing a nucleic acid reaction, e.g., extension, ligation, amplification, etc.). The systems may comprise one or more feature-binding groups. The feature binding groups may be the same or different across partitions; for example, the feature binding groups may comprise a variety of antibodies that bind to different epitopes within a single partition, or the partitions may comprise different feature binding groups that bind to different epitopes or moieties. The systems may include reaction components that are useful, such as, in non-limiting examples, enzymes (e.g., ligases, polymerases, reverse transcriptases, restriction enzymes, etc.), nucleotides bases, etc.

[0241] Also provided herein are compositions useful for systems and methods for barcodingmultiple analytes, e.g., nucleic acid molecules and proteins (e.g., via a nucleic acid molecule, such as a reporter oligonucleotide, comprised in or coupled to a feature binding group). A composition may comprise any of the probes described herein. For example, a composition may comprise a plurality of first probes, a plurality of second probes, a plurality of third probes, and / or a plurality of first probes, a plurality of second probes, and a plurality of third probes. A probe or a set of probes may be designed to target a specific sequence or a set of specific sequences. Such probes may be designed to have the same or different sequences within different partitions. For example, a first composition may comprise a first probe and a second probe designed to target two regions of a first gene, and a second composition may comprise a first probe and a second probe designed to target two regions of a second gene, which second gene is different than the first gene. Similarly, the third probe (or pair of probes) may be designed to target a region of the reporter oligonucleotide (comprising the reporter sequence) or feature probe-binding sequence, which may be the same or different across partitions. A composition may comprise nucleic acid barcode molecules, and / or probe binding molecules, which may optionally be provided coupled to a support (e.g., particle, bead). A composition may comprise capture molecules, optionally coupled to a support. A composition may be a part of or compriseAttorney Docket No.43487-1029601 a reaction mixture, which can include reaction components or reagents, e.g., enzymes, nucleotide bases, catalysts, etc. Methods of RNA-Binding Protein Target Polynucleotide Analysis

[0242] Many genes generate multiple mRNA isoforms. Mechanisms such as alternativesplicing, intron retention, and alternative transcription start / stop sites serve to diversity mRNA sequences, yielding isoforms that often differ in their protein-coding capacity. For example, these mechanisms are particularly common in cells of the central nervous system (CNS), where alternative isoform use is prevalent. The diverse portfolio of CNS isoforms contributes in important ways to a wide range of neural functions. Moreover, dysregulation of isoform expression is implicated in neurological disorders. There is increasing awareness that genetic studies of CNS development, function, and disease will need to take isoform diversity into account. Despite the clear importance, information about the number and identity of CNS mRNA isoforms remains scarce, even within the major transcriptome annotation databases. The CNS is but one of many systems and tissues the state of the art lacks an understanding regarding mRNA isoforms. While RNA sequencing in bulk has led to an explosion of new information about alternative splicing events, the field has difficulty resolving the number of isoforms produced by any given gene. This is particularly important given that different isoforms of transcripts of the same gene can lead to very different outcomes, such as the difference between a disease state and a healthy state for a given cell, tissue, organ, or organism.

[0243] Recognized herein is a need for improved methods for detecting RNA splice junctionsites and profiling distinct RNA isoforms that arise, for example, from alternative splicing or differential exon usage. Alternative splicing or differential exon usage can generate multiple distinct mRNA isoforms from the same precursor RNA (pre-mRNA). The distinct mRNA isoforms can produce distinct proteins with unique architectures and / or unique functions, contributing to the expansion of the eukaryotic proteome and enrichment of phenotypic diversity. Genes that are differentially regulated at the exon level can be functionally associated with development and metabolism. In some cases, RNA mis-splicing can be associated with a disease. In some cases, the methods described herein use probes to detect one or more RNA splice junction sites of a target RNA polynucleotide and profile distinct mRNA isoforms. Additionally, the methods described herein can be combined with single-cell analysis to profile splice junction sites or mRNA isoforms at single-cell resolution and associate particular splice junction sites or particular mRNA isoforms with other functional, genetic, or phenotypic characteristics of the cell. The methods described herein can provide insights into the relationship between particularAttorney Docket No.43487-1029601 RNA splicing events with certain disease states and uncover new drug targets arising from splicing variation or differential exon usage.

[0244] In one aspect, the present disclosure provides a method of nucleic acid analysis. Themethod can comprise (a) providing a sample comprising a cell comprising a target polynucleotide. In some cases, the target polynucleotide is a mature mRNA transcript. In other cases, the target polynucleotide is a pre-mRNA transcript. The target polynucleotide can comprise up to 2, up to 3, up to 4, up to 5, up to 6, up to 7, up to 8, up to 9, up to 10, up to 12, up to 14, up to 16, up to 18, up to 20, up to 30, up to 40, up to 50, up to 75, up to 100, up to 150, up to 200, up to 250, up to 300, or up to 350 exon segments. The target polynucleotide can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 30, at least 40, at least 50, at least 75, at least 100, at least 150, at least 200, at least 250, at least 300, or at least 350 exon segments. The target polynucleotide can comprise up to 2, up to 3, up to 4, up to 5, up to 6, up to 7, up to 8, up to 9, up to 10, up to 12, up to 14, up to 16, up to 18, up to 20, or up to 40 intron segments. The target polynucleotide can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, or at least 40 intron segments. In some cases, the target polynucleotide comprises a first exon segment and a second exon segment, wherein the first exon segment and the second exon segment flank opposite ends of a splice junction site of the target polynucleotide. The target polynucleotide can comprise up to 2, up to 3, up to 4, up to 5, up to 6, up to 7, up to 8, up to 9, up to 10, up to 12, up to 14, up to 16, up to 18, up to 20, up to 30, up to 40, up to 50, up to 75, up to 100, or up to 150 splice junction sites. In some cases, the target polynucleotide comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 30, at least 40, at least 50, at least 75, at least 100, or at least 150 splice junction sites.

[0245] The one or more splice junction sites of the target polynucleotide can be a result ofalternative splicing or mis-splicing. In some cases, a splice junction site of the target polynucleotide is generated by the removal of a nucleic acid segment between the first exon segment and the second exon segment in a precursor RNA molecule to generate the target polynucleotide. The nucleic acid segment that is removed to generate the splice junction site can comprise a portion of an intron segment. In some cases, the nucleic acid segment that is removed to generate the splice junction site comprises a full-length intron segment. The nucleic acid segment that is removed to generate the splice junction site can comprise a portion of an exon segment. In some cases, the nucleic acid segment that is removed to generate the splice junction site comprises a full-length exon segment. For example, the removal of the nucleic acid segmentAttorney Docket No.43487-1029601 can be a result of cassette exon skipping. In some cases, the splice junction site is generated by a mis-splicing event, resulting in a mutation, extension, or deletion in the exon. In some cases, the splice junction site may result from a mis-splicing event resulting in an intron retention.

[0246] In some cases, the slice junction site is generated by a mis-splicing event that isassociated with a disease, such as cancer or a neurodevelopmental disorder. The splice junction site can be in a target polynucleotide that produces a dysfunctional protein. One example is a splice site mutation in dystrophin resulting in loss of dystrophin function, which can result in Duchenne muscular dystrophy. Other examples of disorders resulting mis-splicing events include limb girdle muscular dystrophy type 1B, which can result from intron 9 retention; familial partial lipodystrophy type 2, which can result from intron 8 retention; Hutchinson–Gilford progeria syndrome, which can result from a 150 nt deletion in exon 11; dilated cardiomyopathy, which can result from an extension of an exon 4 or TTN mis-splicing; familial dysautonomia, which can result from exon 20 skipping; Becker muscular dystrophy, which can result from exon 31 partial in-frame skipping; early-onset Parkinson disease, which can result from exon 7 skipping; Frontotemporal dementia with parkinsonism chromosome 17, which can result from increased exon 10 inclusion; X-linked parkinsonism with spasticity, which can result from increased exon 4 exclusion; Amyotrophic lateral sclerosis, which can result from TDP-43 target mis-splicing; limb-girdle muscular dystrophy 1G, which can result from HNRPDL target mis-splicing; or autosomal dominant leukodystrophy, which can result from PTBP1 target mis-splicing.

[0247] In some cases, the target polynucleotide is a distinct mRNA transcript among aplurality of distinct mRNA transcripts. The plurality of distinct mRNA transcripts can be generated from identical pre-mRNAs. Alternatively, the plurality of distinct mRNA transcripts can be generated from different pre-mRNAs. The plurality of distinct mRNA transcripts can be generated from the same DNA gene. Alternatively, the plurality of distinct mRNA transcripts can be generated from different DNA genes.

[0248] In some cases, the target polynucleotide is a distinct mRNA isoform among aplurality of distinct mRNA isoforms. The target polynucleotide can be a distinct mRNA isoform among a plurality of distinct mRNA isoforms generated from the same DNA gene. In some cases, the plurality of distinct mRNA isoforms comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 8, at least 10, at least 15, at least 20, at least 25, at least 50, at least 60, at least 80, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 600, at least 800, at least 1000, at least 1500, at least 2000, at least 4000, at least 6000, at least 8000, or at least 10,000 distinct mRNA isoforms. The plurality of distinct mRNA isoforms can encode proteins with distinct functions or architectures. In some cases, the plurality of distinct mRNA isoforms encode distinct cell surface proteins.Attorney Docket No.43487-1029601

[0249] In some cases, the first target sequence and the second target sequence are directlyadjacent on the target polynucleotide. For example, the first target sequence and the second target sequence can each be located directly adjacent to the splice junction site. Alternatively, the first target sequence and the second target sequence can be separated by a gap region on the target polynucleotide. The gap region can be, for example, at least 1, at least 10, at least 25, at least 50, at least 75, at least 100, at least 200, at least at least 300, at least 400, at least 500, least 600, at least 700, at least 800, at least 900, or at least 1000 nt. The gap region can be up to 1, up to 10, up to 25, up to 50, up to 75, up to 100, up to 200, up to up to 300, up to 400, up to 500, least 600, up to 700, up to 800, up to 900, or up to 1000 nt. For example, the first target sequence or the second target sequence can be at least 1, at least 10, at least 25, at least 50, at least 75, at least 100, at least 200, at least at least 300, at least 400, or at least 500 nt away from the splice junction site.

[0250] The method can further comprise (b) contacting the cell with a first probe, whereinthe first probe hybridizes to a first target sequence of the first exon segment. The method can further comprise contacting the cell with a second probe, wherein the second probe hybridizes to a second target sequence of the second exon segment. In some cases, the first probe or the second probe comprises a probe barcode sequence. The first probe or the second probe can comprise at least 2, at least 3, at least 4, or at least 5 probe barcode sequences. In some cases, the first probe and the second probe collectively comprise at least 2, at least 3, at least 4, or at least 5 probe barcode sequences. The first probe or the second probe can comprise up to 2, up to 3, up to 4, or up to 5 probe barcode sequences. In some cases, the first probe and the second probe collectively comprise up to 2, up to 3, up to 4, or up to 5 probe barcode sequences. In some cases, a probe barcode sequence in the first probe or the second probe identifies the sample.

[0251] The method can further comprise permeabilizing the cell. The cell can bepermeabilized by partially or completely dissolving or disrupting a cell / nuclear membrane or a portion thereof, for example, by contacting the cell with an organic solvent, as described elsewhere herein. In some cases, cell is permeabilized before contacting the cell with the first probe or the second probe. Alternatively, cell can be permeabilized after contacting the cell with the first probe and prior to contacting the cell with the second probe or after contacting the cell with the first probe and the second probe.

[0252] The method can further comprise (c) linking the first probe and the second probetogether, thereby generating a probe-linked nucleic acid molecule comprising the first probe and the second probe. In some cases, the first target sequence and a second target sequence are directly adjacent on the target polynucleotide, and linking the first probe and second probe comprises ligating a first end of the probe with a second end of the second probe to generate theAttorney Docket No.43487-1029601 probe-linked nucleic acid molecule. For instance, as described elsewhere herein, the first probe may comprise a first reactive moiety, and the second probe may comprise a second reactive moiety, wherein the first reactive moiety of the first probe is adjacent to the second reactive moiety of the second probe. The reactive moieties may be joined together via click chemistry or enzymatic ligation as described elsewhere herein. In other cases, the first target sequence and the second target sequence are separated by a gap region, as described herein (e.g., up to 500 or up to 1000 nucleotides) on the target polynucleotide, and linking the first probe and the second probe can comprise performing a nucleic acid extension reaction to fill the gap region to generate the probe-linked nucleic acid molecule – sometimes referred to as a gap-fill approach. In other cases, linking the first probe and the second probe can comprise hybridization of one or more additional probe molecules that hybridize to at least a portion of the gap region, as described elsewhere herein.

[0253] In some cases, the gap-fill approach allows for the identification of new or rareisoforms of the mRNA when information about the junction site or sites are unknown or poorly resolved. Once the junction site(s) is / are identified, probe pairs are created that are used to identify the specific isoform.

[0254] The probe-linked nucleic acid molecule can comprise a barcode sequence or bebarcoded to provide a barcoded probe-linked nucleic acid molecule. The barcode can, for example, identify the sample or cell comprising the target polynucleotide and be used to associate the probe-linked nucleic acid molecule with the sample or cell, and in some cases, other phenotypic or functional characteristics of the sample or cell. In some cases, barcoding can occur prior to generation of the probe-linked nucleic acid molecule, as described elsewhere herein. In some cases, the barcode sequence is a probe barcode sequence in the first probe or the second probe, and linking the first probe and the second probe together generates a probe-linked nucleic acid comprising the probe barcode sequence.

[0255] The method can further comprise using the probe-linked nucleic acid molecule and anoligonucleotide comprising a barcode sequence to generate a barcoded nucleic acid molecule. The barcoded nucleic acid molecule can comprise (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, and (iii) the barcode sequence of the oligonucleotide or reverse complement thereof. In some cases, generating the barcoded nucleic acid molecule occurs in a partition (e.g., a droplet or a well) among a plurality of partitions. In some cases, the partition comprises a single cell and the partition barcode identifies the cell. The barcode sequence can identify the partition from other partitions of the plurality of partitions and be used to associating the probe-linked nucleic acid molecule with the partition.Attorney Docket No.43487-1029601

[0256] In some cases, the method comprises using the probe-linked nucleic acid moleculeand an oligonucleotide comprising a barcode sequence to generate a barcoded nucleic acid molecule comprising two or more distinct barcode sequences. For example, the probe-linked nucleic acid molecule can comprise a first barcode sequence of the first probe or the second probe, and the method can further comprise using the probe-linked nucleic acid molecule and an oligonucleotide comprising a second barcode sequence to generate a barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, (iii) the first barcode sequence or reverse complement thereof, and (iv) the second barcode sequence or reverse complement thereof. Generating the barcoded nucleic acid molecule can occur in a partition among a plurality of partitions. The partition can be a droplet or a well. In some cases, the first barcode sequence identifies the sample and the second barcode sequence identifies the partition from other partitions of the plurality of partitions. In some cases, the partition comprises a single cell and the partition barcode identifies the cell. The first and second barcode sequences collectively can be used to associate the probe-linked nucleic acid molecule with the sample and the partition.

[0257] Generating a barcoded nucleic acid molecule described herein can comprisehybridizing a capture sequence in the oligonucleotide to a capture binding sequence in the probe- linked nucleic acid molecule, and extending the oligonucleotide to generate the barcoded nucleic acid molecule. In some cases, the oligonucleotide is coupled to a bead.

[0258] The method can further comprise (d) identifying a sequence of the probe-linkednucleic acid molecule or derivative thereof, thereby locating the splice junction site of the target polynucleotide. The identified sequence can be a sequence corresponding to the first target sequence or a sequence corresponding to the second target sequence. In some cases, the identified sequence comprises a portion of the first target sequence and a portion of the second target sequence. In some cases, the sequence is identified in the probe-linked nucleic acid molecule. In other cases, the sequence is identified in a derivative of the probe-linked nucleic acid molecule, e.g., a barcoded product, an extension product, or amplification product thereof. The sequence can be identified in a barcoded nucleic acid molecule that is generated from the probe-linked molecule and a separate oligonucleotide. In some cases, the method comprises generating the barcoded nucleic acid molecule prior to (d). In some cases, the sequence is identified in a derivative of the barcoded nucleic acid molecule, e.g., an extension product, or amplification product thereof.

[0259] In some cases, locating the splice junction site of the target polynucleotide identifies amis-splicing event associated with a disease, as described elsewhere herein. For example, locating the splice junction site can identify the intron 9 retention associated with limb girdleAttorney Docket No.43487-1029601 muscular dystrophy type 1B, the intron 8 retention associated with familial partial lipodystrophy type 2, the 150 nt 150 nt deletion in exon 11 associated with Hutchinson–Gilford progeria syndrome, exon 20 skipping associated with familial dysautonomia, or other mis-splicing events as described elsewhere herein.

[0260] In some cases, the target polynucleotide is a distinct mRNA isoform among aplurality of mRNA isoforms, wherein the splice junction site is associated with the distinct mRNA isoform; and locating the splice junction site in (d) thereby identifies the distinct mRNA isoform. In some cases, locating the splice junction site can identify a disease-associated mRNA isoform from a non-disease-associated mRNA isoform. For example, locating the splice junction site can identify and distinguish the mRNA isoform encoding RPS6KB1-2 lacking kinase domain, which can contribute to tumor growth in lung and breast cancer, from the mRNA isoform encoding full-length RPS6KB1-1, which can suppress proliferation of cancer cells. As another example, locating the splice junction site can identify and distinguish the mRNA isoform encoding conventional cyclin D1a and the mRNA isoform encoding cyclin D1b lacking the C- terminal protein domains (characterized by exclusion of exon 5), which is associated with metastasis in breast cancer.

[0261] The method can further comprise identifying a barcode sequence in the probe-linkednucleic acid molecule or derivative thereof, e.g., a barcoded product, an extension product, or amplification product of the probe-linked nucleic acid molecule. The method can comprise identifying the barcode sequence in the barcoded nucleic acid generated from the oligonucleotide and the probe-linked nucleic acid molecule. In some cases, the barcode sequence is identified in a derivative, e.g., extension product or amplification product, of the barcoded nucleic acid generated from the oligonucleotide and the probe-linked nucleic acid molecule.

[0262] The identified barcode sequence in the probe-linked nucleic acid molecule orderivative thereof can provide further information for analyzing the target polynucleotide. For example, the target polynucleotide can be provided in a sample, and the barcode sequence can identify the sample comprising the polynucleotide. The method can further comprise (e) associating the located splice junction site with the sample based on the identity of the barcode sequence. In some cases, the sample is associated with a disease or disorder, and associating the splice junction site with the sample thereby associates the splice junction site with the disease or disorder. The disease or disorder can be, a cancer, a developmental disorder, a neurodegenerative disorder, a genetic disorder, a metabolic disorder, an autoimmune disorder, or a muscular distrophy. In some cases, the disease or disorder is Duchenne muscular dystrophy, limb girdle muscular dystrophy type 1B, familial partial lipodystrophy type 2, Hutchinson–Gilford progeria syndrome, dilated cardiomyopathy, familial dysautonomia, Becker muscular dystrophy, early-Attorney Docket No.43487-1029601 onset Parkinson disease, Frontotemporal dementia with parkinsonism chromosome 17, X-linked parkinsonism with spasticity, amyotrophic lateral sclerosis, limb-girdle muscular dystrophy 1G, autosomal dominant leukodystrophy, Retinitis pigmentosa, myelodysplastic syndromes, microcephalic osteodysplastic primordial dwarfism type 1, or spinal muscular atrophy. In some cases, the target polynucleotide provided is a distinct mRNA isoform among a plurality of mRNA isoforms, wherein the splice junction site is associated with the distinct mRNA isoform; and locating the splice junction site of the target polynucleotide thereby identifies the distinct mRNA isoform. In some cases, the method comprises associating the distinct mRNA isoform with the sample, and thereby, the disease, based on the identity of the barcode sequence. The distinct mRNA isoform can encode a cell surface protein.

[0263] As another example, in some cases, the target polynucleotide is provided in a cell oris derived from a cell, and the barcode sequence identifies the cell comprising the target polynucleotide. The method can further comprise associating the located splice junction site or the identified mRNA isoform with the cell based on the identity of the barcode sequence. If additional functional, genetic, or phenotypic information is known about the cell or sample, by identifying the cell or sample, the barcode sequence can be used to associate the located splice junction site or identified mRNA isoform with the additional functional, genetic, or phenotypic information associated with the cell or sample. In some cases, the barcode sequence comprises other identifying information, such as a unique molecular identifier or a spatial barcode sequence. In some cases, the cell is partitioned into a partition among a plurality of partitions (e.g., droplets or wells) in an operation described herein. The barcode sequence can identify the partition into which the cell is partitioned. In some cases, the cell is partitioned into the partition based on a functional, genetic, or phenotypic characteristic of the cell. In other cases, a functional, genetic, or phenotypic characteristic of the cell is analyzed after the cell is partitioned into the partition. The method can further comprise associating the located splice junction site or identified mRNA isoform with the partition and other information associated with the partition, e.g., a functional, genetic, or phenotypic characteristic analyzed after partitioning the cell into the partition.

[0264] In some cases, the method further comprises identifying a plurality of barcodesequences in the barcoded nucleic acid or derivative thereof and associating the splice junction site with plurality of barcode sequences. For example, the method can comprise associating the splice junction site with a sample based on the identity of a first barcode sequence and associating the splice junction site with a partition based on the identity of a second barcode sequence.Attorney Docket No.43487-1029601

[0265] In some cases, the method further comprises locating a plurality of splice junctionsites. In some cases, the method comprises locating up to 2, up to 3, up to 4, up to 5, up to 6, up to 7, up to 8, up to 9, up to 10, up to 12, up to 14, up to 16, up to 18, up to 20, up to 30, up to 40, up to 50, up to 75, up to 100, or up to 150 splice junction sites. In some cases, the method comprises locating at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 30, at least 40, at least 50, at least 75, at least 100, or at least 150 splice junction sites. The plurality of splice junction sites can be located on a same target polynucleotide or on distinct target polynucleotides.

[0266] In some cases, the method comprises locating a plurality of splice junction sites of asame target polynucleotide. In addition to the first exon segment and the second exon segment that flank opposite ends of the first splice junction site, as described herein, the target polynucleotide can comprise a third exon segment and a fourth exon segment, wherein the third exon segment and the fourth exon segment flank opposite ends of a second splice junction site of the target polynucleotide. In some cases, the second and the third exon segments are two discrete exon segments. In some cases, the second and the third exon segments are the same exon segment, and one end of the same exon segment is directly adjacent to the first exon segment and the other end of the same exon segment is directly adjacent to the fourth exon segment.

[0267] In some cases, in addition to contacting the cell with (i) the first probe, whichhybridizes to the first target sequence of the first exon segment, and (ii) the second probe, which hybridizes to the second target sequence of the second exon segment, as described herein, the method further comprises contacting the cell with: (iii) a third probe, wherein the third probe hybridizes to a third target sequence of the third exon segment. In some cases, the method further comprises contacting the cell with: (iv) a fourth probe, wherein the fourth probe hybridizes to a hybridizes to a fourth target sequence of the fourth exon segment. The first and second probes can together be used to identify the first splice junction site, and the third and fourth probes can together be used to identify the second splice junction site.

[0268] The method can use a unique pair of probes to detect each splice junction site of thetarget polynucleotide. Each pair of probes can comprise a probe barcode sequence. In some cases, each pair of probes collectively comprise up to 2, up to 3, up to 4, or up to 5 probe barcode sequences. In some cases, each pair of probes collectively comprise at least 2, at least 3, at least 4, or at least 5 probe barcode sequences. Each probe can up to 2, up to 3, up to 4, or up to 5 probe barcode sequences. In some cases, each probe comprises at least 2, at least 3, at least 4, or at least 5 probe barcode sequences. In some cases, each pair of probes comprises a common barcode sequence. The common barcode sequence can, for example, identify the sample.Attorney Docket No.43487-1029601

[0269] In some cases, in addition to linking the first and the second probes together,generating the first probe-linked nucleic acid molecule comprising the first probe and the second probe, as described herein, the method further comprises linking the third probe and the fourth probe together, thereby generating a second probe-linked nucleic acid molecule comprising the third probe and the fourth probe. Generating the probe-linked nucleic acid molecule and the second probe-linked nucleic acid molecule can comprise a ligation reaction or a nucleic acid extension reaction, or a combination thereof, as described elsewhere herein.

[0270] As one example, the first target sequence and the second target sequence can bedirectly adjacent on the target polynucleotide, and the third target sequence and the fourth target sequence can be directly adjacent on the first target polynucleotide. The method can comprise ligating a first end of the first probe and a second end of the second probe together to generate the first probe-linked nucleic acid molecule, and ligating a third end of the third probe and a fourth end of the fourth probe together to generate the second probe-linked nucleic acid molecule.

[0271] As another example, the first target sequence and the second target sequence can beseparated by a gap region of up to 1000 nucleotides on the target polynucleotide, and the third target sequence and the fourth target sequence can be directly adjacent on the target polynucleotide. The method can comprise performing a nucleic acid extension reaction to fill the gap region to generate the first probe-linked nucleic acid molecule, and ligating a third end of the third probe and a fourth end of the fourth probe together to generate the second probe-linked nucleic acid molecule.

[0272] As another example, the first target sequence and the second target sequence can beseparated by a first gap region of up to 1000 nucleotides on the target polynucleotide, and the third target sequence and the fourth target sequence can be separated by a second gap region of up to 1000 nucleotides on the target polynucleotide. The method can comprise performing a first nucleic acid extension reaction to fill the first gap region to generate the first probe-linked nucleic acid molecule, and performing a second nucleic acid extension reaction to fill the second gap region to yield the second probe-linked nucleic acid molecule.

[0273] In some cases, the method further comprises generating the first probe-linked nucleicacid molecule and generating the second probe-linked nucleic acid molecule simultaneously. In other cases, the method further comprises generating the first probe-linked nucleic acid molecule and generating the second probe-linked nucleic acid molecule sequentially.

[0274] In some cases, the method further comprises using the first probe-linked nucleic acidmolecule and a first oligonucleotide comprising a barcode sequence to generate a first barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii)Attorney Docket No.43487-1029601 the second target sequence or reverse complement thereof, and (iii) the barcode sequence or reverse complement thereof. In some cases, the method further comprises, using the second probe-linked nucleic acid molecule and a second oligonucleotide comprising the barcode sequence to generate a second barcoded nucleic acid molecule comprising (i) the third target sequence or reverse complement thereof, (ii) the fourth target sequence or reverse complement thereof, and (iii) the barcode sequence or reverse complement thereof. In some cases, generating the first barcoded nucleic acid molecule and second barcoded nucleic acid molecule occurs in a partition (e.g., a droplet or a well) among a plurality of partitions. In some cases, the partition comprises a single cell and the partition barcode identifies the cell. The barcode sequence can identify the partition from other partitions of the plurality of partitions and be used to associating the probe-linked nucleic acid molecule with the partition.

[0275] In some cases, the method further comprises generating a first barcoded nucleic acidmolecule and a second barcoded nucleic acid molecule, wherein both barcoded nucleic acid molecules comprise two or more distinct barcode sequences. For example, the first probe-linked nucleic acid molecule and the second probe-linked molecule can comprise a first barcode sequence, e.g., the common barcode sequence that identifies the sample, and the method can further comprise using the two probe-linked nucleic acid molecules and two oligonucleotides each comprising a second barcode sequence to generate two barcoded nucleic acid molecules each comprising two distinct barcode sequences. The first barcoded nucleic acid molecule can comprise (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, (iii) the first barcode sequence or reverse complement thereof, and (iv) the second barcode sequence or reverse complement thereof. The second barcoded nucleic acid molecule can comprise (i) the third target sequence or reverse complement thereof, (ii) the fourth target sequence or reverse complement thereof, (iii) the first barcode sequence or reverse complement thereof, and (iv) the second barcode sequence or reverse complement thereof. Generating the two barcoded nucleic acid molecules can occur in a partition among a plurality of partitions. The partition can be a droplet or a well. In some cases, the first barcode sequence identifies the sample and the second barcode sequence identifies the partition from other partitions of the plurality of partitions. In some cases, the partition comprises a single cell and the partition barcode identifies the cell. The first and second barcode sequences collectively can be used to associate both probe-linked nucleic acid molecules with the sample and the partition.

[0276] Generating the first barcoded nucleic acid molecule can, for example, comprisehybridizing a first capture sequence in the first oligonucleotide to a first capture binding sequence in the first probe-linked nucleic acid molecule, and extending the oligonucleotide toAttorney Docket No.43487-1029601 generate the first barcoded nucleic acid molecule. Generating the second barcoded nucleic acid molecule can, for example, comprise hybridizing a second capture sequence in the second oligonucleotide to a second capture binding sequence in the second probe-linked nucleic acid molecule, and extending the second oligonucleotide to generate the second barcoded nucleic acid molecule. In some cases, the first oligonucleotide is coupled to a first bead and the second oligonucleotide is coupled to a second bead.

[0277] In some cases, in addition to identifying a sequence locating the first splice junctionsite of the target polynucleotide, the method can further comprise, identifying an additional sequence of the second probe-linked nucleic acid molecule or derivative thereof, thereby locating the splice junction site of the target polynucleotide. The additional identified sequence can be a sequence corresponding to the third target sequence or a sequence corresponding to the fourth target sequence. In some cases, the additional identified sequence comprises a portion of the third target sequence and a portion of the fourth target sequence. In some cases, the additional sequence is identified in the second probe-linked nucleic acid molecule. In other cases, the additional sequence is identified in a derivative of the second probe-linked nucleic acid molecule, e.g., a barcoded product, an extension product, or amplification product thereof. The sequence can be identified in a second barcoded nucleic acid molecule that is generated from the second probe-linked molecule and a separate oligonucleotide. In some cases, the method comprises generating the second barcoded nucleic acid molecule prior to (d). In some cases, the sequence is identified in a derivative of the second barcoded nucleic acid molecule, e.g., an extension product, or amplification product thereof.

[0278] In some cases, locating the first splice junction site and the second splice junction siteidentifies one or more mis-splicing events associated with a disease, as described elsewhere herein.

[0279] In some cases, the target polynucleotide is a distinct mRNA isoform among aplurality of mRNA isoforms, wherein the first splice junction site and the second splice junction site are collectively associated with the distinct mRNA isoform; and locating the first splice junction site and the second splice junction site thereby identifies the distinct mRNA isoform. In some cases, a plurality of splice junction sites are collectively associated with the distinct mRNA isoform and locating the plurality of splice junction sites identifies the distinct mRNA isoform. In some cases, locating the plurality of splice junction sites can identify a disease-associated mRNA isoform from a non-disease-associated mRNA isoform.

[0280] The method can further comprise identifying a barcode sequence in the first probe-linked nucleic acid molecule or derivative thereof and in the second probe-linked nucleic acid molecule or derivative thereof. The method can comprise identifying the barcode sequence in theAttorney Docket No.43487-1029601 barcoded nucleic acid generated from the oligonucleotide and the probe-linked nucleic acid molecule. In some cases, the barcode sequence is identified in a derivative, e.g., extension product or amplification product, of the barcoded nucleic acid generated from the oligonucleotide and the probe-linked nucleic acid molecule. The method can comprise identifying the common barcode sequence, e.g., identifying the sample, or reverse complement thereof in the first probe-linked nucleic acid molecule or derivative thereof. In some cases, the method further comprises identifying the common barcode sequence or reverse complement thereof in the second probe-linked nucleic acid molecule or derivative thereof.

[0281] The identified barcode sequence in the probe-linked nucleic acid molecule orderivative thereof can provide further information for analyzing the target polynucleotide. For example, the target polynucleotide can be provided in a sample, and the common barcode sequence can identify the sample comprising the polynucleotide. The method can further comprise (e) associating the first located splice junction site and the second located splice junction with the sample based on the identity of the common barcode sequence. In some cases, the sample is associated with a disease or disorder, and associating the first splice junction site and the second splice junction site with the sample thereby associates the two splice junction sites with the disease or disorder.

[0282] In some cases, the first splice junction site and the second splice junction site are onthe same target polynucleotide. The target polynucleotide can be a distinct mRNA isoform among a plurality of mRNA isoforms, wherein the first splice junction site and the second splice junction site are collectively associated with the distinct mRNA isoform. Locating the first splice junction site and the second splice junction site of the target polynucleotide can thereby identify the distinct mRNA isoform. In some cases, the method comprises associating the distinct mRNA isoform with the sample, and thereby, the disease, based on the identity of the common barcode sequence. The distinct mRNA isoform can encode a cell surface protein.

[0283] In some cases, the first splice junction site and the second splice junction site are ontwo different target polynucleotides in the same sample. The two target polynucleotides can each be a distinct mRNA isoform, wherein the first splice junction site is associated with a first distinct mRNA isoform and the second splice junction site is associated with a second distinct mRNA isoform. Locating the first splice junction site and the second splice junction site of the target polynucleotide can thereby identify the two distinct mRNA isoforms. In some cases, the method comprises associating the two distinct mRNA isoforms with the sample, and thereby, the disease, based on the identity of the common barcode sequence. The two distinct mRNA isoforms can each encode a cell surface protein.Attorney Docket No.43487-1029601

[0284] As another example, in some cases, the one or more target polynucleotidescomprising the splice junction sites are provided in a cell or is derived from a cell, and the common barcode sequence or the additional barcode sequence identifies the cell. The method can further comprise associating the first located splice junction site and the second located splice junction site with the cell based on the identity of the common barcode sequence or the additional barcode sequence. If additional functional, genetic, or phenotypic information is known about the cell or sample, by identifying the cell or sample, the common barcode sequence or the additional barcode sequence can be used to associate the first located splice junction site and the second located splice junction site with the additional functional, genetic, or phenotypic information associated with the cell or sample. In some cases, the common barcode sequence or the additional barcode sequence comprises other identifying information, such as a unique molecular identifier or a spatial barcode sequence. In some cases, the cell is partitioned into a partition among a plurality of partitions (e.g., droplets or wells) in an operation described herein. The common barcode sequence or the additional barcode sequence can identify the partition into which the cell is partitioned. In some cases, the cell is partitioned into the partition based on a functional, genetic, or phenotypic characteristic of the cell. In other cases, a functional, genetic, or phenotypic characteristic of the cell is analyzed after the cell is partitioned into the partition. The method can further comprise associating the first located splice junction site and the second located splice junction site with the partition and other information associated with the partition, e.g., a functional, genetic, or phenotypic characteristic analyzed after partitioning the cell into the partition.

[0285] In some cases, the method further comprises identifying a plurality of barcodesequences in the first barcoded nucleic acid or derivative thereof and the second barcoded nucleic acid or derivative thereof and associating the first splice junction site and the second splice junction site with plurality of barcode sequences. For example, the method can comprise associating the first splice junction site and the second splice junction site with a sample based on the identity of a first barcode sequence and associating the first splice junction site and the second splice junction site with a partition based on the identity of a second barcode sequence.

[0286] In some cases, the method comprises locating a plurality of splice junction sites (e.g.,at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at...

Claims

Attorney Docket No.43487-1029601 CLAIMS WHAT IS CLAIMED IS:

1. A method of nucleic acid analysis, comprising:(a) providing a sample comprising a cell comprising a target polynucleotide comprising a first exon segment and a second exon segment, wherein the first exon segment and the second exon segment flank opposite ends of a splice junction site of the target polynucleotide; (b) contacting the cell with: (i) a first probe, wherein the first probe hybridizes to a first target sequence of the first exon segment, and (ii) a second probe, wherein the second probe hybridizes to a second target sequence of the second exon segment; (c) linking the first probe and the second probe together, thereby generating a probe- linked nucleic acid molecule comprising the first probe and the second probe; and (d) identifying a sequence of the probe-linked nucleic acid molecule or derivative thereof, thereby locating the splice junction site of the target polynucleotide.

2. The method of claim 1, further comprising, prior to or during (b), permeabilizing the cell.

3. The method of claim 1, wherein the target polynucleotide is a mature mRNA transcript.

4. The method of claim 1, wherein the first target sequence and the second target sequenceare directly adjacent on the target polynucleotide.

5. The method of claim 4, wherein (c) comprises ligating a first end of the first probe with asecond end of the second probe to generate the probe-linked nucleic acid molecule.

6. The method of claim 1, wherein the first target sequence and the second target sequenceare separated by a gap region of up to 1000 nucleotides on the target polynucleotide.

7. The method of claim 6, wherein (c) comprises performing a nucleic acid extensionreaction to fill the gap region to generate the probe-linked nucleic acid molecule.

8. The method of claim 1, wherein, in (b), the second probe comprises a barcode sequence.Attorney Docket No.43487-10296019. The method of claim 8, wherein the probe-linked nucleic acid molecule generated in (c)comprises the barcode sequence, and (d) further comprises identifying the barcode sequence or reverse complement thereof in the probe-linked nucleic acid molecule or derivative thereof.

10. The method of claim 9, wherein the barcode sequence identifies the sample and whereinthe method further comprises (e) associating the splice junction site located in (d) with the sample based on the identity of the barcode sequence.

11. The method of claim 10, wherein the sample is associated with a disease, and (e)comprises associating the splice junction site with the sample, and thereby, the disease, based on the identity of the barcode sequence.

12. The method of claim 11, wherein:(i) in (a), the target polynucleotide is a distinct mRNA isoform among a plurality ofdistinct mRNA isoforms, wherein the splice junction site is associated with the distinct mRNA isoform; (ii) in (d), locating the splice junction site thereby identifies the distinct mRNAisoform; and (iii) (e) comprises associating the distinct mRNA isoform with the sample, andthereby, the disease, based on the identity of the barcode sequence.

13. The method of claim 12, wherein the distinct mRNA isoform encodes a cell surfaceprotein.

14. The method of claim 10, further comprising, prior to (d), using the probe-linked nucleicacid molecule and an oligonucleotide comprising an additional barcode sequence to generate a barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, (iii) the barcode sequence or reverse complement thereof, and (iv) the additional barcode sequence or reverse complement thereof.

15. The method of claim 14, wherein generating the barcoded nucleic acid molecule occursin a partition among a plurality of partitions.Attorney Docket No.43487-102960116. The method of claim 15, wherein the additional barcode sequence identifies the partitionfrom other partitions of the plurality of partitions.

17. The method of claim 16, wherein the partition is a droplet or a well.

18. The method of claim 14, wherein generating the barcoded nucleic acid moleculecomprises hybridizing a capture sequence in the oligonucleotide to a capture binding sequence in the probe-linked nucleic acid molecule, and extending the oligonucleotide to generate the barcoded nucleic acid molecule.

19. The method of claim 18, wherein the oligonucleotide is coupled to a bead.

20. The method of claim 1, further comprising, prior to (d), using the probe-linked nucleicacid molecule and an oligonucleotide comprising a barcode sequence to generate a barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, and (iii) the barcode sequence or reverse complement thereof.

21. The method of claim 20, wherein the barcode sequence identifies the cell, and (d)comprises identifying the splice junction site as associated with the cell based on the identity of the barcode sequence.

22. The method of claim 20, wherein the oligonucleotides is coupled to a bead.

23. The method of claim 1, wherein the target polynucleotide comprises a third exon segmentand a fourth exon segment, wherein the third exon segment and the fourth exon segment flank opposite ends of an additional splice junction site of the target polynucleotide.

24. The method of claim 23, wherein (b) further comprises contacting the cell with:(iii) a third probe, wherein the third probe hybridizes to a third target sequence of the third exon segment, and (iv) a fourth probe, wherein the fourth probe hybridizes to a fourth target sequence of the fourth exon segment.

25. The method of claim 24, wherein (c) further comprises linking the third probe and thefourth probe together, thereby generating an additional probe-linked nucleic acid molecule comprising the third probe and the fourth probe.Attorney Docket No.43487-102960126. The method of claim 25, wherein the first target sequence and the second target sequenceare directly adjacent on the target polynucleotide, and wherein the third target sequence and the fourth target sequence are directly adjacent on the first target polynucleotide.

27. The method of claim 26, wherein (c) comprises (i) ligating a first end of the first probeand a second end of the second probe together to generate the probe-linked nucleic acid molecule, and (ii) ligating a third end of the third probe and a fourth end of the fourth probe together to generate the additional probe-linked nucleic acid molecule.

28. The method of claim 25, wherein the first target sequence and the second target sequenceare separated by a gap region of up to 1000 nucleotides on the target polynucleotide, and wherein the third target sequence and the fourth target sequence are directly adjacent on the target polynucleotide.

29. The method of claim 28, wherein (c) comprises (i) performing a nucleic acid extensionreaction to fill the gap region to generate the probe-linked nucleic acid molecule, and (ii) ligating a third end of the third probe and a fourth end of the fourth probe together to generate the additional probe-linked nucleic acid molecule.

30. The method of claim 25, wherein the first target sequence and the second target sequenceare separated by a first gap region of up to 1000 nucleotides on the target polynucleotide, and wherein the third target sequence and the fourth target sequence are separated by a second gap region of up to 1000 nucleotides on the target polynucleotide.

31. The method of claim 30, wherein (c) comprises (i) performing a first nucleic acidextension reaction to fill the first gap region to generate the probe-linked nucleic acid molecule, and (ii) performing a second nucleic acid extension reaction to fill the second gap region to yield the additional probe-linked nucleic acid molecule.

32. The method of claim 25, further comprising generating the probe-linked nucleic acidmolecule and generating the additional probe-linked nucleic acid molecule simultaneously.

33. The method of claim 25, further comprising generating the probe-linked nucleic acidmolecule and generating the additional probe-linked nucleic acid molecule sequentially.Attorney Docket No.43487-102960134. The method of claim 25, wherein (d) further comprises identifying an additionalsequence of the additional probe-linked nucleic acid molecule or derivative thereof, thereby locating the additional splice junction site of the target polynucleotide.

35. The method of claim 34, wherein, in (b), the first probe and the third probe eachcomprises a common barcode sequence.

36. The method of claim 35, wherein the probe-linked nucleic acid molecule and theadditional probe-linked nucleic acid molecule generated in (c) each comprises the common barcode sequence, and (d) further comprises: (i) identifying the common barcode sequence or reverse complement thereof in theprobe-linked nucleic acid molecule or derivative thereof, and (ii) identifying the common barcode sequence or reverse complement thereof in theadditional probe-linked nucleic acid molecule or derivative thereof.

37. The method of claim 36, wherein the common barcode sequence identifies the sampleand wherein the method further comprises (e) associating the splice junction site and the additional splice junction site located in (d) with the sample based on the identity of the common barcode sequence.

38. The method of claim 37, wherein the sample is associated with a disease, and (e)comprises associating the splice junction site and the additional splice junction site with the sample, and thereby, the disease, based on the identity of the common barcode sequence.

39. The method of claim 38, wherein:(i) in (a), the target polynucleotide is a distinct mRNA isoform among a plurality ofdistinct mRNA isoforms, wherein the splice junction site and the additional splice junction site are collectively associated with the distinct mRNA isoform; (ii) in (d), locating the splice junction site and the additional splice junction site thereby identifies the distinct mRNA isoform; and (iii) (e) comprises associating the distinct mRNA isoform with the sample, andthereby, the disease, based on the identity of the common barcode sequence.Attorney Docket No.43487-102960140. The method of claim 39, wherein the distinct mRNA isoform encodes a cell surfaceprotein.

41. The method of claim 37, further comprising, prior to (d):using the probe-linked nucleic acid molecule and a first oligonucleotide comprising an additional barcode sequence to generate a first barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, (iii) the common barcode sequence or reverse complement thereof, and (iv) the additional barcode sequence or reverse complement thereof; and using the additional probe-linked nucleic acid molecule and a second oligonucleotide comprising the additional barcode sequence to generate a second barcoded nucleic acid molecule comprising (i) the third target sequence or reverse complement thereof, (ii) the fourth target sequence or reverse complement thereof, (iii) the common barcode sequence or reverse complement thereof, and (iv) the additional barcode sequence or reverse complement thereof.

42. The method of claim 41, wherein generating the first barcoded nucleic acid molecule andgenerating the second barcoded nucleic acid molecule occur in a partition among a plurality of partitions.

43. The method of claim 42, wherein the additional barcode sequence identifies the partitionfrom other partitions of the plurality of partitions.

44. The method of claim 43, wherein the partition is a droplet or a well.

45. The method of claim 41, wherein:(i) generating the first barcoded nucleic acid molecule comprises hybridizing a firstcapture sequence in the first oligonucleotide to a first capture binding sequence in the probe-linked nucleic acid molecule, and extending the first oligonucleotide to generate the first barcoded nucleic acid molecule; and (ii) generating the second barcoded nucleic acid molecule comprises hybridizing asecond capture sequence in the second oligonucleotide to a second capture binding sequence in the additional probe-linked nucleic acid molecule, and extending the second oligonucleotide to generate the second barcoded nucleic acid molecule.Attorney Docket No.43487-102960146. The method of claim 45, wherein the first oligonucleotide is coupled to a first bead andthe second oligonucleotide is coupled to a second bead.

47. The method of claim 34, further comprising, prior to (d):I. using the probe-linked nucleic acid molecule and a first oligonucleotidecomprising a barcode sequence to generate a first barcoded nucleic acid molecule comprising (i) the first target sequence or reverse complement thereof, (ii) the second target sequence or reverse complement thereof, and (iii) the barcode sequence or reverse complement thereof; and II. using the additional probe-linked nucleic acid molecule and a secondoligonucleotide comprising the additional barcode sequence to generate a second barcoded nucleic acid molecule comprising (i) the third target sequence or reverse complement thereof, (ii) the fourth target sequence or reverse complement thereof, and (iii) the barcode sequence or reverse complement thereof.

48. The method of claim 47, wherein the barcode sequence identifies the cell, and (d)comprises identifying the splice junction site and the additional splice junction site as associated with the cell based on the identity of the barcode sequence.

Images